Glossary
Searching for:
493 of 493
Id |
Terminology |
Definition |
|---|---|---|
| 394 | Strategic Advisory Group of Experts on Immunization (SAGE) | WHO’s highest-level advisory committee on vaccines and immunization policies. SAGE is a multidisciplinary group of global experts that meets biannually to review evidence and issue recommendations on vaccine use, schedules, booster needs, new vaccines, and other immunization strategies. SAGE’s guidance (e.g. on COVID-19 vaccine prioritization or on use of malaria vaccines) informs WHO policy positions and is often adopted by countries and international partners. |
| 457 | Vaccine nationalism | When governments prioritize securing vaccine doses for their own citizens before making vaccines available to others, often through direct bilateral deals with manufacturers. This self-first approach can lead to hoarding of limited vaccine supplies by wealthy nations, leaving fewer doses for poorer countries. Vaccine nationalism was prominent early in the COVID-19 pandemic, as some countries reserved large quantities of vaccines for themselves. This practice is widely criticized for undermining global health security – no one is safe until everyone is safe – and for prolonging the pandemic’s economic and health damage globally. Equitable initiatives like COVAX arose in part to counter vaccine nationalism by pooling procurement and access. |
| 429 | Travel vaccines | Vaccines recommended for travelers to certain areas to protect them from diseases that may be uncommon at home but endemic elsewhere. Examples include yellow fever vaccine (required for entry to some countries), typhoid vaccine, Japanese encephalitis vaccine, meningococcal vaccine (required for Hajj pilgrims to Saudi Arabia), and rabies pre-exposure vaccine for high-risk itineraries. Travelers should consult health authorities or CDC’s Yellow Book for vaccine recommendations tailored to their destinations. Travel vaccines help individuals avoid illness and also prevent importation of diseases back home. |
| 218 | In Silico Vaccine Design | Vaccine research and development conducted via computer simulation and computational modeling, rather than in wet-lab or animal experiments (“in vitro”/“in vivo”). This includes using bioinformatics tools to identify candidate antigens (as in reverse vaccinology), predicting epitopes and antigen structure, and even simulating immune system responses or clinical trials digitally. In silico design significantly cuts down the initial time and cost by narrowing the vast space of possibilities to a manageable few high-probability candidates before laboratory testing. For example, scientists can use in silico methods to rapidly design a multi-epitope vaccine and check its theoretical population coverage and HLA binding profiles prior to synthesis. While experimental validation is always required, in silico design has become an indispensable first step in modern vaccinology. |
| 258 | Maternal immunization | Vaccinating a pregnant woman to protect both the mother and her infant. Maternal immunization leads to the transplacental transfer of antibodies to the fetus, conferring passive immunity to the newborn. Examples: Tdap vaccine in pregnancy protects the newborn from pertussis in the first months of life; influenza vaccine in pregnancy protects both mother and baby from flu. Maternal antibodies can protect infants until they can be actively vaccinated, although they can also sometimes interfere with infant responses (as in measles). |
| 399 | Structure-based antigen design | Using the 3D structures of pathogens and immune complexes to design better vaccine antigens. A famous example is the prefusion F protein for RSV: researchers found the F protein shape before fusing to cells and stabilized it in that prefusion conformation, which elicits far more potent antibodies. Structure-based design also includes designing immunogens that preserve quaternary epitopes (e.g., specific arrangements of proteins on virus surfaces). Computational protein design algorithms (like Rosetta) allow creation of novel scaffold proteins that present critical epitopes in ideal conformations. These designed antigens can focus the immune response on neutralizing epitopes that the natural pathogen might hide (an approach used in HIV vaccine research for broadly neutralizing antibody epitopes). |
| 332 | Precision Public Health | Using detailed data (genomic, spatial, demographic) and technologies to deliver the right health intervention (e.g. vaccine) at the right time to the right population. |
| 112 | Digital Epidemiology | Use of digital data sources (internet, social media, mobile data) to monitor and predict disease outbreaks and public health trends (as distinct from traditional epidemiology). |
| 414 | Temporal association | Two events that occur around the same time, which may be falsely assumed to be causally related when in fact it could be coincidence. In vaccine safety, distinguishing temporal association from true causation is crucial. For example, if someone develops a symptom a day after vaccination, it’s temporally associated with the vaccine, but further investigation is needed to determine if the vaccine caused it or it was coincidental. Large epidemiologic studies help differentiate true vaccine reactions from temporally associated health events. |
| 442 | Vaccine Confidence | Trust that individuals or communities have in the safety and efficacy of vaccines, the health system delivering them, and the motivations of policy-makers recommending vaccines. |
| 40 | Antisense Oligonucleotide (ASO) Therapy | Treatment using short single-stranded DNA or RNA oligonucleotides that bind complementary mRNA to block its translation or promote its degradation. By “antisense” pairing to target mRNAs, ASOs can silence disease-causing genes or correct splicing errors. This strategy is used in conditions like spinal muscular atrophy and Duchenne muscular dystrophy by skipping or modifying mutant exons. |
| 66 | Circular RNA (circRNA) Therapeutics | Therapeutic use of RNA molecules engineered as covalently closed loops rather than linear strands. Lacking free 5? and 3? ends, circRNAs are highly resistant to exonuclease degradation, giving them much greater stability and a longer half-life in cells (days instead of hours). Properly designed circRNAs can be translated continuously via a rolling-circle mechanism, producing more protein cumulatively than linear mRNA. They also tend to be less immunogenic. CircRNA therapeutics (including circRNA vaccines) are an emerging “next leap” after linear mRNA, aiming to provide durable expression with reduced dosing and cold-chain requirements. |
| 95 | COVAX (COVID-19 Vaccines Global Access) | The vaccines pillar of the ACT Accelerator, co-led by WHO, Gavi, CEPI, and UNICEF, set up to ensure equitable access to COVID-19 vaccines around the world. From 2020–2023, COVAX pooled funds from donors and participating countries to invest in a portfolio of vaccine candidates and negotiate procurement of vaccines. Its aim was to deliver doses for at least 20% of countries’ populations (prioritizing health workers and vulnerable groups) regardless of income level. COVAX enabled the largest vaccine rollout in history, delivering nearly 2 billion doses to 146 economies by the end of 2023 and averting millions of deaths, although it faced challenges in securing enough supply early on. The initiative demonstrated an unprecedented global solidarity mechanism in vaccination. |
| 42 | Artificial Intelligence (AI) in Vaccine Design | The utilization of AI techniques, especially machine learning and deep learning, to solve complex problems in vaccinology. AI models can analyze large datasets (pathogen genomes, immune repertoire sequences, clinical trial results) to find patterns and make predictions that inform vaccine development. For instance, modern neural network models (CNNs, transformers, graph neural networks) significantly improve epitope prediction for B cells and T cells, often outperforming earlier sequence-based methods. AI has also been applied to optimize lipid nanoparticles for mRNA delivery, predict viral evolution, and even design novel immunogen structures. By rapidly exploring high-dimensional data, AI accelerates the identification of vaccine targets and the optimization of vaccine formulations and schedules. |
| 445 | Vaccine diplomacy | The use of vaccines as a tool of international relations and soft power. It refers to countries leveraging vaccine development or delivery to strengthen diplomatic ties, improve their global image, or gain influence. A classic example is the US and USSR collaborating on smallpox eradication during the Cold War – an instance of “science diplomacy.” In modern times, during COVID-19, countries like China and Russia engaged in vaccine diplomacy by donating or selling vaccines (Sinovac, Sputnik V) to other nations to boost goodwill and strategic relationships. Vaccine diplomacy can also mean collaborative development of vaccines by scientists across borders (sometimes termed “vaccine science diplomacy”). While it can bring positive health outcomes to recipient countries, critics note it might come with geopolitical strings attached or be driven by national interests (see vaccine nationalism). Ideally, global health diplomacy focuses on equitable access and cooperation rather than competition. |
| 123 | Drone delivery of vaccines | The use of unmanned aerial vehicles to transport vaccines and medical supplies to hard-to-reach locations. Drones can significantly reduce delivery times to rural or geographically isolated clinics, bypassing poor roads or natural barriers. For example, projects in Ghana and Vanuatu have used drones to deliver childhood vaccines to remote villages that would otherwise require hours of travel. Drones equipped with insulated payload boxes (sometimes temperature-controlled) keep vaccines within required temperatures during flight. Early studies and pilot programs showed that drone delivery is feasible and can be done within cold chain specifications. Scaling up drone networks could become part of immunization infrastructure to ensure timely supply in sparsely populated areas or during emergencies (like getting vaccines to an outbreak site cut off by floods). |
| 408 | Systems Vaccinology | The use of systems biology approaches – integrating multi-omics data (transcriptomics, metabolomics, proteomics, etc.) and computational modeling – to study vaccine responses in a holistic, unbiased manner. Systems vaccinology examines how entire networks of genes and immune pathways are modulated after vaccination. For example, blood gene expression signatures shortly after vaccination have been found that predict the eventual antibody titers weeks later. By capturing the complex immune response as a “system,” this approach aims to identify early biomarkers of efficacy (allowing rapid vaccine testing) and to unravel why individuals or populations differ in vaccine responses. Ultimately, systems vaccinology can guide the design of new vaccines and adjuvants that specifically activate protective immune programs. |
| 357 | Remote temperature monitoring (RTM) | The use of sensors and telemetry to continuously track the temperature of vaccine storage units (fridges, freezers) and during transport, with automatic alerts if temperatures go out of range. Modern RTM devices are IoT-based – they can send data via cellular or satellite networks to central dashboards. This means a fridge in a rural clinic can notify staff by SMS or app notification if, say, the power went out and the temperature rose above 8°C. RTM greatly aids cold chain maintenance by catching cold chain breaks in real time, preventing freeze-thaw damage (e.g., some monitors will alert if a freezer goes too cold and risks freezing vaccines that shouldn’t be frozen). As part of WHO’s EVM (Effective Vaccine Management) standards, many countries are adding RTM to their vaccine stores. It reduces the need for manual checking and logs a permanent record of temperature data for quality assurance. |
| 196 | Hydrogel-Based Vaccine Delivery | The use of hydrogels, networks of hydrophilic polymer chains that can hold large amounts of water, as matrices for delivering vaccine antigens and often adjuvants. Hydrogels can be engineered to form depots at the injection site, releasing antigens over time (sustained delivery) and providing a localized environment that recruits immune cells. They can also be designed as injectable solutions that gel in situ. Hydrogels used in vaccines might be natural (like alginate, chitosan) or synthetic (like polyHEMA or PLGA-PEG block copolymers). They are highly biocompatible and can be made to degrade in a controlled manner. By tuning their properties, one can control the release kinetics of the antigen and adjuvant, addressing the issue of quickly cleared antigens and reducing the need for multiple boosts. Additionally, hydrogels can themselves act as immunomodulatory adjuvants by providing danger signals or simply by their physical properties (causing mild inflammatory response that aids immune activation). Some hydrogels incorporate TLR agonists or cytokines along with the antigen. Others form a scaffold that attracts antigen-presenting cells to the vaccination site. Hydrogel vaccine platforms are being explored for various diseases and even cancer, as they allow co-delivery of tumor antigens and immune stimulators in a tumor resection cavity (forming a vaccine depot in situ). Overall, hydrogels represent a materials-science-driven approach to vaccination, aiming to optimize the timing, location, and context in which the immune system encounters antigens for a more potent and durable response. |
| 217 | In silico clinical trials (digital vaccine trials) | The use of computer simulations to model vaccine behavior in virtual populations. This can include simulating immune responses using mathematical models or agent-based models of how a vaccine might affect disease spread in a population. While not a substitute for real trials, in silico trials help optimize dose regimens, predict efficacy under various scenarios, or anticipate outcomes in populations not included in initial trials. During COVID-19, researchers employed computational models to predict optimal vaccination strategies (for example, spacing of doses) and to simulate vaccine impact on pandemic dynamics before real-world data was available. |
| 41 | Artificial Intelligence (AI) | The use of computer algorithms to perform tasks that typically require human intelligence; in health, AI can analyze large data streams for patterns (contextual term; includes algorithmic threat potential). |
| 146 | Epitope Prediction | The use of bioinformatics and machine learning tools to predict which parts of an antigen are likely to be immunogenic epitopes. Epitope prediction can focus on B-cell epitope prediction (identifying surface-exposed, flexible or hydrophilic regions on proteins that antibodies might bind) or T-cell epitope prediction (finding peptides with high affinity for common MHC alleles). Modern epitope prediction algorithms incorporate vast datasets of known epitopes and features like amino acid properties, structural motifs, and neural network models to improve accuracy. Accurate in silico epitope prediction accelerates vaccine design by narrowing down antigen regions to test in experiments. |
| 488 | Xenotransplantation (vaccine-related) | The use of animal materials in vaccine production. This might be seen in older vaccines that were grown on animal tissues (e.g., early polio vaccines in monkey kidney cells, or yellow fever vaccine in chicken eggs). Regulatory authorities have strict checks to prevent xenozoonoses (cross-species infections) via vaccines. Modern recombinant technology reduces reliance on primary animal tissues, but egg-based vaccine production (for influenza) still exists and is a form of xenotransplantation (using chick embryos). |
| 255 | Machine learning in vaccine design | The use of AI algorithms to improve prediction of vaccine targets and immune responses. Machine learning can analyze large datasets (genomic, immunological, clinical trial data) to find patterns such as features of a protein that make it a good immunogen or signatures that predict vaccine efficacy. For example, deep learning networks have been trained to predict peptide-MHC binding or to model antibody structures. AI-assisted vaccine design holds promise to reduce the vaccine design timeline from months to dayscepi.net by suggesting optimal antigen designs and even adjuvant combinations. CEPI and others are investing in AI to generate vaccine candidates optimized for broad protection and manufacturability. |
| 61 | Centers for Disease Control and Prevention (CDC) | The United States federal public health agency responsible for disease prevention and control, including immunization programs. The CDC conducts vaccine research, provides vaccination schedules and recommendations (often via ACIP), and monitors vaccine safety (e.g., co-managing VAERS). It plays a leading role in outbreak response and public health guidance in the U.S. and globally. |
| 155 | Food and Drug Administration (FDA) | The U.S. regulatory agency responsible for evaluating and approving vaccines (and other drugs/biologics) for use, and for monitoring their safety, effectiveness, and quality. The FDA’s Center for Biologics Evaluation and Research (CBER) rigorously reviews vaccine trial data for approval. The FDA also oversees manufacturing standards (GMP) and can issue Emergency Use Authorizations to make vaccines available during crises. |
| 391 | Sterilizing Immunity | The type of immunity that completely prevents a pathogen from establishing infection in the host. If a person has sterilizing immunity, they will not get infected at all upon exposure – meaning no asymptomatic carriage, no transient replication, nothing. This is the “gold standard” for vaccines but is not always achieved. For example, the polio vaccine can induce sterilizing immunity such that the virus cannot even replicate in the gut, whereas some other vaccines (like pertussis vaccines) protect against disease but not necessarily colonization or transmission. Sterilizing immunity usually requires very robust neutralizing antibody presence at the points of entry (e.g., high mucosal IgA for a respiratory virus) or other immediate effector mechanisms. Many effective vaccines do not confer fully sterilizing immunity but still protect against clinical illness (e.g., the flu vaccine may allow mild or asymptomatic infection but prevents severe disease). In the context of COVID-19 vaccines, initial hopes were for sterilizing immunity (no infection), but it turned out the vaccines were better at preventing severe outcomes than preventing any infection especially with new variants. Achieving sterilizing immunity is ideal for blocking transmission and eradicating a disease, but it is a high bar and not necessary for a vaccine to be very useful. |
| 108 | Deltoid | The triangular muscle of the upper arm/shoulder. The deltoid is a common site for intramuscular injection of vaccines in adults and older children. For example, flu shots and COVID-19 vaccines are typically given in the deltoid muscle. (Infants often receive IM injections in the anterolateral thigh instead.) |
| 430 | TRIPS Agreement and vaccine IP waivers | The Trade-Related Aspects of Intellectual Property Rights agreement, enforced by the WTO, sets global minimum standards for IP protection, including patents on pharmaceuticals. During the COVID-19 pandemic, India and South Africa led a proposal for a TRIPS waiver for COVID medical products, arguing that temporarily waiving patents would enable more manufacturers in low-income countries to produce vaccines, treatments, and diagnostics without legal barriers. After long negotiations, WTO members agreed in June 2022 on a limited waiver for COVID-19 vaccines (allowing production under compulsory license without the patent-holder’s permission primarily for domestic use and some export). The impact of this waiver has been debated – some say it came too late and was too narrow; others worry about precedent. Nonetheless, the TRIPS waiver debate highlighted the tension between IP rights and public health in a pandemic. Compulsory licensing (permitted under TRIPS for emergencies) is another mechanism – some countries like Canada and Israel issued or considered compulsory licenses to import or produce COVID-19 drugs. The broader question is how to ensure IP regimes don’t hinder timely access to vaccines globally, and the waiver was one attempt at a solution. |
| 208 | Immunization schedule | The timeline of recommended vaccine doses for different age groups (and risk groups) as advised by health authorities. Schedules specify the ages for each dose, the number of doses, and intervals between doses for each vaccine. For example, the CDC childhood immunization schedule in the U.S. outlines doses at birth, 2 months, 4 months, 6 months, etc., through adolescence. Adhering to the schedule is important for optimal protection, since it is based on when immunity will be most effective and when maternal antibodies wane. |
| 354 | Reactogenicity | The tendency of a vaccine to produce common, transient side effects stemming from the activation of the innate immune response. These reactions can include injection-site pain, redness, swelling, fever, headache, muscle aches, and fatigue – essentially the inflammatory symptoms that often accompany vaccination. Reactogenicity is not the same as serious adverse events; rather, it refers to expected, usually mild and self-limited reactions. For example, COVID-19 mRNA vaccines are quite reactogenic, frequently causing short-term systemic symptoms like fever or chills, whereas some older vaccines are less so. While a certain level of reactogenicity is normal (it can indicate the vaccine is engaging the immune system), excessive reactogenicity can affect vaccine acceptance. Vaccine developers aim for formulations that are immunogenic yet minimize unnecessary inflammation. Monitoring reactogenicity in trials (through diary cards for solicited symptoms) is an important part of assessing a vaccine’s safety and tolerability. |
| 236 | Knowledge Synthesis | The systematic aggregation and summarization of research findings (e.g. through systematic reviews, meta-analyses) to inform practice and policy. |
| 376 | Serology | The study or diagnostic examination of blood serum, especially with regard to the response of the immune system (antibodies or other immunological markers). In practice, serologic tests detect the presence and quantity of antibodies to specific antigens in serum. Serology can determine if someone has been exposed to a pathogen or has been vaccinated (by detecting antibodies). It is widely used for surveillance (e.g., serosurveys for measles immunity) and in research (measuring antibody titers post-vaccination). |
| 116 | Dissemination Science | The study of methods to effectively communicate and spread research findings and evidence-based interventions to target audiences. |
| 412 | Task Shifting | The strategic delegation of tasks (e.g. vaccine administration) from highly trained health workers to cadres with shorter training, to improve service coverage and reduce bottlenecks. |
| 307 | Pandemic Preparedness | The state of being ready to respond effectively to a pandemic threat, through a combination of surveillance, infrastructure, planning, stockpiles, and rapid response capabilities (including vaccine development and deployment). Key components of pandemic preparedness for vaccines include: platforms that allow swift creation of vaccines (like mRNA or viral vectors that can be quickly retargeted), manufacturing surge capacity worldwide, regulatory pathways for emergency approvals, and frameworks like COVAX to ensure global access. Preparedness also means having research on “prototype pathogens” done in advance (e.g., having vaccine candidates and assays ready for virus families of concern – as was partly done for coronaviruses, enabling the rapid COVID-19 vaccine rollout). Stockpiling certain vaccines (as done for pandemic influenza or Ebola) and raw materials is another element. International coordination (e.g., WHO’s Pandemic Influenza Preparedness framework) provides guidance and agreements on sample sharing and benefit sharing. The COVID-19 pandemic highlighted strengths and weaknesses: unprecedented speed in vaccine development, but also inequities in distribution and supply bottlenecks. Future preparedness efforts include establishing mRNA vaccine hubs in different continents, maintaining libraries of viral sequences and immunogens, and running periodic simulations/drills. Preparedness isn’t just scientific; it encompasses legal tools (like Emergency Use Authorization), funding arrangements (e.g., CEPI’s mission to fund “Disease X” vaccines upfront), and global governance (such as a potential pandemic treaty). The ultimate goal is to shorten the time from pathogen emergence to vaccine rollout (the “100-day mission” proposed by CEPI) and to ensure that all regions can access tools concurrently, thereby blunting or preventing pandemics. |
| 386 | Social determinants of health (and immunization) | The socio-economic and environmental factors (such as income, education, living conditions, gender, and ethnicity) that influence health outcomes and access to services. These determinants affect immunization inequities – for instance, children from poorer families or marginalized ethnic groups often have lower vaccine coverage due to factors like weaker health infrastructure, parental education, or discrimination. Policy-makers analyze social determinants to design interventions (like engaging community leaders, providing cash transfers, or mobile clinics) that can mitigate these barriers. Addressing social determinants is crucial to improve immunization rates in hard-to-reach populations and to ensure that vaccines benefit all segments of the population equally. |
| 385 | Social Determinants of Health | The social and economic conditions (e.g. education, income, cultural norms) that influence individual and population health outcomes, including immunization behaviors (not a single source; general concept). |
| 433 | Ultra-cold chain (UCC) | The segment of the vaccine cold chain that involves storage and transport at extremely low temperatures, typically below –60°C. Ultra-cold chain capability became a household concern with COVID-19 mRNA vaccines (like Pfizer’s) requiring about –70°C storage. It necessitates specialized ultra-low temperature freezers and dry ice shipping containers. An ultra-cold chain system must maintain these temperatures until shortly before use. For instance, UNICEF in 2021 delivered hundreds of ultra-cold freezers to countries to support mRNA vaccine rollout. Managing UCC is challenging in hot climates or remote areas due to power and equipment needs, and it prompted innovations like more stable formulations and portable cooling devices. UCC is generally reserved for vaccines that cannot tolerate standard 2–8°C refrigeration. |
| 319 | Phase II trial | The second phase of clinical trials, involving more people (hundreds) and often including some from target populations (varied ages, etc.). Phase II trials continue to evaluate safety (including short-term side effects and risks) and assess immunogenicity in more detail, often refining the dosage or schedule. They may be randomized and controlled. The goal is to determine the optimal dose and gather enough safety/immunogenicity data to justify moving to a large efficacy trial. |
| 223 | Infodemiology | The science of distribution and determinants of information (especially online) in populations, to inform public health and policy. |
| 316 | Pharmacovigilance (for vaccines) | The science and activities related to detecting, assessing, understanding, and preventing adverse effects or any other vaccine-related problems. Vaccine pharmacovigilance encompasses all AEFI surveillance, from passive reporting systems (like the VAERS in the US) to active monitoring (like sentinel hospital surveillance or phase IV studies). The goal is to identify true safety signals amidst the noise of coincidental events, for example: investigating if there is a higher than expected rate of an outcome like Guillain-Barré syndrome after a new vaccine. A strong pharmacovigilance system will rapidly pick up safety concerns and enable regulators to take evidence-based action (such as adding a warning, or in rare cases, withdrawing a vaccine). International collaboration (e.g., sharing data through WHO’s database) enhances pharmacovigilance by providing larger datasets to assess causality. |
| 315 | Pharmacovigilance | The science and activities related to detecting, assessing, understanding, and preventing adverse effects or any other problems related to medical products (like vaccines). Vaccine pharmacovigilance involves monitoring vaccine safety after licensure, for instance: through systems like VAERS and VSD, and studies investigating rare events. It includes signal detection (noticing possible safety issues), evaluation of whether vaccines caused observed adverse events, and taking action (like updating guidance or withdrawing a vaccine) if needed. Pharmacovigilance is crucial for maintaining public trust and ensuring benefits of vaccines continue to far outweigh risks. |
| 345 | Quarantine | The restriction of movement or separation of individuals who have been exposed to a contagious disease, to see if they become sick, in order to prevent further spread. Quarantine is a public health measure often used alongside vaccination to control outbreaks. For instance, unvaccinated persons exposed to measles may be quarantined for the incubation period (~21 days) if they cannot receive post-exposure prophylaxis. During the COVID-19 pandemic, quarantine (staying home for a set number of days after exposure) was widely used to curb transmission. (Isolation, by contrast, applies to those known to be infected.) |
| 202 | Immune response | The reaction of the immune system to foreign substances (antigens). An immune response can be humoral (production of antibodies by B cells) or cell-mediated (activation of T cells and other immune cells), and often both. After vaccination, the desired immune response is the creation of memory B and T cells and, for many vaccines, neutralizing antibodies specific to the pathogen. The strength and quality of an immune response can be measured by assays (e.g., antibody titers, T-cell proliferation). |
| 235 | Kinetics of immune response | The rate and magnitude of the immune system’s response after vaccination. This term is often used in immunology studies to describe how quickly antibodies rise (e.g., peak by 2–4 weeks post-vaccination) or how long they persist (antibody waning over years), as well as T-cell response timelines. Understanding immune kinetics helps determine optimal vaccine timing (e.g., spacing of doses) and when boosters may be needed. |
| 68 | Clonal expansion | The rapid multiplication of antigen-specific lymphocytes (B cells or T cells) after activation by their specific antigen. When a T cell or B cell recognizes its antigen (with the help of other signals), it proliferates to produce many identical “clones” of itself – a process essential to mounting an effective immune response. “Clonal expansion is the proliferation of antigen-specific lymphocytes in response to antigenic stimulation”. This expansion precedes differentiation into effector cells. For example, a single T cell recognizing a virus peptide can clonally expand to thousands of T cells to fight the infection. Clonal expansion ensures that rare lymphocytes specific to a pathogen become numerous enough to clear the infection. |
| 311 | Passive immunization | The provision of immunity by transferring antibodies (or immune cells) from an immune individual to a non-immune individual, rather than the individual generating an immune response themselves. Examples include maternal antibodies passed to the baby (naturally via placenta or colostrum), or medical treatments like administering immune globulin or monoclonal antibodies for rapid protection. Passive immunity provides immediate but temporary protection, as the antibodies will eventually degrade (over weeks to months) and no long-lived immunity is conferred. “Active immunization with antigen… is called active immunization to distinguish it from transfer of antibody to an unimmunized individual, which is called passive immunization”. Vaccination is active immunization (the person’s immune system is actively prompted to respond), whereas an anti-rabies immunoglobulin shot after a bite is passive immunization. Passive immunization is critical in post-exposure prophylaxis scenarios (rabies, hepatitis B, etc.) and is also how antitoxins work (e.g., anti-tetanus or anti-venom antibodies). |
| 437 | Uptake (vaccine uptake) | The proportion of the target population that actually receives a vaccine. Uptake is influenced by factors like access, recommendations, and public acceptance. For example, if a new vaccine is introduced and 80% of the eligible population gets it, one would say the uptake is 80%. Public health programs aim to maximize uptake to reach herd immunity thresholds. Low uptake (due to hesitancy or other barriers) can result in continued disease transmission despite vaccine availability. |
| 335 | Prevalence | The proportion of individuals in a population who have a particular disease or condition at a specific point in time or over a specified period. In vaccine terms, one might discuss the prevalence of immunity (e.g., seroprevalence of antibodies) or the prevalence of a disease (which vaccines aim to reduce). For example, the prevalence of hepatitis B carriers in a population can drastically decline after two decades of universal vaccination. (Prevalence differs from incidence, which is the rate of new cases in a time period). |
| 352 | Reach | The proportion of a target population that is served or affected by an intervention or program in a given context. |
| 207 | Immunization coverage rate | The proportion of a target population that has received a specified vaccine (or vaccine series). Coverage is usually expressed as a percentage – for example, the percentage of infants who received their third dose of DTP (DTP3) by 12 months of age. Coverage is a key indicator of program performance and access.Countries track coverage for each antigen (DTP3, MCV1 for measles, etc.) annually, through administrative data (reports of doses given divided by estimated population) and through surveys. High coverage (e.g., ?90% nationally and ?80% in every district) is needed to achieve herd immunity for many diseases and is the goal of initiatives like the Expanded Programme on Immunization. |
| 463 | Vaccine thermostability | The property of a vaccine to retain potency at higher-than-usual temperatures. Improving thermostability is a major R&D goal because it relaxes cold chain requirements. This can be achieved through formulation science (adding stabilizers like sugars, using glassy matrices in lyophilization, or selecting more stable vaccine strains). For instance, some rotavirus vaccines and the MenAfriVac meningitis vaccine were formulated to be stable atabout 40°C for a few days (enabling CTC use). Thermostability data are required for WHO prequalification; vaccines are classified by VVM category based on heat stability. Highly thermostable vaccines reduce cold chain burdens, vaccine wastage (from heat damage), and allow novel delivery methods like vaccine packs delivered by mail without refrigeration (as was piloted for some freeze-dried COVID-19 vaccines in development). |
| 303 | Original antigenic sin (immune imprinting) | The propensity of the immune system, when encountering a slightly altered version of a previously encountered antigen (such as a new strain of virus), to preferentially utilize memory responses (antibodies or T cells) specific to the original antigen rather than generating new responses to the changed epitopes. This phenomenon can lead to suboptimal immunity against the new strain. It is described as the immune system being “trapped” by the first version of the antigen it saw. In practical terms, “the propensity of the immune system to preferentially use immunological memory based on a previous infection when a second, slightly different version of that pathogen is encountered”. Original antigenic sin was first noted with influenza viruses and has implications for sequential infections and vaccine updates (as well as in COVID-19 immune imprinting studies). |
| 166 | Germinal center reaction | The process that occurs in germinal centers of lymph nodes and spleen following vaccination (or infection) where B cells undergo proliferation, somatic hypermutation, and selection for higher-affinity variants. It’s a crucial part of how vaccines lead to strong, long-lasting antibody responses and affinity maturation. A successful vaccine often triggers robust germinal center responses, resulting in memory B cells and long-lived plasma cells that reside in bone marrow producing high-affinity antibodies. Some new vaccine strategies explicitly focus on germinal center biology – for instance, using slow-release antigen or certain adjuvants to prolong germinal center activity and drive extensive antibody maturation (important for difficult targets like HIV broadly neutralizing antibodies). Scientists measure germinal center B cells in lymphoid tissue (in animal models or occasionally in vaccine trial participants’ fine-needle aspirates of lymph nodes) to evaluate this aspect of immunogenicity. |
| 106 | De-implementation | The process of reducing or eliminating ineffective or harmful practices in healthcare to improve system performance. |
| 237 | Knowledge Translation | The process of moving research knowledge into health practice or policy, including dissemination, adaptation, and implementation to improve health outcomes. |
| 205 | Immunization | The process of inducing immunity to an infectious agent in an individual, typically by administering a vaccine (active immunization). Colloquially, “immunization” is often used interchangeably with vaccination, though technically immunization can also refer to gaining immunity via infection or via passive transfer of antibodies. Public health immunization programs focus on achieving high rates of immunization in the population to prevent disease outbreaks. |
| 145 | Epitope mapping | The process of identifying the specific antigenic determinants (epitopes) on an antigen that are recognized by an antibody or by a T-cell receptor. In the context of antibodies, epitope mapping pinpoints the amino acids or region of an antigen that an antibody binds. This can be done experimentally (e.g., by testing overlapping peptides or mutational analysis, or X-ray crystallography of antigen–antibody complexes) or computationally. “Epitope mapping is the process of experimentally identifying the binding site, or epitope, of an antibody on its target antigen”. It is crucial in vaccine design and antibody therapy development, as it reveals which parts of a pathogen are immunogenic and accessible. For T cells, epitope mapping determines the peptide fragments presented by MHC that T-cell receptors recognize. |
| 251 | Lyophilization | The process of freeze-drying a vaccine to a powder form, which enhances its stability for storage and transport. Many vaccines (e.g., measles-mumps-rubella, BCG, some cholera vaccines) are lyophilized and supplied as a dried cake or powder in a vial; they are reconstituted with a diluent (usually sterile water) at the time of use. Lyophilized vaccines are less sensitive to temperature excursions than liquid formulations, which helps in maintaining potency in the cold chain. |
| 371 | Scenario Planning | The process of developing multiple plausible future scenarios (narratives) about how factors may evolve, to identify uncertainties and guide strategic planning (as part of foresight). |
| 143 | Epidemic Intelligence | The process of detecting, verifying, and analyzing public health events that may pose a threat, aiming to speed up outbreak detection and response (as used by WHO/ECDC)asset-scienceinsociety.eu. |
| 356 | Regulatory harmonization | The process of aligning vaccine (and other medical product) regulatory standards and procedures across different jurisdictions to simplify and expedite product approval. Harmonization efforts encourage regulators to adopt uniform technical guidelines and recognize each other’s reviews. For example, initiatives like the African Vaccine Regulatory Forum and the developing African Medicines Agency aim to harmonize and strengthen regulatory processes, so that vaccines proven safe and effective can be authorized concurrently in multiple countries, avoiding duplicative efforts. |
| 76 | Community Engagement | The process of actively involving community members as partners and decision-makers in the design and implementation of health programs, recognizing them as key actors (not just beneficiaries) in social change. |
| 101 | Cross-presentation | The process by which certain antigen-presenting cells (especially dendritic cells) take up extracellular (exogenous) antigens and then present peptide fragments of those antigens on MHC class I molecules to CD8? T cells. This is a special exception to the usual MHC rules, enabling the activation of cytotoxic T lymphocytes against viruses or tumors that might not directly infect dendritic cells. “Cross-presentation is the process by which exogenous proteins are processed and presented as peptides on MHC class I”. It allows the immune system to generate CD8 T cell responses to, say, a virus that only infects non-APC cells, by having dendritic cells ingest virus-infected cell debris or antigen and then “cross-present” those antigens on MHC I. This is critical for anti-tumor immunity and vaccines that aim to elicit CD8 T-cell responses (for instance, certain cancer vaccines or vectored vaccines rely on cross-presentation). |
| 18 | Affinity maturation | The process by which B cells produce antibodies with increasingly higher affinity for their antigen during an immune response. Affinity maturation occurs in germinal centers and is driven by somatic hypermutation and selection for B cells with improved antigen binding. It “refers to the increase in the affinity for the specific antigen of the antibodies produced during the course of a humoral immune response”ncbi.nlm.nih.gov, particularly evident upon secondary or repeated immunizations. |
| 32 | Antigen presentation | The process by which antigen-presenting cells (APCs) display peptide fragments of antigens on their surface bound to Major Histocompatibility Complex (MHC) molecules, for recognition by T cells. T cells cannot usually recognize intact proteins; they see processed peptides on MHC. Thus, “antigen presentation is a vital immune process, Because T cells recognize only fragmented antigens displayed on cell surfaces, antigen processing must occur before the antigen fragment can be recognized”. In this process, intracellular antigens are presented on MHC class I (to CD8? T cells) and extracellular antigens on MHC class II (to CD4? T cells), enabling the activation of T cells and the adaptive immune response. |
| 448 | Vaccine equity | The principle that everyone – regardless of wealth, geography, or demographic factors – should have fair access to lifesaving vaccines. It implies proactive efforts to reach underserved populations and remove barriers to vaccination. As defined by CDC, “vaccine equity is when everyone, regardless of socioeconomic status, race, ethnicity, or geographic location, has a fair and just opportunity to be vaccinated”. In practice, achieving vaccine equity involves distributing vaccines to low-resource countries at affordable costs, ensuring rural areas have supply, and addressing social determinants (like transportation or misinformation) that cause disparities in uptake. Global vaccine equity became a prominent issue during COVID-19 – while some countries achieved >70% coverage, others struggled to reach even 10% in 2021. Initiatives like COVAX and the African Vaccine Acquisition Trust (AVAT) were aimed at closing this gap. Vaccine equity also concerns within-country disparities: ensuring minority and marginalized communities have equal access and are not left behind in immunization programs. |
| 120 | Dose-sparing (fractional dose) | The practice of using a fraction of the normal vaccine dose to stretch vaccine supply, while still aiming for effective immunity. For example, during outbreaks or shortages, one-fifth doses of inactivated polio vaccine have been used intradermally as a dose-sparing strategy. Careful studies are done to ensure fractional doses are still efficacious. Dose-sparing can increase the number of people who can be protected when vaccine quantities are limited. |
| 387 | Social Listening | The practice of monitoring and analyzing online and community communications (social media, forums, news) to understand public concerns, rumors, and sentiment about health issues (as recommended by WHO; see discussion in [76]). |
| 119 | Dose sharing | The practice of countries sharing their vaccine doses with others, typically by donating surplus doses or diverting a portion of their secured supply. Dose sharing became a key component of global COVID-19 vaccine equity efforts – higher-income countries pledged to donate billions of doses via COVAX or bilaterally. For example, countries in the G7 and European Union shared doses they purchased (especially once their domestic demand tapered) with low-income countries. Effective dose sharing requires that donated vaccines have sufficient shelf-life and that receiving countries are prepared to use them promptly. It represents solidarity in action, though it came later in the pandemic response after initial vaccine nationalism. |
| 99 | Crisis communication (for vaccines) | The practice of communicating promptly, transparently, and effectively during a vaccine-related crisis or scare. Whether it’s an outbreak of a vaccine-preventable disease, the discovery of a safety issue, or a surge of anti-vaccine misinformation, health authorities must convey facts and guidance to the public under high-pressure conditions. Key principles include acknowledging uncertainties, empathizing with public fears, providing clear instructions (e.g., where to get vaccinated during an outbreak), and correcting false rumors swiftly. A well-handled vaccine crisis communication can maintain or even restore public trust – for example, openly explaining an AEFI investigation’s findings and the steps being taken. Poor communication, on the other hand, can fuel panic or erode confidence. Thus, many immunization programs have risk communication plans in place and train spokespersons in advance to manage potential crises. |
| 446 | Vaccine Effectiveness | The performance of a vaccine in the real world, i.e., how well it reduces disease in vaccinated populations under routine conditions. Effectiveness is measured observationally after a vaccine is rolled out (via cohort or case-control studies), and it can be influenced by factors like population demography, adherence to dosing schedules, cold-chain maintenance, variant strains, etc. Generally, effectiveness is somewhat lower than the efficacy observed in trials, because real-world conditions are less controlled – for example, some individuals might be immunocompromised or might not complete the series on time. An example: if a COVID-19 vaccine had 95% efficacy in trials, post-licensure studies might find, say, 88% effectiveness against hospitalization in the general population (perhaps lower in elderly subgroups, etc.). Effectiveness studies are crucial for confirming a vaccine’s impact and guiding policy (they may reveal the need for booster doses or indicate how a vaccine performs against new variants). In summary, efficacy refers to ideal conditions (trials), while effectiveness refers to typical conditions– both are important metrics in vaccinology. |
| 131 | Efficacy (Vaccine efficacy) | The percentage reduction in disease incidence in a vaccinated group compared to an unvaccinated group under optimal conditions (typically measured in a Phase III clinical trial). For example, “90% efficacy” means the vaccinated group had 90% fewer cases of the disease than the placebo group. Efficacy is determined in trials (which are controlled environments) and answers how well the vaccine works in the trial setting. (See also Effectiveness.) |
| 447 | Vaccine Efficacy | The percentage reduction in disease incidence in a vaccinated group compared to an unvaccinated (placebo) group under ideal and controlled conditions (a clinical trial). It answers the question: “How well does the vaccine work in the trial population?” For example, 95% efficacy means 95% fewer cases of disease occurred among the vaccinated than would have occurred if they had not been vaccinated. High efficacy in Phase III is a strong indicator a vaccine will be useful. However, efficacy is measured in specific conditions – participants are often healthy and followed closely. It does not always translate directly to real-world performance (see vaccine effectiveness). Efficacy can also be reported against different endpoints (e.g., efficacy against infection vs. efficacy against severe disease). Regulatory agencies typically require a predefined minimal efficacy (for instance, >50%) for approval. |
| 465 | Vaccine wastage rate | The percentage of vaccine doses supplied that are not administered to people and are wasted. Wastage can occur due to various reasons: open vial wastage (remaining doses in multi-dose vials that cannot be used before expiry once opened), vials expiring unused, breakage, or exposure to out-of-range temperatures. For example, a 10-dose vial of a vaccine might immunize only 8 people before the rest expires – that’s a 20% wastage rate. Wastage rates are factored into vaccine needs forecasting (higher expected wastage means ordering more doses). Program managers try to minimize wastage through strategies like the open vial policy (which allows certain vaccines to be kept and used in subsequent sessions for up to 28 days after opening, if proper refrigeration is maintained) and by training health workers on dose-sparing practices. Some wastage is inevitable in reaching remote populations, but excessive wastage points to inefficiencies in the system. |
| 124 | Dropout rate | The percentage of children who start but do not complete a recommended vaccine series. It is often measured between an initial dose and the final dose in a series – for example, the DTP1 to DTP3 dropout rate indicates what fraction of infants who got a first DTP dose did not receive the third dose. Formally, the dropout rate = ((% coverage with first dose – % coverage with last dose) / % coverage with first dose) * 100%. A high dropout rate suggests issues with follow-up or access (families unable to return for subsequent shots, or trust issues after the first contact). Program managers monitor dropout as a quality and equity indicator – low dropout (under 10%) is desired, meaning those who start vaccination continue to completion. |
| 444 | Vaccine Coverage | The percentage of a target population that has been vaccinated with the relevant vaccine. It’s a key public health metric indicating how well an immunization program is reaching the community. Coverage can be expressed in various ways: by specific antigen (e.g., “measles coverage among 1-year-olds is 90%”) or by composite indicators (like the proportion of children who received all recommended vaccines by age 2). A commonly used measure is coverage with the third dose of DTP (DPT3) in infants, as it reflects the strength of the routine infant immunization system. High coverage is usually needed for herd immunity in vaccine-preventable diseases (typically >80–95% depending on disease). Coverage is assessed through administrative data (doses given vs target population size) and surveys (e.g., Demographic and Health Surveys, WHO’s cluster surveys). Gaps in coverage can lead to outbreaks, as seen when measles coverage dips below herd immunity thresholds. There can be disparities in coverage within countries (urban vs rural, wealth quintiles, etc.), and reaching the “last mile” – the so-called zero-dose children who haven’t received any routine vaccines – is a focus of global initiatives. For COVID-19, tracking vaccine coverage by age and risk group has been critical to guide policy. Ultimately, vaccine coverage reflects both supply (availability, access) and demand (acceptance) factors. Efforts to improve coverage involve strengthening health services, reducing missed opportunities (e.g., vaccinating whenever possible), community engagement, and sometimes policy measures like school entry requirements. |
| 8 | Adaptive immunity (acquired immunity) | The part of the immune system that develops a specific response to pathogens upon exposure. It is mediated by lymphocytes (B cells and T cells) and features immunological memory. Adaptive immune responses are slower on first exposure but can provide long-lasting protection (including a faster, stronger response on subsequent exposures). |
| 459 | Vaccine Refusal | The outright decision not to vaccinate oneself or one’s dependents; the extreme end of the hesitancy spectrum (definition generally known). |
| 281 | National Immunization Program (NIP) | The organizational structure within a country’s health system that manages vaccination services. NIPs are responsible for planning, procuring vaccines, training health workers, running outreach clinics, recording data, and monitoring coverage and safety. A strong NIP is characterized by good cold chain infrastructure, steady financing (often with Gavi support in poorer countries), political commitment, and integration with primary health care. Many countries have expanded their NIPs significantly in recent decades (adding many new vaccines). NIPs often have to innovate to reach the last 10% of children – using strategies like Reaching Every District (RED), now updated to Reaching Every Community, which focuses on microplanning at local levels and community engagement to improve routine immunization. During COVID-19, NIPs faced a dual challenge: roll out a new adult vaccine program while maintaining routine child immunization – a stress test that revealed resilience in some areas and fragility in others. Strengthening NIPs is central to achieving IA2030 goals. |
| 405 | Surveillance (disease surveillance) | The ongoing systematic collection, analysis, and interpretation of health data for planning, implementation, and evaluation of public health practice. In vaccine contexts, surveillance refers to tracking the incidence of vaccine-preventable diseases (to measure impact of vaccines and detect outbreaks) and monitoring for adverse events following immunization (to assure safety). For example, acute flaccid paralysis surveillance is used to find polio cases in the field, and lab networks confirm if poliovirus is present – vital for polio eradication efforts. Similarly, surveillance for measles and rubella cases guides immunization activities. |
| 142 | Epidemic | The occurrence of disease cases in a community or region at a rate clearly in excess of normal expectancy. An epidemic refers to an outbreak that grows and affects many individuals in a short time. If an epidemic spreads over multiple countries or continents, it may be termed a pandemic. Vaccination can curb epidemics by reducing the susceptible population and breaking chains of transmission. |
| 369 | SARS-CoV-2 | The novel coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2) identified in 2019 that is the cause of COVID-19. It is an RNA virus with a characteristic spike protein on its surface (the main target of COVID vaccines). SARS-CoV-2 spreads primarily through respiratory droplets and has caused a global pandemic. Vaccines developed against SARS-CoV-2 (including mRNA, viral vector, protein subunit, and inactivated vaccines) largely focus on inducing immunity to the Spike (S) glycoprotein, which the virus uses to enter human cells. Variants of SARS-CoV-2 with mutations in Spike have emerged, and vaccine strategies have adapted (booster doses, updated strain vaccines) to maintain protection. |
| 192 | Human–Animal Interface | The myriad ways in which humans interact with animals (e.g. through domestication, wildlife trade, habitat encroachment), which can facilitate the transmission of pathogens across species. |
| 214 | Immunosurveillance | The monitoring of the immune status of individuals or populations, often to guide public health actions. This term can refer to the immune system’s natural “surveillance” for cancer or pathogens, but in vaccinology, it might describe surveillance programs that assess immunity levels in a population (e.g., serosurveys for antibody prevalence) or post-vaccine immune monitoring. Seroprevalence studies and disease surveillance together inform whether herd immunity thresholds are met or if booster campaigns are needed. |
| 77 | Community immunity (Herd immunity) | The indirect protection from an infectious disease that occurs when a sufficient proportion of the population is immune, thereby reducing spread of the disease. If enough people are vaccinated or immune (through prior infection), transmission chains are disrupted, protecting individuals who are not immune. Herd immunity thresholds vary by disease (e.g. ~95% for measles). Community immunity is especially important for protecting those who cannot be vaccinated (like newborns or the immunocompromised). |
| 182 | Herd immunity (community immunity) | The indirect protection from an infectious disease that occurs when a sufficient portion of the population is immune, thereby reducing the likelihood of infection for individuals who lack immunity. Herd immunity can be achieved through vaccination or through prior illness, and it means that chains of transmission are disrupted because most people cannot catch and spread the disease. Each disease has a herd immunity threshold – for a very contagious virus like measles, about 95% of the population needs immunity to protect the rest. Vaccine policies aim to reach coverage levels high enough to establish herd immunity, which is critical for protecting those who cannot be vaccinated (such as newborns or immunocompromised individuals) and for possibly eradicating diseases. |
| 480 | Waning Immunity | The gradual loss of immune protection over time after an infection or vaccination. Immunity is not always lifelong; antibody levels can decline, and memory cells can reduce in function or number, leading to increased susceptibility to disease after a certain period. For example, pertussis immunity wanes a few years after the last dose of acellular vaccine, which is why booster shots (Tdap) are recommended in adolescence and adulthood. Waning can be due to a natural decay of immune response or due to antigenic changes in the pathogen (making the old response less relevant). Vaccine efficacy over time is closely watched – e.g., measles vaccine generally induces long-lived immunity, but influenza vaccine effectiveness wanes within a year (partly due to drift and partly due to immune decline). Monitoring antibody titers or breakthrough infection rates over years post-vaccination helps determine if and when booster doses are needed. For COVID-19, noticeable waning of protection against mild infection over 6–12 months was observed, prompting booster recommendations to restore immunity. Factors affecting waning include the vaccine platform, the dosing interval, and individual differences (e.g., older adults often experience faster waning). |
| 37 | Antigenic Drift | The gradual accumulation of small mutations in a pathogen’s antigens (such as viral surface proteins) over time, which can alter epitopes and allow the pathogen to partially evade existing immunity. This term is often used in the context of influenza virus: as the virus replicates, point mutations in the hemagglutinin and neuraminidase genes lead to amino acid changes. If enough changes accrue, antibodies from prior infections or vaccines may bind less effectively, reducing protection. Antigenic drift is why seasonal influenza vaccines must be updated frequently. It contrasts with antigenic shift, which is a sudden major change. Monitoring antigenic drift (e.g., via antigenic cartography and serology) is critical for keeping vaccines effective against circulating strains. |
| 435 | Universal Health Coverage (UHC) | The goal that all people can access the health services they need (preventive, curative, and rehabilitative) without suffering financial hardship. Vaccination is a foundational component of UHC – it’s an essential service that should be available to all, and it offers broad public health benefits. Strengthening immunization programs helps advance UHC by bringing people into contact with the health system and providing a highly cost-effective service. Conversely, achieving high vaccine coverage is one of the indicators of UHC. Equity in immunization (reaching all socio-economic groups) is a litmus test for UHC progress. |
| 206 | Immunization Agenda 2030 (IA2030) | The global strategy for vaccines and immunization for the decade 2021–2030, endorsed by the World Health Assembly. IA2030’s vision is “A world where everyone, everywhere, at every age fully benefits from vaccines.” It sets targets such as reducing the number of zero-dose children by 50% and achieving 90% coverage for essential vaccines globally. IA2030 is organized around seven strategic priorities (including coverage & equity, life-course & integration, outbreak response, etc.) and emphasizes country ownership, partnership, and innovation. It succeeds the Global Vaccine Action Plan (2011–2020) and provides a framework for countries and partners to align their immunization efforts with a focus on equity (leave no one behind) and resiliency of immunization services. |
| 169 | Global Vaccine Action Plan (GVAP) | The global immunization strategy for the decade 2011–2020, endorsed by the World Health Assembly in 2012. GVAP aimed to extend the full benefits of immunization to all by 2020, with targets like reaching 90% national coverage for all vaccines in all countries and introducing new vaccines nationwide. It was developed by WHO, UNICEF, Gavi, and others. GVAP had six strategic objectives, including strengthening routine immunization systems, ensuring equity (like reaching every community), integrating immunization with other health services, and spurring R&D for next-generation vaccines. While progress was made (e.g., reduction in child mortality due to vaccines), GVAP fell short on some goals, coverage plateaued globally in the mid-80%s and multiple polio and measles goals were missed. An independent review committee monitored GVAP and pointed out areas like inadequate funding and gaps in accountability. The lessons from GVAP fed into the design of Immunization Agenda 2030 (IA2030), the next decade’s plan. |
| 164 | Geometric Mean Titer (GMT) | The geometric mean of antibody titers in a group of subjects – a summary statistic commonly used in vaccine studies because antibody titers are typically measured on a logarithmic dilution scale. To compute a GMT, individual titers are log<sub>10</sub>-transformed, the arithmetic mean of the logs is calculated, then converted back by the antilog. This approach downweights very high outliers and ensures a more normal distribution of data. The GMT is often reported with a 95% confidence interval. For instance, if in a vaccine group the individual neutralizing titers are 40, 80, 160, etc., the GMT might be ~80. Researchers use GMTs to compare immune responses between groups (e.g., vaccine vs placebo, or different dose levels). An increase in GMT post-vaccination indicates an overall rise in antibody levels in the cohort. Regulatory criteria for vaccine licensure sometimes include demonstrating a certain GMT ratio compared to an older vaccine. |
| 3 | Accine Intelligence | The gathering and analysis of data (epidemiological, genomic, behavioural) to guide vaccine strategy and policy decisions (contextual term combining many tools above). |
| 317 | Phase I trial | The first stage of testing a new vaccine or therapy in humans, focused primarily on safety. Phase I trials are usually small (tens of healthy adult volunteers) and aim to determine a safe dosage range, identify side effects, and sometimes get an initial read on immune response. “Phase I human clinical trials usually involve 20 to 100 volunteers and focus on detecting serious adverse reactions”. In vaccine Phase I, researchers assess whether the vaccine is well-tolerated and look at basic immunogenicity (though efficacy is not evaluated at this stage). This phase is critical for ensuring it’s reasonable to proceed to broader testing. |
| 318 | Phase I trial | The first stage of human clinical testing of a vaccine, typically involving a small number of healthy volunteers (dozens). Phase I studies focus primarily on safety (checking for adverse reactions) and often also gather preliminary data on immunogenicity (does the vaccine provoke an immune response). These trials may also explore different dose levels. For example, a Phase I trial might test a low, medium, and high dose in 60 adults to see which is safe and immunogenic. |
| 239 | Last-mile vaccine delivery | The final stage of vaccine distribution where doses reach the remote or local clinics and ultimately patients. “Last mile” challenges include transporting vaccines over rough terrain, maintaining cold chain in areas with no electricity, and coordinating storage with local health schedules. Innovations in last-mile delivery include the use of drones to fly vaccines to isolated regions, solar-powered refrigerators in off-grid clinics, and incentivized community health worker networks. Effective last-mile solutions are critical for equity – ensuring the vaccines not only arrive in country but actually get to every community. Monitoring tools like eVIN (electronic Vaccine Intelligence Network) help track stock and cold chain status at the last mile, preventing stockouts or wastage. |
| 406 | Sustainment (Sustainability) | The extent to which an intervention is maintained over time and becomes part of routine practice within an organization or system. |
| 390 | Spillover | The event by which a pathogen maintained in one species (the reservoir) crosses over to infect individuals of another species, leading to new outbreaks in the recipient host population. |
| 73 | Codon optimization | The engineering of a gene’s DNA/RNA sequence to use codons (nucleotide triplets) that are more efficiently translated by the host organism, without changing the amino acid sequence of the encoded protein. Different organisms have preferences for certain codons (codon usage bias); optimizing a gene (for instance, a vaccine antigen gene) for a given expression system can greatly increase protein yield. In practice, “codon optimization is the process of modifying a gene’s codon usage to enhance its expression in a specific host”. For example, mRNA vaccine sequences are codon-optimized for human cells, and DNA vaccine plasmids are codon-optimized to improve antigen production in the vaccine recipient. |
| 87 | Convenience (and access) | The ease with which one can receive a vaccine – including factors like the availability of vaccines near one’s home, the cost (if any), clinic hours, and the cultural acceptability of services. In the 3 Cs model, “convenience” issues are a major contributor to under-vaccination. Even willing parents might not get their child vaccinated if the clinic is too far or wait times are long. Improving convenience means reducing geographic, financial, and time barriers – for example, offering immunization on market days, using mobile clinics in remote areas, integrating services so multiple needs are met in one visit, and ensuring vaccines are free of charge. High coverage in many countries has been achieved by actively bringing vaccination closer to communities (through outreach and periodic campaigns), thus overcoming convenience hurdles. |
| 375 | Seroconversion | The development of detectable specific antibodies in the blood of an individual who was previously antibody-negative for that pathogen. In vaccine trials, “seroconversion” is often defined as either a rise from undetectable to a certain positive titer, or a significant increase (e.g., four-fold) in antibody titer from baseline. It signifies that the person’s immune system has responded to either infection or vaccination by producing antibodies. For example, if a subject had no measles IgG before but has a high titer after vaccination, they have seroconverted. Seroconversion rates (the percentage of subjects who seroconvert) are a key outcome in phase II vaccine studies. However, presence of antibodies (seroconversion) doesn’t always equal protection; the quality and persistence of those antibodies also matter. Still, seroconversion is a useful binary indicator of whether a vaccine “took” in an individual. |
| 374 | Seroconversion | The development of detectable antibodies in the blood of an individual who was previously seronegative (had no antibodies). In vaccinology, seroconversion refers to the immune system’s successful response to a vaccine – for instance, if before vaccination a person has no antibodies to measles, and after vaccination they have measurable antibody titers, they have seroconverted. Many vaccine trials report “seroconversion rates” (the percentage of participants who mount a predefined antibody response). Seroconversion is evidence of an immune response, although the level needed for protection can vary by disease. |
| 225 | Innate immune sensing | The detection of pathogens or danger signals by the innate immune system through germline-encoded pattern recognition receptors (PRRs). Innate immune sensing is the first line of immune defense, wherein cells like dendritic cells, macrophages, neutrophils, and others recognize common molecular motifs associated with pathogens (PAMPs) or with tissue damage (DAMPs). Examples of PRRs include Toll-like receptors (surface or endosomal sensors of microbial molecules), RIG-I-like receptors (cytosolic RNA sensors), NOD-like receptors (cytosolic sensors that can form inflammasomes), and cGAS-STING (cytosolic DNA sensing). Upon recognition of a threat, these sensors trigger signaling pathways that lead to inflammatory cytokine production, interferons, and upregulation of co-stimulatory molecules, thereby activating both local defenses and shaping adaptive immunity. In essence, innate immune sensing provides an immediate, broad response and the necessary context to initiate antigen-specific adaptive responses. |
| 152 | Fidelity | The degree to which an intervention or program is implemented as intended, without omitting or altering core components. |
| 485 | World Health Assembly (WHA) | The decision-making body of the World Health Organization, where all Member States convene annually to set global health policies. The WHA adopts resolutions and targets related to immunization – for example, endorsing the Immunization Agenda 2030 strategic framework, or calling for global eradication of diseases. Vaccine policy-making at the WHA can spur international commitment (such as the resolution for measles elimination goals, or declaring World Immunization Week). The WHA’s support is often critical for mobilizing political will and resources for immunization initiatives worldwide. |
| 12 | Adoption | The decision or action by a stakeholder (e.g. health provider or organization) to employ an effective intervention or practice. |
| 238 | Last-Mile Delivery | The crucial final stage in the vaccine supply chain that ensures vaccines reach their intended communities and recipients, often involving innovative logistics to reach remote or underserved areas. |
| 183 | Herd immunity threshold | The critical proportion of a population that needs to be immune (via vaccination or prior infection) to an infectious disease such that the disease can no longer spread easily within that population. At this threshold (or above), even individuals who are not immune enjoy indirect protection because the chains of transmission are interrupted. The herd immunity threshold (HIT) is related to the pathogen’s basic reproduction number R? by the formula HIT = 1 – 1/R?. For example, if R? is 5, the threshold is 1 – 1/5 = 80% immune needed. “The herd immunity threshold is the proportion of a population that need to be immune in order for an infectious disease to become stable in that community” (i.e., no sustained outbreaks). Achieving this threshold via vaccination is the goal of many immunization programs (for instance, around 95% vaccine coverage for measles is needed given its high R?). If immunity falls below the threshold, outbreaks can occur. Herd immunity thresholds assume a well-mixed population and no other interventions; real-world factors can modify the effective threshold. |
| 94 | COVAX | The COVID-19 Vaccine Global Access Facility – a worldwide initiative co-led by WHO, Gavi, and CEPI to ensure equitable access to COVID-19 vaccines. COVAX is one of the three pillars of the ACT-Accelerator. Its aim has been to pool funds from higher-income countries and donors to finance vaccines for lower-income countries, and to create a global procurement pool so that vaccines are distributed based on need, not just purchasing power. Through COVAX, by 2021–2022, doses were shipped to participating countries (especially the 92 AMC-eligible countries that receive donor-funded doses). COVAX faced challenges (insufficient early supply, export bans, etc.), but it delivered over a billion doses. Importantly, it established the principle of global solidarity for vaccines during a pandemic. COVAX also had to set up a no-fault compensation program for vaccine injuries and navigate complex liability and indemnification deals with manufacturers. While not perfect, COVAX marked the first large-scale attempt at global vaccine sharing during an ongoing pandemic. |
| 455 | Vaccine logistics in pandemics | The COVID-19 experience brought new logistics concepts: ultra-rapid scale-up of manufacturing, dry ice supply chains for ultra-cold shipping, setting up mass vaccination sites (sometimes drive-through), and global allocation mechanisms (COVAX) with their own distribution channels. One challenge was coordinating lot release and tracking for billions of doses, including donations. Another was the reverse logistics of packaging waste (e.g., safe disposal of millions of syringes). Innovations included mega cold storage hubs, flight temperature monitoring, and using military logistics for civilian vaccine distribution in some countries. This highlighted that vaccine logistics is as much about planning and coordination as about equipment – an efficient “last mile” involved scheduling systems (often digital) for appointments to avoid crowds and ensure doses were used optimally each day. |
| 475 | Viral sovereignty | The concept that a nation has sovereign rights over pathogens (viruses, etc.) found within its territory. This term gained prominence in 2007 when Indonesia refused to share H5N1 avian flu samples with WHO, asserting that viral isolates were the country’s property and complaining that shared samples were used to develop vaccines which Indonesia then had to buy. “Viral sovereignty is when individual nations assert that viruses isolated from within their jurisdictions are their sovereign property.”. This stance ties into debates on fairness: developing countries want assurances of access to resulting vaccines or benefits if they share pathogen samples (an equity issue). Critics argue that in a pandemic, delaying or restricting sample sharing endangers global health. The Nagoya Protocol (related to access and benefit sharing of genetic resources) further complicated this landscape by possibly including pathogens. Viral sovereignty versus global common good is a live tension – the pandemic treaty negotiations aim to resolve it by ensuring rapid sharing of pathogens in return for guaranteed access to countermeasures for the source country. |
| 422 | Titers (Antibody titers) | The concentration of antibodies in the blood, usually measured by serial dilution in laboratory tests. A titer is often reported as the highest dilution of serum that still produces a positive test reaction (for example, a titer of 1:160 means antibodies are detectable when the serum is diluted 160-fold). Antibody titers can indicate immunity – for instance, an HBsAg antibody titer ?10 mIU/mL is considered protective for hepatitis B. After vaccination, titers peak then often decline over time; if they drop below a protective threshold, a booster may be recommended. Titer testing is used in healthcare to verify immunity for certain diseases (like measles or hepatitis B in healthcare workers). |
| 26 | Antibody Titer | The concentration of antibodies in blood, typically expressed as the highest dilution of serum that still yields a detectable binding or functional reaction in an assay. For example, a titer of 1:160 in a hemagglutination inhibition test means serum can be diluted 160-fold and still prevent virus-induced RBC clumping. Higher titer = more antibodies. Titers are often reported as geometric mean titers (GMTs) across a group. In vaccine trials, a rise in antibody titer post-vaccination (e.g., 4-fold increase from baseline) indicates seroconversion. Protective thresholds are sometimes defined in terms of titer (e.g., an HAI titer ?1:40 for influenza). Titers are assay-dependent: neutralizing titers (by virus neutralization) and ELISA binding titers are measured differently. They provide a quantitative handle on humoral immunogenicity and are a primary data point for comparing vaccine formulations or dosing regimens. |
| 203 | Immune system | The complex network of cells, tissues, and organs that defends the body against infections and other foreign substances. It includes innate components (e.g. physical barriers, phagocytes, complement) and adaptive components (B cells, T cells, antibodies). The immune system’s primary function is to distinguish self from non-self and eliminate harmful invaders. Vaccines work by safely training the immune system to recognize and combat specific pathogens. |
| 434 | UNICEF Supply Division | The branch of UNICEF responsible for procuring vaccines and related supplies (syringes, cold chain equipment) for low- and middle-income countries. As one of the largest buyers of vaccines in the world, UNICEF leverages economies of scale and competitive tenders to obtain low prices. It manages the supply logistics – from manufacturer to countries – ensuring timely delivery and proper storage. Through mechanisms like its revolving fund and stockpile management, the UNICEF Supply Division has been pivotal in preventing stockouts and enabling the introduction of new vaccines in poorer countries. |
| 193 | Humoral immunity | The aspect of immunity mediated by macromolecules in extracellular fluids, primarily antibodies produced by B cells. In humoral immune responses, antibodies bind pathogens or toxins, neutralizing them and tagging them for destruction. Vaccines are excellent at inducing humoral immunity; for instance, neutralizing antibody titers are a key humoral correlate of protection for many viral vaccines. (Contrast with cell-mediated immunity.) |
| 211 | Immunoinformatics (Computational immunology) | The application of computational methods and bioinformatics to immunology and vaccine development. Key goals include predicting B-cell and T-cell epitopes, modeling antigen-antibody interactions, and analyzing immune response data. Immunoinformatics tools can screen pathogen genomes for epitopes that match human HLA molecules (for T-cells) or have surface exposure (for B-cells), accelerating the design of vaccines and guiding experiments. This field also handles big data from systems vaccinology studies to identify correlates of protection or signatures of immunity. |
| 50 | Blockchain for vaccine supply chain | The application of blockchain technology to create transparent and tamper-proof records of vaccine batches as they move through the supply chain. In a blockchain-based vaccine ledger, each handoff (manufacturer to shipper to warehouse to clinic) and each temperature log could be recorded as a block. This could improve trust and traceability, for example: proving that a vaccine was maintained in range or that a dose administered is authentic and not counterfeit. Some pilot projects (like in Bangladesh and by private firms) have explored blockchain to track COVID-19 vaccine distribution, enhancing data security and enabling smart contracts (automatically triggering reorder when stock is low). While in early stages, such systems may play a role in future global campaigns to ensure real-time visibility and integrity of vaccine deliveries. |
| 212 | Immunosenescence | The age-related decline in immune system function. As people (or animals) age, both the innate and adaptive immune responses undergo qualitative and quantitative changes: T-cell and B-cell populations shrink in diversity, vaccines elicit weaker responses, and baseline inflammation may increase (“inflammaging”). “Immunosenescence is the age-related decline in immune function” marked by diminished protective immunity. Consequences include increased susceptibility to infections (and worse outcomes when infected), reduced vaccine efficacy in the elderly, and possibly higher risk of cancers (due to reduced immune surveillance). Features of immunosenescence include thymic involution (less T-cell output), accumulation of memory and effector T cells with contraction of the naive T-cell pool, decreased B-cell repertoire and antibody affinity in responses, and dysregulated innate cell activity. Understanding immunosenescence guides strategies like adjuvanted or high-dose vaccines for older adults. |
| 136 | Emergency Preparedness (re vaccines) | The advance planning and actions taken to ensure rapid development, approval, and distribution of vaccines in response to a public health emergency (such as a pandemic or bioterrorism event). This includes research programs, platforms that allow quick vaccine design (like mRNA technology), stockpiling of vaccines (e.g., smallpox vaccine), and regulatory mechanisms like EUAs. The COVID-19 pandemic highlighted the importance of vaccine emergency preparedness (e.g., the U.S. Operation Warp Speed program). |
| 439 | Vaccination | The act of administering a vaccine to confer immunity against a disease. This term is often used interchangeably with immunization, though technically vaccination refers specifically to giving the vaccine (for example, an injection or oral dose), whereas immunization refers to the process of becoming immune (which can happen via vaccination or natural infection). The term originates from “vacca,” Latin for cow, after the cowpox material used by Edward Jenner in the first smallpox vaccine. |
| 5 | ACT-Accelerator | The Access to COVID-19 Tools Accelerator, a global collaboration launched in April 2020 to accelerate development and equitable access to COVID-19 vaccines, therapeutics, and diagnostics. It comprised four pillars: Vaccines (COVAX), Therapeutics, Diagnostics, and Health Systems connector. The ACT-A brought together international organizations (WHO, Gavi, CEPI, Global Fund, Unitaid, World Bank, etc.) in an unprecedented effort. Its vaccine pillar, COVAX, we discussed. The therapeutics pillar worked on treatments (like dexamethasone, monoclonals), and diagnostics pillar on expanding testing (like distributing rapid tests). While the ACT-A had successes (billions of dollars raised, large volume of tools delivered), it also faced criticism about speed and scale, and by 2022 plans were in motion to wind it down or transition its functions. Nonetheless, ACT-Accelerator was a landmark in global health cooperation for a pandemic, establishing structures that might be revived or adapted for future emergencies. |
| 102 | Cultural Competence | The ability of healthcare providers and systems to effectively deliver services that meet the social, cultural, and linguistic needs of diverse patient populations. |
| 210 | Immunogenicity | The ability of a vaccine or antigen to provoke an immune response in the body. In vaccine development, immunogenicity typically refers to the magnitude and quality of immune responses (such as antibody titers or T-cell activity) induced by the vaccine. High immunogenicity is generally desired, but it must also be appropriate (e.g., correct antibody type or T-cell profile for protection). Immunogenicity is measured in clinical trials as a surrogate of vaccine effect, but not all immune responses guarantee protection. Factors like age, genetics, and adjuvants can influence a vaccine’s immunogenicity. A vaccine must balance immunogenicity with safety – overly strong reactions can cause adverse effects (see reactogenicity), whereas weak immunogenicity may yield insufficient protection. |
| 403 | Surge Capacity | The ability of a health system to expand quickly beyond normal services to meet an increased demand for care (e.g. during a large outbreak or mass vaccination campaign). |
| 329 | Polyfunctional T cells | T cells (usually CD4? or CD8?) that can produce multiple cytokines simultaneously (for example, IFN-?, TNF-?, IL-2 all together). Polyfunctional T cells are considered a quality marker of a robust cellular immune response. Many effective vaccines (like yellow fever) induce T cells that are polyfunctional. The presence of such cells often correlates with better protection, as they can orchestrate diverse immune functions. In vaccine studies, flow cytometry is used to identify T cells producing 2, 3, or more cytokines at once. Polyfunctionality often goes hand-in-hand with long-lived memory and effective clearance of pathogens. Vaccine researchers aim to elicit these cells, especially for diseases where T-cell immunity is key (HIV, TB, malaria). |
| 74 | Cognitive Biases | Systematic patterns of deviation from rational judgment (e.g. confirmation bias), which can influence how people perceive and respond to health information (no single-citation definition provided). |
| 188 | Horizon Scanning (Scanning) | Systematic examination of information and early signals (e.g. scientific publications, news, technology trends) about potential threats and opportunities, to anticipate changes in vaccine and disease landscapes. |
| 107 | Deepfake (Media) | Synthetic media (audio, images, video) created or altered by AI to convincingly mimic real individuals or events, posing risks for disinformation campaigns (conceptual threat) |
| 254 | Machine Learning & Deep Learning (in Immunology) | Subsets of AI particularly relevant to computational vaccinology. Machine learning refers to algorithms that learn from data to make predictions or classifications – for example, support vector machines or random forests used to classify peptides as binders vs. non-binders to an MHC allele. Deep learning uses neural network architectures with many layers (deep neural nets) to automatically learn complex features; these have achieved unprecedented accuracy in tasks like protein structure prediction (e.g. DeepMind’s AlphaFold) and B-cell epitope mapping. Deep learning models (such as autoencoders or transformers) can capture the subtle sequence and structural characteristics that make an epitope immunogenic. Together, machine learning and deep learning are now core tools in immunoinformatics, enabling data-driven vaccine design that continuously improves as more immunological data become available. |
| 337 | Priority groups | Sub-populations identified to receive vaccines first or on a priority basis, usually because they are at higher risk of disease or are critical to the pandemic response. Common priority groups include healthcare and frontline workers (high exposure risk), the elderly and those with chronic illnesses (high risk of severe outcomes), and other essential workers. Defining priority groups is a key aspect of vaccine policy during constrained supply or initial rollout of a new vaccine (e.g., COVID-19). SAGE and national immunization committees issue guidance on priority groups to ensure the limited doses available are used to achieve the greatest health impact and to protect the most vulnerable or critical portions of society. Prioritization plans must also consider equity so that underserved groups within those categories are effectively reached. |
| 198 | Immune evasion | Strategies utilized by pathogens (or tumor cells) to avoid detection or elimination by the host’s immune system. This broad term encompasses antigenic variation, molecular mimicry, inhibition of antigen presentation, resisting complement or phagocytosis, hiding in latent form, suppressing immune cell function, etc. Essentially, it is any mechanism that allows an invader to “evade the biological mechanisms of recognition or defense by the immune system”. Examples include: viruses like cytomegalovirus downregulating MHC molecules, HIV hiding in latent reservoirs and mutating rapidly, tumors expressing PD-L1 to suppress T cells, or parasites like schistosomes coating themselves in host proteins. Immune evasion tactics are critical determinants of pathogen persistence and disease chronicity, and understanding them guides vaccine and therapeutic development. |
| 195 | Implementation Strategies | Specific methods or techniques (e.g. training, reminders, workflow redesign) used to enhance adoption, implementation, and sustainment of evidence-based practices. |
| 127 | Echo Chamber | Social or online environments where individuals predominantly encounter information or opinions that mirror and reinforce their own beliefs, reducing exposure to differing viewpoints. |
| 365 | RNA Aptamers | Short single-stranded RNA molecules (often 30–100 bases) selected from random libraries for high-affinity binding to specific targets (proteins, small molecules, etc.). Aptamers fold into unique 3D structures, acting like “chemical antibodies.” They can block protein function or deliver payloads. An example is pegaptanib, an RNA aptamer drug that binds VEGF to treat macular degeneration. |
| 98 | CpG motifs | Short DNA sequence motifs consisting of an unmethylated cytosine followed by guanine in a phosphate-linked sequence (“CpG” dinucleotides) that have immunostimulatory properties. CpG motifs are recognized as danger signals by the innate immune system (via Toll-like receptor 9 in endosomes) because they are common in bacterial and viral genomes but relatively rare and often methylated in vertebrate DNA. “Unmethylated CpG motifs” in DNA act as pathogen-associated molecular patterns that trigger immune activation. Synthetically produced CpG oligodeoxynucleotides are used as vaccine adjuvants to stimulate a Th1-biased immune response. In the context of DNA vaccines, incorporating CpG motifs into plasmids can enhance the vaccine’s immunogenicity by activating innate responses. |
| 378 | Serosurvey (Seroprevalence Study) | Serosurveys are done by collecting blood samples from a representative sample of the population and performing serological tests. They help infer past infection rates, immunity gaps, and the impact of vaccination programs. For example, a serosurvey might find that 95% of adults have antibodies to measles (due to vaccination), but only 70% of infants do – indicating a need to boost coverage. During pandemics, serosurveys have been crucial to estimate true infection spread (including asymptomatic cases) by checking how many people developed antibodies. In vaccine evaluation, serosurveys can also assess herd immunity levels or identify pockets of susceptibles in a community. |
| 65 | Chickenpox | See Varicella. (Chickenpox is the common name for varicella, a contagious disease caused by varicella-zoster virus) |
| 493 | Zoster vaccine | See Shingles. (Two zoster vaccines have existed: Zostavax, a live attenuated zoster vaccine, and Shingrix, a recombinant subunit zoster vaccine. The latter is now preferred due to higher efficacy. Both aim to boost varicella-zoster immunity in older adults to prevent shingles.) |
| 184 | Herpes zoster | See Shingles. (Herpes zoster is the medical name for shingles, the reactivation of latent varicella-zoster virus.) |
| 234 | Killed vaccine | See Inactivated vaccine. (A “killed” vaccine is another term for an inactivated vaccine, in which the pathogen has been rendered non-infectious. The Salk polio vaccine, for example, is a killed virus vaccine.) |
| 461 | Vaccine schedule | See Immunization schedule. (The recommended timing and spacing of vaccines for different age groups to provide optimal protection.) |
| 302 | Original antigenic sin | See Immune imprinting. (This older term is synonymous with immune imprinting – the glossary entry on immune imprinting covers this concept.) |
| 186 | Hib | See Haemophilus influenzae type b. |
| 157 | Fractional dose | See Dose-sparing. (A fractional dose refers to using a portion of the full vaccine dose to vaccinate more people when supply is limited, with evidence suggesting adequate immunity from the smaller dose.) |
| 72 | Herd immunity | See Community immunity. (The term “herd immunity” refers to community-level protection that arises when a high percentage of the population is immune, indirectly protecting those who are not immune.) |
| 248 | Live vaccine (Live attenuated vaccine) | See Attenuated vaccine. (A vaccine prepared from live microbes that have been attenuated to remove their virulence, while retaining their ability to replicate to a limited extent in the host. Live vaccines elicit strong, long-lasting immune responses often after one dose, but must be used with caution in pregnant or immunosuppressed individuals.) |
| 163 | Genomic Surveillance | Routine sequencing of pathogen genomes to track genetic changes (mutations) in viruses/bacteria, enabling the identification of new variants and monitoring of their spread. |
| 270 | Monitoring & evaluation in immunization | Robust M&E systems are essential to track progress and guide decisions. Key monitoring indicators include vaccination coverage rates (e.g., the percentage of children receiving DTP3 by age 1, which is a classic benchmark), dropout rates (difference between first and third dose coverage indicating program continuity), and surveillance indicators (like % of suspected cases tested). Newer metrics introduced include the number of zero-dose children (for equity) and coverage equity indices (coverage in the poorest quintile vs richest, etc.). Tools like WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) provide annual estimates that sometimes adjust official reported data. The IA2030 Scorecard publicly displays progress on goals. For evaluation, periodic EPI Reviews or Effective Vaccine Management (EVM) assessments check program quality. Programmatically, data use at local level (like monthly coverage monitoring charts) helps pinpoint pockets of low coverage for corrective action (e.g., an underperforming health post). In recent years, there is emphasis on real-time monitoring using electronic registries or mobile apps, which can improve timeliness of interventions (like identifying a district where coverage is lagging mid-year and doing an outreach push there). The COVID-19 vaccine rollout accelerated adoption of digital systems for tracking adult vaccination, which might carry over to routine programs. |
| 417 | Therapeutic Ribozymes | RNA molecules with catalytic activity used to cut or alter specific RNAs. Engineered ribozymes (e.g. hammerhead ribozymes) can be designed to cleave disease-related RNAs, thereby inactivating them. Although ribozyme drugs have been less common than ASOs or siRNAs (due to delivery challenges), they represent an early form of RNA therapeutic exploiting RNA’s enzymatic potential. |
| 333 | Preclinical studies | Research conducted to assess a vaccine or drug candidate’s safety, toxicity, and biological activity before it is tested in humans. Preclinical studies include in vitro experiments (e.g., cell culture studies) and in vivo experiments in animal models. For vaccines, preclinical evaluation often involves demonstrating immunogenicity (does it provoke an immune response in animals?) and preliminary efficacy (does it protect the animal from a challenge infection?) as well as safety (checking for any pathological changes or toxic effects in animals). Only if preclinical results are favorable can a product advance to clinical (human) trials. As noted, “vaccines undergo extensive safety and efficacy evaluations in the laboratory and in animals, in sequential phases, prior to licensure”. These studies must comply with regulatory standards (e.g., GLP – Good Laboratory Practice). Preclinical data form the backbone of an IND application to authorities like the FDA to authorize human trials. |
| 151 | Febrile | Relating to fever. A febrile response means an elevated body temperature. After vaccination, some individuals (especially children) may have a febrile reaction (fever) as part of the immune response. Febrile seizures in infants can be a side effect of fever from any cause, including post-vaccine fever (e.g., after MMR or flu vaccine), but these seizures are typically rare and not harmful long-term. |
| 389 | Solar-powered cold chain equipment | Refrigerators and freezers that run on solar energy, often with battery storage or with “ice-lined” designs to maintain cooling overnight. These have been game-changers for remote clinics off the electrical grid. WHO certifies certain solar direct-drive fridges that can keep vaccines at 2–8°C using only solar panels, a big improvement from older kerosene fridges. Widespread deployment of solar fridges in sub-Saharan Africa and Asia has expanded the reach of routine immunization by equipping health posts in villages with reliable cooling. They require adequate sun exposure and maintenance, but eliminate dependency on fuel or intermittent grid power. Coupled with remote monitoring, supervisors can see if a solar unit has issues (like dust on panels or component failure) before vaccines spoil. |
| 416 | Th1/Th2 Response (T-Helper Polarization) | Refers to the pattern of CD4? T helper cell responses, which can skew toward a Th1-type or Th2-type profile, each characterized by different cytokines and immune effects. A Th1 response is dominated by cytokines like IFN-?, IL-2, and TNF-?, and it activates macrophages and cytotoxic T cells – important for immunity against intracellular pathogens (viruses, some bacteria) and for strong cellular immunity. A Th2 response is characterized by IL-4, IL-5, IL-13, and promotes B cell antibody production (especially IgE and certain IgG subclasses), eosinophil activation, and is effective against parasites and for mucosal antibody responses, but can contribute to allergies. Vaccines may preferentially induce Th1 or Th2 responses depending on their formulation and adjuvants. For instance, the BCG vaccine induces a Th1-skewed response (desired for tuberculosis). Alum adjuvant often leads to a Th2-biased response with strong antibody production. The Th1/Th2 balance can influence vaccine efficacy and safety – excessive Th2 can theoretically lead to allergic phenotypes or ineffective immunity for certain diseases (e.g., the old formalin-inactivated RSV vaccine caused an imbalanced Th2 response linked to enhanced disease). Modern adjuvants like AS01 intentionally drive a Th1 response for pathogens like malaria or shingles. Thus, understanding and tuning Th polarization is a component of rational vaccine design to match the immune response to the pathogen’s requirements. |
| 296 | Novel vaccine platform | Refers to new technologies for vaccines, such as mRNA vaccines, DNA vaccines, viral vector vaccines, VLP (virus-like particle) vaccines, etc., beyond the traditional live-attenuated or inactivated approaches. These novel platforms can accelerate development (as seen with mRNA COVID vaccines) and sometimes induce different immune profiles. For instance, viral vector platforms (like the adenovirus vectors) and nucleic acid platforms (mRNA/DNA) are being explored for many diseases due to their flexibility and speed of design. |
| 6 | Active Immunity | Protective immunity generated by the person’s own immune system in response to an antigen, as opposed to passive transfer of immunity. Active immunity can be acquired through natural infection or through vaccination. When active immunity is induced, the immune system will produce an adaptive response (antibodies, memory B and T cells), which usually confers long-lasting protection, often for years or a lifetime, especially after certain infections or multiple vaccine doses. For example, contracting measles or receiving the measles vaccine typically yields active immunity that prevents future measles illness. Active immunity might take weeks to develop after first exposure (time for immune activation and maturation). Vaccination is essentially an attempt to induce active immunity without the harm of disease. In contrast, see passive immunity where pre-formed antibodies are provided. Active immunity may sometimes wane, necessitating boosters, and it might not protect against all strains (if the antigen changes). |
| 204 | Immunity | Protection against a disease, indicated by the body’s ability to quickly control or eliminate the infection before illness occurs. Immunity can be active (generated by the person’s own immune system after infection or vaccination) or passive (conferred by antibodies made elsewhere and transferred, e.g. maternal antibodies or immune globulin). The presence of specific antibodies or memory immune cells is evidence of immunity. Effective vaccines aim to induce long-lasting immunity. |
| 156 | Formative Evaluation | Ongoing assessment during program development or implementation to provide feedback for improvement, focusing on feasibility, acceptability, and initial effectiveness. |
| 297 | Off-target effects (of vaccines) | Non-specific effects of vaccines that are not directly related to immunity against the target disease. Some epidemiological observations have suggested that certain vaccines (like measles or BCG) might reduce all-cause mortality beyond their intended protection, possibly by training the immune system in broad ways. These are sometimes called “off-target” or “non-specific” effects. Research is ongoing, and this remains a debated area. |
| 392 | Stock management and transparency systems | Modern immunization programs utilize electronic stock management systems (like eVIN mentioned above, or simpler SMS reporting tools) to know exactly what quantity of each vaccine is available at each location. This prevents stockouts (where a clinic runs out of a needed vaccine) and gluts (where too much stock leads to expiry). Systems may also track batch numbers for traceability (important if a batch is recalled or for investigating AEFIs). Gavi and WHO promote such systems as part of immunization supply chain optimization, including dashboards that can be viewed at district, national, and global levels for vaccine flows. During COVID-19, transparency systems were developed to track donations and deliveries (e.g., the COVAX stock dashboard) to ensure vaccines reached intended countries and were used before expiry. |
| 291 | Next-generation adjuvants | Modern adjuvants designed to precisely modulate the immune response to vaccines. Classical adjuvants like aluminum salts (alum) mainly enhance antibody production (Th2-biased). New adjuvants target innate immune receptors (TLRs, cGAS-STING pathway, etc.) to shape the adaptive response. Examples include TLR agonists like CpG Oligodinucleotide (TLR9 agonist) used in Hepatitis B vaccine (Heplisav-B), AS01 (used in the Shingrix vaccine, contains MPL – a TLR4 agonist – plus QS-21 saponin, driving strong Th1 responses), and AS03 (squalene emulsion with tocopherol, used in some influenza and COVID vaccines to broaden response). Another example is Matrix-M, a saponin-based nanoparticle adjuvant in Novavax’s COVID-19 vaccine. Advanced adjuvants can promote cytotoxic T-cell responses or mucosal IgA, etc., depending on the need. They are critical for vaccines against challenging pathogens (TB, HIV, malaria) where just an antibody response isn’t enough. |
| 263 | Messenger RNA (mRNA) Therapeutics | Medical use of synthetic mRNA molecules to direct cells to produce a therapeutic protein. Unlike DNA therapies, mRNA does not need to enter the nucleus or integrate into the genome (avoiding insertional mutagenesis). mRNA therapeutics can encode enzymes, cytokines, or other proteins for treating diseases (e.g. metabolic disorders, cancer), effectively turning the body’s cells into temporary “factories” for the desired protein. |
| 90 | Correlates of protection | Measurable immune parameters that statistically correlate with protection against infection or disease. A correlate of protection (CoP) is typically an antibody titer or cellular immunity measure that, when above a certain threshold, indicates an individual is protected. For example, neutralizing antibody levels are a well-known correlate of protection for many viruses, higher titers often equate to lower infection risk. CoPs are vital for vaccine development and regulatory approval because they can serve as s+B165urrogates for efficacy, allowing immunobridging trials (e.g., approving a vaccine for a new age group by showing it raises antibodies to the same level as in adults). Identifying a solid correlate (or surrogate endpoint) streamlines vaccine updates and comparisons, though not all diseases have clear correlates (HIV being a notable example where correlates remain elusive). |
| 253 | Lyophilized vaccine and diluent management | Many vaccines are freeze-dried (lyophilized) to improve their stability at higher temperatures, but they require reconstitution with a diluent before administration (e.g., measles vaccine). A logistics consideration is that lyophilized vaccines often tolerate heat better in powder form, but once reconstituted (mixed), they must be kept cold and used within a short time (usually 6 hours). Programs must ensure availability of the correct diluent with the vaccine and train staff in proper reconstitution. While lyophilization helps with storage, it adds steps at point of use. Some innovations aim to produce liquid stable formulations to avoid this, but lyophilized formats remain common for less stable vaccines. |
| 260 | Measles and rubella elimination goals | Many regions of the world set targets to eliminate measles and rubella, leveraging high childhood immunization coverage and supplementary campaigns. Elimination is defined as interruption of endemic transmission in a region for at least 12 months (with robust surveillance). While some regions (like the Americas in 2016) declared measles eliminated, gaps in vaccination and importations led to re-establishment of transmission. Measles is so contagious that it demands >95% two-dose coverage to halt spread. The global community under GVAP had goals for measles elimination in at least 5 of 6 WHO regions by 2020 – which were not met. Rubella (and congenital rubella syndrome) is targeted alongside measles because it uses the same combined MMR vaccine platform. These goals drive policy – countries introduce second dose of measles vaccine, do periodic catch-up campaigns, and enhance surveillance (every suspected measles rash illness should be investigated and tested). While not yet achieved, measles elimination remains a barometer of immunization program strength; setbacks in measles control often highlight broader weaknesses (like declining coverage or hesitancy). |
| 224 | Infoveillance | Longitudinal monitoring of information (e.g. social media trends, search queries) as an informal surveillance system to detect and track health events and misinformation. |
| 215 | Implementation Outcomes | Key effects of deliberate efforts to use a new practice (e.g. acceptability, feasibility, adoption, reach, fidelity, sustainability) that signal implementation success. |
| 168 | Global surveillance of vaccine-preventable diseases | International monitoring systems track incidence of diseases like polio, measles, rubella, yellow fever, etc., to inform vaccination efforts. For example, the Global Polio Eradication Initiative (GPEI) runs a massive surveillance network for acute flaccid paralysis (to catch polio cases) and environmental surveillance (testing sewage for poliovirus). Rapid detection allows for targeted immunization responses (polio campaigns when virus is found). Similarly, measles surveillance (including lab confirmation of strains) helps identify gaps in immunity and guide supplementary immunization activities. Integrated Disease Surveillance in many countries combines routine case reporting with outbreak investigation. The data flows to WHO and partners, enabling global reports (like “measles cases up 30% this year, signaling immunity gaps”). This monitoring is essential to achieve and sustain control/elimination – it provides the feedback loop to vaccination programs. With COVID-19, many surveillance systems were repurposed or strained, and now there’s an effort to restore and improve VPD surveillance (e.g., using some of the molecular testing capacity built for COVID to also test for diseases like influenza, measles, etc.). Surveillance and immunization go hand in hand – one identifies where vaccines are needed, the other provides the protection. |
| 364 | Risk–benefit analysis | In vaccine policy, the assessment of the benefits of vaccination (e.g., disease cases and complications prevented) versus the potential risks (e.g., side effects). All vaccines undergo rigorous risk–benefit analysis during development and by regulatory authorities. For instance, if a vaccine has a very rare serious adverse event (say 1 in 100,000) but prevents a life-threatening disease in 1 in 1,000 people, the benefit vastly outweighs the risk. Risk–benefit analyses are revisited if new safety data emerge. During emergencies, EUAs rely on a favorable risk–benefit balance in the context of the urgent need. Clear communication of this analysis is important for public trust (e.g., explaining that the small risk of an adverse event is far outweighed by the protection the vaccine offers). |
| 173 | Graduation/Transition (from donor support) | In vaccine financing, graduation refers to a country phasing out of eligibility for external subsidies (like Gavi support) as its economy grows, transitioning to fully self-financed immunization. During the transition period, countries are expected to increase domestic funding for vaccines year by year. The goal is to ensure that when aid ends, the country can sustain high immunization coverage with its own resources. Successful transition requires careful planning, political commitment, and often a dedicated immunization budget line to avoid any backsliding in coverage. |
| 341 | Public health emergency | In the vaccine context, this refers to a situation such as a pandemic or outbreak where normal healthcare resources are strained and special measures (like EUAs, mass vaccination campaigns, travel restrictions) are implemented to control the spread. During public health emergencies, vaccine development and deployment may be expedited, and agencies like WHO may declare a Public Health Emergency of International Concern (PHEIC) (as was done for polio in 2014, Zika in 2016, COVID-19 in 2020, etc.) to mobilize global action. |
| 360 | Return on Investment (ROI) | In the vaccine context, ROI is the ratio of economic benefits gained to costs incurred for immunization. It captures the broader value of vaccination, including healthcare costs averted, productivity gains, and other societal benefits. Studies have found routine immunization to yield a very high ROI – for example, WHO estimates a return of about $44 for every $1 spent when accounting for broader social and economic benefits. Such analyses underscore that immunization is not only life-saving but economically advantageous for societies. |
| 231 | Investigational New Drug (IND) | In the United States, an IND is an application submitted to the FDA seeking permission to start clinical trials of a new drug or biologic (including vaccines) in humans. It contains data from preclinical testing, manufacturing information, and protocols for proposed clinical studies. An IND must be cleared (or allowed to proceed) before a candidate vaccine or therapy can be tested in people. It is literally a “request for authorization from the FDA to administer an investigational drug to humans”. The IND process ensures that there are sufficient safety data (typically animal toxicity studies) and quality controls in place to justify human testing. In common language, when a product is “in IND stage,” it means it’s in clinical trials. Related, after trials, a Biologics License Application (BLA) or New Drug Application (NDA) is submitted for approval to market the product. |
| 428 | Transparency in clinical trials and data sharing | In the context of vaccine R&D and approval, transparency refers to making protocols, results, and safety data publicly available. This became a major point during COVID-19: regulators and companies released trial protocols (which is uncommon) to build public trust, and Phase III results were published or reported in detail through press releases and journals. Additionally, WHO coordinated a Solidarity Trial for vaccines where multiple candidates would be tested with a common protocol, and data pooled – an approach to increase efficiency and transparency. Sharing of genomic data of the virus (via GISAID) and post-market surveillance data between countries was also unprecedented. Transparency extends to procurement: some contracts between governments and vaccine manufacturers remained secret, drawing criticism. Advocates argue that publishing contracts, prices, and trial data is crucial for accountability and to allow scientists to conduct independent analyses (for example, analyzing raw trial data to verify efficacy). This experience may set new norms where at least during public health emergencies, a higher level of openness is expected. |
| 80 | Complacency (regarding vaccines) | In the context of vaccine hesitancy, complacency refers to a scenario where perceived risks of vaccine-preventable diseases are low, and vaccination is not deemed a necessary or high-priority action. For instance, in a community that has not seen measles for years, some might become complacent, thinking the disease is no longer a threat, leading to lower vaccination uptake. Complacency can arise from successful disease control (the very success of vaccines can breed apathy) or from lack of awareness. Addressing complacency involves education about the continued risk of diseases and emphasizing the benefits of vaccination for maintaining disease elimination and protecting future generations. |
| 158 | Freeze prevention and the “Shake Test” | In the cold chain, freezing is as dangerous as heat for some vaccines (especially those containing aluminum adjuvant, like DTP, which are ruined if frozen). Freeze prevention methods include using freeze-safe ice packs (conditioned packs that are allowed to warm to 0°C before use) and installing freeze guards in refrigerators. The Shake Test is a field test to check if a suspect vaccine vial (like one that might have been frozen) has been damaged: the vial is shaken and observed – if the adjuvant has aggregated (due to freezing) the vial’s content will clump and settle rapidly compared to a fresh vial. This simple test helps workers avoid using potency-lost vaccines. Modern cold chain equipment also increasingly has freeze protection (some new fridges are “solar direct drive” and maintain stable temps with no freezing risk). |
| 310 | Passive immunity | Immunity conferred by transferring antibodies from an outside source, rather than the individual’s own immune system making them. Passive immunity provides immediate, short-term protection. Examples: maternal antibodies passed to a baby (transplacentally or through breast milk) provide passive immunity to newborns, and administration of monoclonal antibodies or immunoglobulin (like rabies Ig after a bite, or antitoxin for diphtheria) provides passive immunity. Passive immunity wanes as the antibodies degrade (weeks to months). |
| 275 | Mucosal immunity | Immune responses that occur at mucosal surfaces (such as the lining of the respiratory, gastrointestinal, and genitourinary tracts), which are the primary entry points for many pathogens. Mucosal immunity is characterized by specialized immune structures (e.g., Peyer’s patches in gut, tonsils), immune cells (like mucosal dendritic cells), and immunoglobulin class IgA in its secretory form (sIgA). Secretory IgA is the hallmark antibody of mucosal immunity; it can neutralize pathogens in the lumen without causing inflammation. “Mucosal immunity depends to a large extent on secretory IgA, an antibody that coats mucosal surfaces… and can protect against infection at those sites”. A strong mucosal immune response (for instance, from an intranasal or oral vaccine) can prevent infection at the portal of entry by inducing local IgA, tissue-resident memory T cells, etc. Mucosal immunity often operates somewhat independently of systemic immunity – for example, high serum IgG might not equate to high IgA in bronchoalveolar fluid. Vaccines like the oral polio vaccine or intranasal flu vaccine specifically aim to elicit mucosal immunity. |
| 24 | Anti-vector immunity | Immune responses directed against a vaccine’s delivery vector (such as a viral vector), which can reduce the vaccine’s effectiveness. If an individual has pre-existing immunity to the vector (e.g. a common adenovirus), the immune system may neutralize the vector before it delivers the antigen. This “so-called ‘anti-vector immunity’” can cause the immune system to recognize and destroy a viral vector before it delivers its payload, meaning the vaccine may not work. Anti-vector immunity is a challenge for viral-vector booster shots, and strategies like using less common serotypes or heterologous vectors are employed to mitigate it. |
| 60 | Cell-mediated immunity | Immune protection mediated primarily by T cells and other immune cells, rather than antibodies. In cell-mediated immunity, cytotoxic T lymphocytes, helper T cells, natural killer cells, and macrophages play key roles in recognizing and destroying infected cells or cancer cells. This arm of the adaptive immune system is crucial for defense against intracellular pathogens (like viruses) and does not involve antibody production. (Compare humoral immunity.) |
| 262 | Meningococcal disease | Illness caused by Neisseria meningitidis (meningococcus) bacteria. It often refers to meningococcal meningitis or septicemia. Several serogroups (strains defined by capsule antigens) cause disease globally, notably A, B, C, W, Y. Meningococcal disease can progress rapidly and be fatal. Meningococcal vaccines are of two main types: conjugate vaccines (covering ACWY serogroups) and recombinant protein vaccines (for serogroup B). These vaccines are recommended for adolescents in many countries and for high-risk groups, and they have significantly reduced incidence of meningitis in vaccinated populations. |
| 187 | HIV/AIDS | Human Immunodeficiency Virus (HIV) is the virus that causes Acquired Immune Deficiency Syndrome (AIDS). There is currently no licensed HIV vaccine, although research is active. People with HIV (especially untreated) have compromised immune systems and are at higher risk for certain infections, so additional vaccines (like pneumococcal, meningococcal, Hib, and HPV vaccines) and booster doses are often recommended. HIV infection is a contraindication for live attenuated vaccines only if the person is severely immunosuppressed; otherwise, many vaccines are indicated to protect immunocompromised individuals. |
| 130 | Effectiveness (Vaccine effectiveness) | How well a vaccine performs in real-world conditions at preventing outcomes of interest (infection, disease, hospitalization, etc.). Effectiveness is assessed through observational studies after a vaccine is deployed to the public. It can differ from efficacy due to population differences and “field” conditions (e.g., adherence, storage issues). For instance, a COVID-19 vaccine with 95% efficacy in trials might show a slightly lower effectiveness in the general population due to logistics and variant changes. |
| 299 | Open vial policy | Guidelines that allow certain multi-dose vaccine vials to be used in multiple sessions over a period of time after opening, rather than discarded at the end of a session. WHO’s open vial policy (OVP) applies to vaccines that do not contain preservative yet have been shown to remain stable and sterile for a time post-opening (many lyophilized vaccines must be discarded within hours after reconstitution, but some liquid vaccines in multi-dose vials can be kept). For example, WHO extended the open vial policy to allow using opened vials of HPV, PCV, and other vaccines in subsequent sessions up to 28 days, provided proper handling (if they contain preservative). This policy significantly reduces vaccine wastage. It requires training health workers on dating opened vials and storing them correctly. Open vial policy is a simple but impactful practice in vaccine logistics that saves cost and increases availability without compromising safety. |
| 268 | Misinformation | False or inaccurate information shared without intent to mislead; those who share it may believe it is true. |
| 115 | Disinformation | False information deliberately created or disseminated with the intent to deceive, mislead, or harm. |
| 105 | Danger-associated molecular patterns (DAMPs) | Endogenous molecules released by stressed or dying cells that signal tissue damage and trigger innate immune responses. DAMPs (also known as alarmins) can include proteins like HMGB1, heat-shock proteins, ATP, DNA, mitochondrial molecules, etc., that are normally hidden inside cells but are exposed during cell injury. The immune system recognizes DAMPs via pattern recognition receptors, similar to how it recognizes PAMPs, leading to inflammation and repair processes. In short, “danger-associated molecular patterns are host-derived molecules that can initiate and perpetuate immune responses following cellular damage or stress”. DAMP detection underlies phenomena like sterile inflammation (in absence of infection) – for example, uric acid crystals acting as DAMPs in gout, or HMGB1 released in tissue injury alerting the immune system. |
| 458 | Vaccine passports (digital health certificates) | Documentation (often digital/mobile app-based) proving one’s vaccination status, used to enable international travel or entry into certain venues during outbreaks. COVID-19 saw the rollout of the EU’s Digital COVID Certificate and similar systems, which show if someone is vaccinated (or tested/recovered). Vaccine passports raised policy and ethical debates: proponents noted they could safely reopen travel and economies by reducing transmission risk; opponents raised concerns about equity (people without access to vaccines would be disadvantaged) and privacy. Historically, an international “vaccine passport” exists for yellow fever – under the IHR, travelers to certain countries must show the WHO “Yellow Card” with proof of yellow fever vaccination. The new twist was using QR codes and interoperable databases for COVID. In global health law, discussions are ongoing about whether such digital certificates should be part of future IHR revisions (WHO is working on a digital certification framework). The challenge is balancing disease control with individual rights and global consistency (for instance, which vaccines are recognized, as not all countries used the same vaccines). |
| 140 | Endemic | Describing a disease or pathogen that is constantly present in a certain geographic area or population at a baseline level. An endemic disease (such as varicella in many countries before widespread vaccination) has a steady state of occurrence. For example, malaria is endemic in parts of Africa. Endemic contrasts with epidemic (a surge above baseline) and pandemic (global epidemic). |
| 7 | Adaptation | Deliberate modification of an evidence-based practice to improve its fit with specific contexts while maintaining core components. |
| 370 | Scale-up | Deliberate efforts to expand the reach of an intervention (e.g. a new vaccine strategy) to a wider population or more settings in order to impact public health. |
| 453 | Vaccine hesitancy | Delay in acceptance or refusal of vaccines despite availability of vaccination services. Vaccine hesitancy is complex and context-specific, varying across time and place. It is influenced by factors such as complacency (perceived low risk of disease), convenience (access to vaccines), and confidence (trust in vaccine safety and efficacy and in health systems. WHO has identified vaccine hesitancy as a significant threat to global health, as it can lead to decreased coverage and resurgence of diseases. Combating hesitancy involves community engagement, education, and addressing misinformation. |
| 128 | Economies of scale | Cost advantages that arise when vaccines are produced or procured in larger volumes. High-volume orders or manufacturing runs can reduce the cost per dose (through spreading fixed costs and bulk discounts). In global vaccine supply, leveraging economies of scale – for instance via UNICEF’s bulk procurement on behalf of many countries – has been critical in driving down vaccine prices (as seen with drastically lower prices for high-volume purchases of vaccines like the pentavalent shot). |
| 388 | Social Mobilization | Coordinated efforts to engage and involve all segments of society (e.g. community leaders, NGOs, media) to build demand for vaccination and create supportive environments for immunization. |
| 309 | Passive cooling devices | Containers that keep vaccines cold without electricity, using ice packs or phase-change materials. Examples include vaccine carriers and cold boxes used in the field. Health workers might pack daily vaccine supplies in a small insulated vaccine carrier with conditioned ice packs to maintain 2–8°C throughout an immunization session. For longer transport, larger cold boxes can hold vaccines at safe temperatures for 2–5 days (depending on ambient conditions), useful for outreach to areas without refrigeration. Newer passive devices use advanced phase-change materials that can maintain stable temperatures without the risk of freezing (certain materials melt at, say, +5°C and absorb heat to hold that temperature). These devices are crucial for extending vaccines beyond the reach of fridges – essentially mobile pieces of cold chain. They are relatively “low-tech” but must be correctly prepared (e.g., ice packs properly frozen or conditioned). |
| 313 | Pathogen-associated molecular patterns (PAMPs) | Conserved molecular structures common to many pathogens (and not present, or with distinct features, in the host) that are recognized by the innate immune system’s pattern recognition receptors. PAMPs are signatures of microbial invaders – examples include lipopolysaccharide (LPS) of Gram-negative bacteria, peptidoglycan and lipoteichoic acid of Gram-positive bacteria, flagellin, unmethylated CpG DNA, double-stranded RNA of viruses, fungal beta-glucans, etc. They are “conserved molecular structures found on pathogens that are recognized by the innate immune system”. Recognition of PAMPs by PRRs (like Toll-like receptors, NOD-like receptors, etc.) triggers immediate innate responses such as inflammation and interferon production. PAMPs essentially alert the host to the presence of “foreign” material. Because they are fundamental to pathogen survival (e.g., LPS is needed for bacterial outer membrane integrity), they are not easily mutated just to evade the host, making them reliable indicators of infection. |
| 407 | Synergistic Forecasting | Combining multiple models or data sources to improve prediction of outbreak trajectories or vaccine needs (conceptual term in forecasting). |
| 91 | Correlates of vaccine-mediated immunity | Beyond the classic correlates of protection, researchers examine systems biology correlates or composite signatures. These can include gene expression patterns (“transcriptional correlates”), polyfunctional T-cell profiles, or particular memory B cell frequencies that associate with protection or with adverse outcomes. For example, a certain ratio of antibody subtypes or an Fc receptor-binding profile might correlate with reduced risk of infection (this is part of systems serology). By identifying such complex correlates, we gain insight into what immune features a vaccine should strive to induce. An example from systems serology: in HIV vaccine trials, the presence of IgG that engaged NK cell receptors correlated with lower infection rates, suggesting that antibodies leveraging innate immune cell killing (ADCC) were beneficial. |
| 266 | MicroRNA (miRNA) Therapeutics | Approaches targeting microRNAs – the 22-nt non-coding RNAs that post-transcriptionally regulate gene expression. Strategies include miRNA mimics (to restore a beneficial miRNA lost in disease) and antagomirs (antisense inhibitors of overactive miRNAs). By modulating miRNA networks, these therapies aim to adjust entire gene pathways (e.g. in cancer or fibrosis). |
| 279 | Nanoparticle vaccine | Any vaccine that uses nanoparticles as carriers or antigen display scaffolds. This broad category includes lipid nanoparticles (for mRNA) as well as protein or polymer nanoparticles that present antigens in dense arrays. For example, some nanoparticle vaccines arrange multiple copies of a viral epitope on a self-assembling protein nanoparticle to mimic a virus (such as nanoparticle flu vaccines displaying hemagglutinin spikes). Nanoparticle delivery can enhance uptake by immune cells and often acts as its own adjuvant. The Novavax COVID-19 vaccine (NVX-CoV2373) is a protein nanoparticle vaccine comprised of spike protein nanoclusters with a saponin-based adjuvant. |
| 14 | Adverse Event Following Immunization (AEFI) | Any untoward medical occurrence which follows vaccination, and may or may not be caused by the vaccine. This official definition means an AEFI could be any unfavorable sign, symptom, illness, or abnormal laboratory finding that happens after immunization. Most AEFIs are mild and expected (like fever or soreness), but some can be serious (e.g., allergic reaction). Health systems maintain AEFI surveillance to detect any rare or unexpected vaccine reactions. When an AEFI is reported, it is investigated to determine if it’s coincidental or vaccine-related (causal). Robust monitoring of AEFIs and transparent communication about them is key to maintaining public trust. For instance, if a cluster of AEFIs occurs, an expert committee will review and advise if any action (like temporarily pausing a batch or updating guidance) is needed. |
| 381 | Side effect | Any unintended effect of a medication or vaccine that occurs in addition to the desired therapeutic effect. In vaccines, “side effect” usually refers to mild adverse reactions such as soreness at injection site, fever, or fatigue. Serious side effects are very rare. Common side effects are a result of the immune response (e.g., cytokine release causing fever) or local reactions. Vaccine information statements list common side effects and their expected duration. It’s important to distinguish side effects from coincidental events. (See Adverse reaction and Adverse event.) |
| 31 | Antigen | Any substance that is recognized as foreign by the immune system and triggers an immune response. Vaccine antigens are often weakened pathogens or pieces of pathogens (such as proteins or polysaccharides) that induce immunity. The presence of an antigen in the body leads to antibody production or cellular immunity to fight that specific agent. |
| 359 | Reservoir | Any living organism (animal, human, vector) or environment in which an infectious agent normally lives and multiplies, serving as a source for transmission to susceptible hosts. |
| 55 | Broadly neutralizing antibodies (bnAbs) | Antibodies capable of neutralizing a wide range of strains of a given pathogen by targeting conserved epitopes. They are especially discussed in the context of highly variable viruses like HIV, influenza, or dengue. For example, certain bnAbs against HIV can neutralize 90%+ of global isolates by binding to sites on the virus that mutate little. Achieving bnAb responses is a goal of next-gen vaccines (e.g., universal flu vaccines or HIV vaccines). These antibodies often have unique features, extensive somatic hypermutation, long loops, or the ability to penetrate glycan shields on viruses. Vaccines may employ strategies like sequential immunogens (prime with one variant, boost with another) to coax the immune system into developing bnAbs. Broadly neutralizing antibodies are considered a benchmark for pan-variant or universal vaccine success. |
| 334 | Predictive Analytics | Analytical methods (often using machine learning) applied to large datasets (e.g. genomic or epidemiological data) to forecast health events such as outbreaks or vaccine demand (conceptual term; applied in vaccine intelligence). |
| 15 | Adverse reaction (side effect) | An undesirable medical condition that has been demonstrated to be caused by a vaccine. Evidence for causality typically comes from studies (clinical trials, epidemiologic studies). A confirmed adverse reaction is also known as a side effect. (By contrast, an “adverse event” might be coincidental) |
| 222 | Infodemic | An overabundance of information (some accurate, much not) that spreads rapidly during an outbreak, making it hard for people to find trustworthy guidance. The term, coined by WHO, describes the deluge of rumors, misinformation, and conspiracy theories that often accompany epidemics (exacerbated by social media). An infodemic can undermine the public’s trust in vaccines and health interventions (for instance, false claims about COVID-19 vaccines causing infertility led some to avoid them). Managing the infodemic is now seen as a crucial part of outbreak response: it involves proactive dissemination of correct information, debunking harmful myths, and engaging influencers and media to steer narratives. Infodemic management teams were activated by WHO during COVID-19 to monitor misinformation trends and coordinate counter-messaging. |
| 240 | Lean (Total Quality) Management | An organizational approach adapted from manufacturing (Toyota Production System) that emphasizes reducing waste and optimizing processes (e.g. in vaccine delivery) to improve healthcare quality. |
| 278 | Nagoya Protocol (access and benefit-sharing) | An international treaty (supplemental to the Convention on Biological Diversity) that went into effect in 2014, governing how genetic resources (from plants, animals, microbes) can be accessed and how benefits from their use are shared. While not originally drafted with human pathogens in mind, it potentially applies to them as “genetic resources.” This became controversial: if a country invokes Nagoya for a virus sample, it could require users of that sample (e.g., a foreign lab or company) to obtain consent and possibly share benefits (like part of vaccine profits). Proponents say this ensures fairness to countries providing pathogen samples; opponents say it could impede rapid data and sample sharing during outbreaks, slowing down vaccine development. During COVID-19, most sample/data sharing was free and rapid (through platforms like GISAID for sequences), but some worry future cooperation could be hampered if Nagoya rules aren’t clarified. The WHO has called for pathogens of pandemic potential to be treated separately from the Nagoya Protocol, to avoid barriers to surveillance and response. |
| 409 | Systems vaccinology | An integrative approach applying systems biology (high-throughput “omics” and bioinformatics) to study vaccine responses. Instead of looking at one or two immune markers, systems vaccinology profiles thousands of variables (gene expression, proteomics, metabolomics, immune cell populations) after vaccination to get a holistic view of the immune response. By analyzing this big data, researchers can identify early molecular signatures that predict vaccine efficacy or discover novel correlates of protection. For instance, specific gene expression patterns 1–2 days post-vaccination have been found to predict the magnitude of antibody responses weeks later. Systems vaccinology helps unravel why vaccines immunize effectively in some people or populations but not others, guiding improvements and personalized strategies. |
| 13 | Advance Market Commitment (AMC) | An innovative financing mechanism in which donors guarantee a future market for a vaccine by pledging funds to subsidize its price once developed. The AMC model incentivizes manufacturers to invest in R&D and expand production capacity for vaccines needed in low-income countries, on the condition that the vaccines will be supplied at affordable prices in the long term. (Example: the AMC for pneumococcal vaccines facilitated industry commitment to provide doses at a low price for Gavi-supported countries.) |
| 96 | COVID-19 (Coronavirus Disease 2019) | An infectious respiratory disease caused by the novel coronavirus SARS-CoV-2, first identified in late 2019. COVID-19 can range from mild symptoms to severe illness or death. Multiple vaccines were developed globally in 2020–2021 to combat the COVID-19 pandemic (using mRNA, viral vector, protein subunit, and other platforms), which have proven highly effective in preventing severe disease and reducing mortality. |
| 139 | Emerging Infection | An infectious disease that has recently appeared or increased in incidence or geographic range, often due to factors like environmental change or pathogen mutation. |
| 492 | Zoonosis (zoonotic disease) | An infectious disease that can be transmitted from animals to humans. Many emerging infectious diseases are zoonotic (e.g., Ebola, avian influenza, COVID-19 likely from a wildlife source). While not all zoonoses have vaccines (e.g., HIV originated as a zoonosis; no vaccine yet), many veterinary vaccines indirectly protect humans (e.g., vaccinating dogs against rabies, livestock against Brucella). Some human vaccines are for zoonoses – e.g., rabies vaccine, yellow fever vaccine. Zoonoses remind us that controlling diseases in animal reservoirs (One Health approach) is part of preventing human outbreaks. |
| 53 | Breakthrough infection | An infection that occurs in a person who is fully vaccinated against that disease. While vaccines greatly reduce the risk of illness, they are not 100% effective, so some vaccinated individuals may still get infected (often with milder symptoms). For instance, COVID-19 vaccine breakthrough infections tended to be mild; vaccines still protected against severe outcomes. Monitoring breakthrough cases helps assess vaccine effectiveness in the real world. |
| 400 | Subclinical infection | An infection that does not produce noticeable symptoms in the host. Subclinical (or inapparent) infections still induce an immune response and can sometimes transmit to others even though the infected person isn’t aware. Many vaccine-preventable diseases can have subclinical cases – for instance, poliovirus infects far more people subclinically than it paralyzes. Vaccines can prevent both clinical and subclinical infections (e.g., preventing asymptomatic carriage), though some vaccines are better at preventing disease than infection. Monitoring subclinical infection is important in diseases like polio during endgame eradication (to ensure no silent circulation). |
| 295 | Nosocomial infection | An infection acquired in a hospital or healthcare setting. (While not specific to vaccination, preventing nosocomial infections is a public health goal; certain vaccines are given to healthcare workers to reduce the risk of spreading infections in hospitals – e.g., hepatitis B, influenza). |
| 322 | Placebo | An inactive substance or treatment designed to resemble the vaccine but having no therapeutic effect, used as a control in clinical trials. In vaccine trials, the placebo may be a saline injection or other inert injection. Comparing outcomes between the vaccine group and the placebo group allows researchers to attribute differences (like lower disease rates or side effects) to the vaccine itself. Participants are often blinded to whether they received vaccine or placebo. After a trial, effective vaccines are usually offered to those who were in the placebo group. |
| 423 | Toxoid | An inactivated toxin used as a vaccine antigen. Some bacteria (like C. diphtheriae and C. tetani) cause disease via exotoxins. By chemically inactivating the toxin (typically with formalin), one obtains a toxoid that is non-toxic but still immunogenic. The diphtheria and tetanus components of DTaP/Tdap vaccines are toxoids – they induce the body to make neutralizing antibodies against the toxin, thereby preventing the disease without exposing the person to the toxin’s harm. Toxoids often require booster shots (e.g., tetanus toxoid every 10 years) because antibody levels can wane. |
| 28 | Antibody-dependent cellular phagocytosis (ADCP) | An immune effector process in which phagocytic cells (such as macrophages or neutrophils) ingest and eliminate targets opsonized by antibodies. In ADCP, antibodies coat a pathogen or infected cell and those antibody “flags” are recognized by Fc receptors on phagocytes, leading to engulfment. For example, tumor cells or virus-infected cells opsonized by IgG can be bound and phagocytosed by macrophages. This mechanism “promotes [the] clearance of [the target] from the body by phagocytic immune cells”. ADCP contributes to the potency of therapeutic antibodies and the immune clearance of pathogens. |
| 33 | Antigen-presenting cell (APC) | An immune cell that processes antigens and presents pieces of them on its surface bound to MHC molecules, in order to activate T cells. Examples of professional APCs are dendritic cells, macrophages, and B cells. APCs that encounter vaccine antigens will display antigen fragments “like a trophy” on their surface and migrate to lymph nodes to find T cells, thus initiating the adaptive immune response. |
| 67 | Circular RNA (circRNA) vaccine | An experimental RNA vaccine platform using covalently closed circular RNA molecules encoding an antigen. CircRNAs are highly stable compared to linear mRNA and can drive prolonged protein expression; a recent circRNA vaccine for SARS-CoV-2 showed more sustained antigen production and a stronger neutralizing antibody response than a linear mRNA vaccine. This stability and durability make circRNA vaccines a promising next-generation approach. |
| 306 | Pandemic | An epidemic that has spread over multiple countries or continents, usually affecting a large number of people. A pandemic occurs when a new pathogen (or new strain) emerges that can transmit efficiently and few people are immune – as seen with the COVID-19 pandemic or the 1918 influenza pandemic. Vaccination is a critical tool in pandemic response (e.g., the rapid development of COVID-19 vaccines). International coordination via WHO is used to declare and respond to pandemics. |
| 380 | Short Hairpin RNA (shRNA) | An engineered RNA molecule with a tight hairpin turn able to be processed inside cells into siRNA. Typically delivered via DNA plasmids or viral vectors, shRNAs provide a sustained RNAi effect by continuously producing siRNAs in vivo. They are used in research and gene therapy settings to achieve long-term gene silencing for diseases. |
| 468 | Vaccinomics | An emerging field combining “vaccine” and “-omics,” referring to the study of how genetic and systems-level factors influence vaccine responses, and the application of this knowledge to vaccine design. In one sense, vaccinomics was defined as the application of immunogenetics and genomics to understand molecular mechanisms of vaccine response. It encompasses identifying human genetic variations (e.g. HLA types, cytokine gene polymorphisms) that affect vaccine efficacy or adverse reactions, and tailoring vaccine strategies accordingly (the premise of “personalized vaccinology”). Vaccinomics also involves high-throughput profiling of immune responses (transcriptomics, proteomics) to discover correlates of protection and new adjuvant targets. |
| 469 | Vaccinomics and personalized vaccinology | An emerging field at the intersection of immunogenetics, systems biology, and vaccinology that studies how genetic and other individual factors influence vaccine responses. “Vaccinomics” involves analyzing individuals’ HLA types, gene expression responses, and other biomarkers to understand why vaccine responses vary. The ultimate aim is personalized vaccines or vaccination strategies (e.g., predicting if someone might need an extra booster or a different vaccine type based on their genetic profile). As large datasets (from biobanks or systems vaccinology studies) become available, machine learning in vaccinomics may identify genetic signatures associated with non-response or adverse reactions, leading to tailored approaches to immunization. |
| 103 | Cyberbiosecurity | An emerging discipline focused on protecting biological data, lab processes, and biotechnology infrastructure from cyber threats, recognizing the convergence of biology and information technology. |
| 93 | Cost–benefit analysis (CBA) | An economic evaluation that compares the monetary value of all benefits of a vaccination program to its costs. In CBA, health outcomes (like lives saved, illnesses prevented) are assigned a monetary value (e.g. using willingness-to-pay or economic productivity estimates), and then summed benefits are weighed against program costs to calculate metrics like net benefit or benefit-cost ratio. A benefit-cost ratio >1 or a positive net benefit indicates that the immunization’s benefits exceed its costs in dollar terms, supporting investment from a societal perspective. |
| 58 | Budget impact analysis | An assessment that estimates the expected change in annual healthcare spending of adopting a new vaccine in a national program. Unlike cost-effectiveness (which focuses on value per health outcome), budget impact analysis evaluates affordability by projecting expenditures over a multi-year period, given the size of the target population and vaccine price. Policy-makers use it to ensure a new vaccine (e.g. HPV vaccine introduction) is financially feasible and to plan for the fiscal resources required, complementing the value-for-money perspective with a cash-flow perspective. |
| 350 | Rational Vaccine Design | An approach to developing vaccines based on scientific understanding of the pathogen and immune system, using logical design principles rather than purely empirical trial-and-error. Rational design often involves identifying protective antigens and epitopes a priori, modifying antigens to enhance stability or expose neutralizing sites (see structural vaccinology), selecting optimal delivery platforms, and choosing adjuvants that steer immunity appropriately (e.g., toward Th1 cellular responses for an intracellular pathogen). It contrasts with traditional methods where pathogens were attenuated or killed without knowing specifics of the immune response. Rational design is enabled by advances in molecular biology, structural biology, and immunology – for instance, structure-guided stabilization of antigens or tailoring mRNA vaccine coding sequences for optimal translation. The result is vaccines that are designed to elicit specific immune mechanisms known to correlate with protection, thereby improving the chances of efficacy. This approach has been crucial in creating vaccines for challenging viruses (RSV, HIV, COVID-19) in the 21st century. |
| 363 | Risk Communication and Community Engagement (RCCE) | An approach that combines timely dissemination of information with two-way engagement of communities before and during public health emergencies. Risk communication means conveying clear, actionable messages about health risks and protective behaviors, and community engagement means dialoguing with communities, understanding their perceptions, and involving them in the response. RCCE ensures people are informed, heard, and empowered to act. In immunization campaigns, RCCE might involve holding community meetings with local leaders, using mass media to explain vaccine benefits and side effects, and setting up feedback hotlines. During COVID-19, for example, RCCE was vital: it helped address vaccine fears by listening to concerns and tailoring messages. Essentially, RCCE is about building trust and enabling communities to make informed decisions – it “systematically engages and communicates with people to encourage healthy behaviors” during outbreaks. |
| 353 | Reaching Every District (RED) strategy | An approach introduced by WHO and UNICEF in 2002 to improve immunization coverage by focusing on strengthening service delivery at the district and community levels. The RED strategy aims for at least 80% coverage in every district. It has five operational components: (1) re-establishing outreach services to reach remote populations; (2) supportive supervision of health staff; (3) linking services with communities (engaging community leaders and volunteers); (4) monitoring and using data for action at the local level; and (5) planning and management of resources (micro-planning) at district level. RED’s core idea is that by empowering each district to identify and solve its immunization problems (like poor micro-plans or lack of community trust), the national program as a whole will perform better and more equitably. |
| 298 | One Health | An approach and concept recognizing that the health of humans, animals, and the environment are interlinked, and thus policy and research should integrate these domains – particularly in preventing and controlling diseases that move between animals and humans (zoonoses). In the context of vaccines, One Health might involve developing vaccines for animal populations to prevent human disease (for instance, vaccinating cattle against Brucella to prevent brucellosis in people, or wild rodents against plague, etc.), or monitoring pathogens in wildlife to inform human vaccine needs. It also means collaborative efforts between physicians, veterinarians, and environmental scientists. For example, rabies control is classic One Health: vaccinating dogs (the animal reservoir) via mass campaigns has huge human health benefits by stopping transmission. One Health approach in pandemic preparedness includes surveillance of viruses in animal hosts and developing veterinary vaccines that could curb a spillover (like avian influenza in poultry). It also emphasizes environmental factors – e.g., deforestation driving bats closer to human dwellings, thus a need for vaccines against bat-borne viruses. By breaking down silos between human and veterinary vaccinology and considering ecosystem health, One Health aims for more effective prevention strategies. In sum, One Health is not a vaccine term per se, but a paradigm within which vaccine strategies are developed, acknowledging that controlling a disease may require immunizing across species and protecting ecosystems to ultimately safeguard human health. |
| 83 | Conserved epitope | An antigenic region (epitope) that remains largely unchanged (highly conserved) across different strains or variants of a pathogen. Because it is conserved, an immune response targeting that epitope can potentially recognize and respond to a broad range of strains. For example, certain flu virus or coronavirus surface protein regions are conserved and thus are targets for broadly neutralizing antibodies. The importance of such epitopes is highlighted by the search for universal vaccines: “highly conserved epitopes… are essential for the design of universal vaccines and broadly neutralizing antibodies”. A conserved epitope might avoid mutation due to functional constraints on the pathogen, making it an Achilles’ heel that vaccines and therapies seek to exploit. |
| 285 | Neoantigen | An antigen that is entirely new to the immune system – not present in the normal genome – typically arising from tumor-specific mutations (in cancer) or from newly emergent pathogens. In oncology, neoantigens are peptides resulting from somatic mutations in tumor cells that create novel protein sequences (“non-self” to the patient’s immune system). “Neoantigen refers to antigens that result from somatic mutations in tumor cells generating mutant peptides distinguished from wild-type” proteins. These are attractive targets for cancer immunotherapy because they are only on cancer cells and not on normal cells, thus an immune response to them would specifically attack the tumor. Neoantigen-based vaccines attempt to immunize the patient against their own tumor’s unique mutations. In infectious disease, one might loosely use “neoantigen” to describe new epitopes in a novel pathogen strain (though usually the term is used in cancer). The presence of neoantigens explains phenomena like why certain tumors can be recognized by the immune system (e.g., tumors with high mutational burden have many neoantigens and tend to be more immunogenic). |
| 290 | Neutralizing antibody | An antibody that not only binds to a pathogen but also interferes with its ability to infect cells, thereby “neutralizing” the threat. Neutralizing antibodies often target key parts of a virus (like the receptor-binding domain of a virus’s surface protein) and prevent the virus from attaching to or entering host cells. Vaccines aim to induce robust neutralizing antibody responses. For example, vaccines against poliovirus or SARS-CoV-2 are evaluated by the level of neutralizing antibodies they elicit, since these correlate with protection. |
| 289 | Neutralizing Antibody | An antibody that defends a cell from a pathogen by binding to it and blocking its infection or toxic effect. Neutralizing antibodies (nAbs) typically bind to critical surface structures (like viral receptor-binding sites) and directly prevent the pathogen from entering host cells or mediating damage. They are often the goal of vaccines for viruses such as poliovirus, measles, or SARS-CoV-2, because their presence in sufficient quantity usually indicates protection. Neutralizing capacity is determined by functional assays (e.g., virus neutralization tests) rather than just binding. Not all binding antibodies are neutralizing – some may attach to the pathogen without blocking it. Thus, vaccine studies focus on generating high titers of nAbs, and measuring neutralization is a key immunogenicity endpoint. For instance, neutralizing antibody titers against influenza HAI of 1:40 have been associated with ~50% protection in population studies. High levels of neutralizing antibodies are often considered a correlate of protection for many viral vaccines. |
| 47 | Binding (Non-neutralizing) Antibody | An antibody that attaches to an antigen but does not necessarily block infection or toxin action. Such antibodies recognize the pathogen, marking it for immune attack (via opsonization, complement activation, etc.), but they don’t neutralize it on their own. Non-neutralizing antibodies can still contribute to protection through mechanisms like antibody-dependent cellular phagocytosis or cytotoxicity (ADCP, ADCC). However, in some cases they can also contribute to pathology (e.g., facilitating infection in ADE). Vaccine-induced antibody responses are often a mix of neutralizing and non-neutralizing. While neutralizing antibodies are usually preferred, a robust overall antibody response – including non-neutralizing functions – can be beneficial. Modern immune assays (like systems serology) profile both neutralization and Fc-mediated functions of antibodies to fully characterize vaccine-induced humoral immunity. |
| 56 | Broadly neutralizing antibody (bnAb) | An antibody capable of neutralizing a wide range of strains of a pathogen, rather than just a narrow subset. bnAbs usually target highly conserved epitopes on pathogens. For example, in HIV, broadly neutralizing antibodies can inactivate many divergent HIV-1 strains by binding conserved sites on the viral envelope. They are defined by their breadth of reactivity: “broadly neutralizing antibodies… recognize and block many types of [a virus] from entering healthy cells”. These antibodies are of great interest for vaccine development, as a vaccine that elicits bnAbs could provide protection against diverse strains or variants of a virus (such as various HIV clades or influenza subtypes). |
| 427 | Transboundary Disease | An animal (or zoonotic) disease with significant socioeconomic impact that can readily spread across national borders and requires coordinated international control measures. |
| 51 | Booster dose | An additional dose of a vaccine given after the primary vaccination series, intended to “boost” the immune system by re-exposing it to the antigen and thereby enhance or restore immunity that may have waned over time. A booster renews immune memory and often raises antibody titers back to protective levels. In other words, “a booster dose is an extra administration of a vaccine after an earlier (primer) dose”, re-exposing the immune system to the antigen to increase immunity to protective levels. Many vaccines (e.g., tetanus, pertussis) require periodic boosters to maintain long-term protection. |
| 52 | Booster dose (Booster shot) | An additional dose of a vaccine given after the primary series, at an interval of months or years, to “boost” the immune response back to protective levels. Over time, immunity from the initial vaccination can wane; a booster restores high antibody titers or immune memory, prolonging protection. For example, a tetanus-diphtheria booster is recommended every 10 years. |
| 179 | Hepatitis A | An acute viral liver disease transmitted through contaminated food or water or close personal contact. Hepatitis A causes fever, malaise, jaundice, and can occasionally be severe, though it is usually self-limited. The hepatitis A vaccine is an inactivated vaccine that provides long-term protection and is recommended for children and for travelers to endemic areas. |
| 395 | Strategic Foresight | An action-oriented discipline related to futures studies; it explores potential future scenarios to help organizations prepare and make informed decisions for long-term strategies. |
| 438 | Urticaria | Also known as hives – red, itchy, raised welts on the skin, often due to an allergic reaction. Urticaria can occur as a mild allergic reaction to a vaccine component (e.g., gelatin or latex or yeast). It is usually transient and manageable with antihistamines. Urticaria without other symptoms is not life-threatening, but if it occurs together with throat swelling or difficulty breathing, it could be an early sign of anaphylaxis and warrants immediate medical attention. Individuals who develop urticaria after one dose of a vaccine should be evaluated by a physician before additional doses. |
| 59 | Catch-up vaccination | Administration of vaccines on an accelerated schedule to individuals who are behind the recommended immunization schedule. Catch-up schedules are designed to provide missed vaccine doses at the minimum safe intervals to “catch up” a child or adult to the routine recommendations. (For example, a child who missed early doses might get doses closer together than usual, per CDC catch-up guidelines.) |
| 432 | Tularemia | A zoonotic bacterial disease (caused by Francisella tularensis) that can be transmitted via tick/deer fly bites or handling infected animals. Symptoms include fever, skin ulcers, and swollen glands. There is no widely used commercial vaccine for tularemia in the general public, but tularemia is considered a potential bioterrorism agent. An investigational live attenuated tularemia vaccine has been used in laboratory workers. Tularemia is rare, and prevention focuses on avoiding vectors and using protective measures in endemic areas. |
| 25 | Antibody | A Y-shaped protein made by B cells (plasma cells) of the immune system in response to an antigen (foreign substance). Antibodies bind to specific antigens (such as parts of viruses or bacteria) and help neutralize or destroy the pathogen. For example, after vaccination, the body produces antibodies that recognize that pathogen. |
| 138 | Emergency Use Listing (EUL) | A WHO procedure for expediting availability of vaccines (or other products) during a public health emergency. The EUL is a risk-based assessment of the quality, safety and efficacy data on unlicensed or new products, with the aim of listing them for emergency use. It allows WHO and procurement agencies to recommend a vaccine while national regulatory approvals are still underway. During COVID-19, for example, WHO’s Emergency Use Listing of various vaccines signaled to countries that those vaccines met acceptable standards, aiding their global rollout. |
| 367 | Rotavirus | A virus that is a leading cause of severe diarrhea and vomiting in infants and young children worldwide. Rotavirus can cause dehydration and was responsible for many hospitalizations and deaths before vaccines were introduced. Two oral rotavirus vaccines (live attenuated) are in use globally. These vaccines have greatly reduced rotavirus hospitalizations. Rotavirus vaccines are given in early infancy (e.g., at 2 and 4 months of age) and are unique as oral vaccines that replicate in the gut to induce immunity. While generally safe, they have a very small association with intussusception (a rare type of bowel blockage), on the order of ~1–2 per 100,000 recipients – but the benefits in preventing severe diarrhea far outweigh that risk. |
| 467 | Vaccinia | A virus related to smallpox (Variola) and cowpox that is used as the live virus in smallpox vaccines. Vaccinia virus causes a localized infection (the characteristic vaccine lesion) and induces immunity protecting against smallpox. The origin of vaccinia is somewhat obscure, but it’s essentially the virus that has been passaged and used for vaccination over centuries. Modern smallpox vaccines, like ACAM2000, contain vaccinia virus. Vaccinia can cause vaccinia infection in rare cases (e.g., inadvertent autoinoculation to eyes or eczema vaccinatum in those with eczema), which is why smallpox vaccine is now given mostly only to military or lab personnel at risk. |
| 180 | Hepatitis B | A viral infection of the liver transmitted via infected blood, sexual contact, or from mother to infant at birth. Hepatitis B can become chronic and lead to cirrhosis or liver cancer. The hepatitis B vaccine is a recombinant subunit vaccine (containing HBsAg surface antigen) that induces protective antibodies. It is usually given to newborns and has greatly reduced perinatal and childhood HBV infections. |
| 489 | Yellow fever | A viral hemorrhagic fever transmitted by Aedes mosquitoes in parts of Africa and South America. It can cause high fever, jaundice, bleeding, and has a significant fatality rate. The yellow fever vaccine is a live attenuated vaccine (17D strain) that is highly effective and provides long-lasting immunity (often lifelong). cdc.gov. It is required for entry into certain countries (per International Health Regulations) and has controlled YF outbreaks. However, the vaccine can (very rarely) cause serious adverse effects like viscerotropic disease, especially in certain individuals (e.g., the immunocompromised or the elderly). |
| 347 | Rabies | A viral disease that causes fatal encephalitis (brain inflammation). It is transmitted via saliva from the bite of an infected animal (e.g., dogs, bats). Once symptoms appear, rabies is almost always fatal. Rabies is preventable through vaccination: there are effective rabies vaccines for humans and animals. Humans at risk (veterinarians, travelers to high-risk areas) can get pre-exposure vaccination, and anyone exposed to a potentially rabid animal should receive prompt post-exposure prophylaxis (PEP) consisting of wound cleaning, rabies vaccine series, and rabies immune globulin as needed. Rabies vaccination of dogs is a cornerstone of preventing human rabies worldwide. |
| 471 | Variant (viral variant) | A version of a virus that has undergone mutation(s) resulting in genetic changes. Some variants are designated “Variants of Concern” if they impact public health (e.g., increased transmissibility or immune escape). For example, SARS-CoV-2 has had variants like Alpha, Delta, Omicron. Vaccines may need to be updated or boosted to maintain effectiveness against new variants if they differ significantly from the original strain. Influenza virus variants change so frequently (antigenic drift) that vaccine strains are reviewed and updated annually. Monitoring variants is a key part of vaccine strategy (as with COVID-19 and flu). |
| 372 | Self-Amplifying mRNA (saRNA) | A variant of mRNA that encodes not only the target antigen but also a replicase enzyme enabling the RNA to make copies of itself inside the cell. Originally derived from alphavirus genomes, saRNAs amplify antigen production from a small initial dose. This can yield strong immune responses at lower doses of RNA, though careful design is needed to manage reactogenicity. Self-amplifying mRNA is being explored in next-generation vaccines and therapeutics to increase potency. |
| 358 | Replicon RNA vaccine | A vaccine utilizing a self-replicating RNA molecule (replicon) derived from a virus genome that has been stripped of structural genes. The replicon carries the antigen gene and replicase genes; once in a cell, it continuously copies itself, yielding abundant antigen but no viral particles. Replicon RNA vaccines (also called self-replicating RNA vaccines) can induce strong immune responses due to sustained antigen production, and they formed the basis of some COVID-19 vaccine candidates. |
| 436 | Universal vaccine | A vaccine that would provide broad protection against all (or nearly all) strains of a given pathogen. This term is commonly used in the context of a “universal influenza vaccine,” which researchers are trying to develop to protect against all flu strains (potentially obviating the need for annual updates) by targeting conserved parts of the virus. Another example is efforts toward a “universal coronavirus vaccine” that could stop not only SARS-CoV-2 variants but also future novel coronaviruses. Achieving such breadth of protection is scientifically challenging. |
| 484 | Whole-cell vaccine | A vaccine that uses the entire pathogen (though killed/inactivated, or attenuated if live) rather than only parts of it. Traditional inactivated vaccines (polio, whole-cell pertussis, some flu) and live attenuated vaccines (measles, etc.) are whole-cell (or whole-virion) vaccines. The term is often used to contrast with subunit vaccines. For example, whole-cell pertussis vaccine (DTP) contained entire Bordetella pertussis bacteria that were killed, whereas the newer acellular pertussis (DTaP) contains only specific purified antigens. Whole-cell vaccines often have broader antigen content (potentially invoking wider immunity) but sometimes more reactogenicity. |
| 474 | Viral replicon particle (VRP) vaccine | A vaccine that uses replication-competent viral RNA packaged into viral particles, but lacking one or more essential genes so they cannot produce new infectious virus. Upon infection of a cell, the replicon RNA replicates and expresses the antigen. An example is alphavirus replicon particles, where structural genes are replaced by an antigen gene; the VRP enters cells and amplifies the antigen RNA. VRP vaccines effectively deliver self-amplifying RNA in vivo. They induce strong immunity (including T-cell responses) but are non-pathogenic because they cannot spread. (Platforms like Venezuelan equine encephalitis virus replicon particles have been tested for vaccines.) |
| 274 | mRNA vaccine (nucleoside-modified) | A vaccine that uses messenger RNA encoding an antigen, delivered into the body usually via lipid nanoparticles. Advanced mRNA vaccines incorporate modified nucleosides (e.g., pseudouridine) in the RNA to reduce innate immune sensing and increase RNA stability and translation. This technology proved its worth in COVID-19 vaccines, which demonstrated that nucleoside-modified mRNA in lipid nanoparticles can safely induce robust immune responses. The modifications (often called modRNA) lead to higher protein yield and less inflammation, making modern mRNA vaccines highly effective. |
| 273 | mRNA Vaccine | A vaccine that uses messenger RNA encoding an antigen (usually a viral protein) to induce an immune response. The mRNA, typically formulated in a lipid nanoparticle for delivery, is taken up by host cells, which then translate it into the target antigen (e.g., the spike protein of SARS-CoV-2). The antigen is produced in situ and presented to the immune system, eliciting both antibody and T-cell responses. mRNA vaccines are a new technology that gained prominence with COVID-19 vaccines (Pfizer-BioNTech and Moderna). They do not contain any live virus, and the mRNA does not enter the nucleus or alter DNA. An advantage of mRNA vaccines is speed and flexibility of design – once the sequence of the antigen is known, mRNA can be synthesized rapidly. They also induce potent responses with a correct formulation (enhanced by nucleoside modifications in the mRNA and effective delivery via LNPs). A disadvantage is their instability (requiring ultra-cold storage, though formulations are improving) and reactogenicity (they can cause strong transient inflammation). mRNA vaccine technology is being explored for other diseases (influenza, Zika, cancer neoantigens) given its success. Importantly, mRNA vaccines represent active immunization by briefly turning the body’s own cells into antigen factories, without any risk of infection. |
| 117 | DNA vaccine | A vaccine that uses a plasmid containing DNA encoding an antigen (such as a viral protein) to induce immunity. After injection, the host’s cells take up the DNA, produce the antigen, and trigger an immune response. DNA vaccines are a form of nucleic acid vaccine (like mRNA vaccines). While several veterinary DNA vaccines exist, human DNA vaccines are still in development (e.g., DNA vaccine candidates for Zika, COVID-19). DNA vaccines are stable and easy to produce, but delivering them effectively into cells is a key challenge. |
| 476 | Viral Vector Vaccine | A vaccine that uses a harmless virus (the “vector”) to deliver genetic material encoding an antigen from a target pathogen, thereby inducing an immune response to that antigen. The vector is often a non-replicating or attenuated virus engineered so it cannot cause disease itself. Examples of vectors include adenoviruses, poxviruses (like Modified Vaccinia Ankara, MVA), and others. Inside the body, the vector infects cells and those cells produce the vaccine antigen (e.g., the Ebola virus glycoprotein in the Ervebo vaccine, which uses a VSV vector, or the SARS-CoV-2 spike in J&J’s COVID-19 vaccine using an adenovirus 26 vector). This approach can generate robust immune responses, both antibody and T-cell, because it mimics a natural infection to some degree – the vector can trigger innate immunity and present antigen on MHC I and II. Viral vectors can be replicating (able to copy themselves a limited number of times, amplifying antigen expression) or non-replicating (each vector particle enters a cell and expresses antigen, but cannot create new virions). Advantages include strong immunogenicity and no adjuvant typically needed. Disadvantages: pre-existing immunity to the vector can reduce efficacy (for instance, common human adenovirus vectors might be neutralized by prior exposure; this was addressed by using rare serotypes like Ad26 or chimpanzee adenoviruses). Viral vector vaccines have now seen success in humans – e.g., the Ebola vaccine (rVSV-ZEBOV), COVID-19 vaccines (AstraZeneca/Oxford [ChAdOx1], J&J [Ad26]), and others in development (TB, HIV). |
| 343 | Quadrivalent vaccine | A vaccine that protects against four strains of a pathogen. Examples include quadrivalent influenza vaccines (containing four flu virus strains: two A subtypes and two B lineages) and HPV vaccine (Gardasil 4) which covered four HPV types (6, 11, 16, 18). The term “quadrivalent” simply indicates four-valent (tetravalent). There are also bivalent (2) and 9-valent HPV vaccines, etc. Using a quadrivalent instead of trivalent flu vaccine, for instance, broadens protection by adding an additional B strain. |
| 301 | Oral Vaccine | A vaccine that is ingested by mouth, typically to provoke immunity in the gut mucosa as well as systemic immunity. The prime examples are the oral polio vaccine (OPV) and oral rotavirus vaccines. Oral polio (Sabin vaccine) is a live attenuated virus given as drops – it replicates in the intestine and induces both serum IgG and mucosal IgA, contributing to gut immunity that blocks person-to-person spread. Oral rotavirus vaccines are live attenuated rotaviruses that replicate in the gut and induce local and systemic immunity, protecting infants from diarrheal disease. Other oral vaccines include the oral typhoid vaccine (Ty21a live attenuated Salmonella typhi) and the cholera vaccine (which in some formulations is a killed whole-cell bacteria with a subunit toxoid, taken orally). Advantages of oral vaccines are needle-free administration and often easier mass delivery (e.g., OPV could be given by volunteers with minimal training). They excel at generating mucosal IgA which is crucial for enteric pathogens. A challenge is that the vaccine must survive the acidic stomach and digestive enzymes – encapsulation or buffering is sometimes needed (as with some newer oral polio formulations). Oral vaccines can sometimes have interference by concurrent food or other enteric infections, and in populations with high maternal antibody or malnutrition, responses can be blunted. Still, oral vaccines have been instrumental (OPV was key in polio eradication progress). Research continues into oral formulations for other diseases (including COVID-19, where a capsule vaccine is being explored). Oral delivery is also patient-friendly, especially for children. |
| 419 | Thermostable Vaccine Formulation | A vaccine that has been formulated or stabilized to withstand higher temperatures (and/or freezing) without losing efficacy, allowing it to be stored or transported outside the traditional cold chain. This is crucial for improving vaccine access in areas with limited refrigeration. Techniques to achieve thermostability include lyophilization (freeze-drying) vaccines into powder form, using stabilizing excipients (sugars like trehalose, polymers, amino acids) that protect antigens at ambient temperatures, or engineering more stable antigen molecules (via sequence modification). For example, some newer rotavirus and meningococcal vaccines have improved stability at room temp. Controlled Temperature Chain (CTC) campaigns have been piloted, where a vaccine is certified to remain potent for a certain number of days at elevated temps (e.g., a meningitis A conjugate vaccine was allowed at up to 40°C for 4 days during a campaign). Thermostable formulations of measles and other vaccines are being researched – one approach is thin-film freeze drying or spray drying to create particles that can endure heat. Another is encapsulating antigens in glassy sugar matrices. By making vaccines less dependent on refrigeration, we can greatly reduce wastage and expand coverage in remote regions. A notable success is thermostable dry formulation of the Hepatitis B vaccine that showed stability at 37°C for months. Additionally, some new platforms inherently improve stability (e.g., RNA vaccines in liquid are delicate, but if lyophilized with proper buffers they become much more stable). Overall, thermostable vaccines are a key goal for global health – transforming vaccine supply logistics by mitigating the “cold chain” burden. |
| 277 | Multivalent vaccine | A vaccine that contains multiple antigens or antigenic variants, providing protection against more than one strain of a microorganism or against multiple different diseases in one shot. Examples: the seasonal influenza vaccine is quadrivalent (containing four flu strains), PCV13 is a 13-valent pneumococcal conjugate vaccine (with 13 serotype antigens), and the MMR vaccine is multivalent (protecting against 3 diseases). Multivalent vaccines reduce the number of injections needed for broad protection. (Sometimes “polyvalent” is used synonymously.) |
| 355 | Recombinant vaccine | A vaccine produced through recombinant DNA technology. This usually means inserting the gene that encodes a desired antigen into an expression system (like yeast, bacteria, or cell line) to produce large quantities of that antigen, which is then formulated into a vaccine. Examples: the hepatitis B vaccine is a recombinant subunit vaccine (HBsAg protein made in yeast); the HPV vaccines are recombinant virus-like particles produced in yeast or insect cells. Recombinant vaccines can also involve viral vectors – for instance, the recombinant rVSV-ZEBOV Ebola vaccine uses a vesicular stomatitis virus genetically engineered to express an Ebola virus protein. Recombinant technology allows vaccines that do not require growing large amounts of pathogenic virus or bacteria. |
| 326 | Plasmid DNA vaccine | A vaccine platform that uses a circular DNA plasmid carrying a gene for the antigen. When injected (often with a device like a gene gun or electroporation for cell entry), cells take up the plasmid and produce the antigen protein internally, stimulating an immune response. DNA vaccines are relatively stable and easy to produce. While early DNA vaccines had modest immunogenicity in humans, improvements (such as optimized promoters and delivery methods) have renewed interest. DNA vaccines are part of “third-generation” vaccines and were pursued for diseases like Zika and COVID-19. |
| 424 | Toxoid Vaccine | A vaccine made from a toxin (poison) that has been inactivated (usually by formalin treatment) so that it is no longer harmful but still immunogenic. This approach is used for bacterial diseases where a toxin is the main cause of illness. Classic toxoid vaccines are diphtheria and tetanus vaccines: the diphtheria and tetanus toxins are inactivated to “toxoids” and formulated with an adjuvant (alum). When administered, the body produces antibodies against the toxin. If the person is later infected by Clostridium tetani or Corynebacterium diphtheriae, those antibodies will neutralize the toxins and prevent disease, even though they don’t directly kill the bacteria. Toxoid vaccines have been extremely effective and have a good safety record. They typically require a series of shots (and boosters every 10 years for tetanus) because, as protein antigens with adjuvant, immunity can wane over time. Another example is the newer toxoid-based vaccine for Clostridioides difficile in development (aiming to neutralize its toxins). In summary, toxoid vaccines convert a pathogen’s chief virulence factor into its own Achilles heel by safely exposing the immune system to a harmless version of the toxin. |
| 220 | Inactivated vaccine | A vaccine made from a pathogen that has been killed (inactivated) by chemical or physical means, or from pieces of the pathogen, so it cannot cause disease. Inactivated whole-cell vaccines (e.g., injectable polio vaccine, some influenza vaccines) contain entire viruses or bacteria that are dead. They often require multiple doses and booster shots to maintain immunity, as they typically induce primarily antibody-mediated immunity without replicating in the host. Inactivated vaccines are generally very safe even in immunocompromised people (since the organism is not live). |
| 43 | Attenuated vaccine (live attenuated vaccine) | A vaccine made from a live pathogen that has been weakened (attenuated) so that it cannot cause severe disease, but can still induce a robust immune response. Live attenuated vaccines include measles, mumps, rubella (MMR), varicella (chickenpox), yellow fever, and some influenza and rotavirus vaccines. These vaccines usually produce long-lasting immunity but are generally contraindicated in immunocompromised individuals. |
| 418 | Therapeutic Vaccine (Cancer/Chronic Infection Vaccine) | A vaccine given to an individual who already has a disease, with the goal of treating or ameliorating that disease by stimulating an immune attack against relevant antigens. Unlike prophylactic vaccines (given to prevent infection), therapeutic vaccines target persistent pathogens (e.g., therapeutic HIV or hepatitis B vaccines under study) or cancers (tumor antigen vaccines) to help the immune system recognize and destroy diseased cells. For example, Sipuleucel-T is an FDA-approved therapeutic cancer vaccine for prostate cancer that activates the patient’s immune cells against a tumor antigen. Therapeutic vaccine design often overlaps with immunotherapy and may use novel platforms like mRNA or dendritic cell loading to induce strong cell-mediated immunity. |
| 361 | Reverse Vaccinology | A vaccine development strategy that starts from pathogen genetic data (genome sequences) rather than the traditional lab culture approach. In reverse vaccinology, bioinformatic screening is used to identify genes encoding surface or secreted proteins that could be good vaccine antigens. Dozens or hundreds of candidates can be predicted in silico and then tested experimentally. This approach, first pioneered in 2000 for Neisseria meningitidis B, massively accelerates antigen discovery by surveying the entire pathogen genome for vaccine targets. Reverse vaccinology has since led to approved vaccines (e.g., MenB) and is widely used for pathogens that are difficult to culture or have many strains. |
| 54 | Broad-spectrum vaccine | A vaccine designed to protect against multiple strains or species of a pathogen. (This term is general; for instance, a “universal influenza vaccine” would be a broad-spectrum flu vaccine effective against diverse flu strains.) Broad-spectrum or multivalent vaccines contain multiple antigens or antigen variants to broaden protection (e.g., pneumococcal conjugate vaccines covering many serotypes). (See also multivalent vaccine.) |
| 57 | Broadly protective (universal) vaccine | A vaccine designed to protect against all or most strains of a pathogen, including future variants. This term is often applied to efforts like a “universal influenza vaccine” that would cover all flu A subtypes, or a “universal coronavirus vaccine” covering current and emergent coronaviruses. Achieving broad protection usually requires focusing the immune response on conserved parts of the virus. Strategies include presenting conserved epitopes (e.g., the stalk of the flu hemagglutinin) or mosaic antigens that include pieces from many strains. The ideal broadly protective vaccine would not need updating when the pathogen evolves. It’s a high priority in research, leveraging structure-guided design, novel vectors, and nanoparticle platforms to induce cross-reactive neutralizing antibodies or T cells. |
| 271 | Monovalent vaccine | A vaccine designed to protect against a single strain or single antigen of a pathogen. “Monovalent” literally means one-valence (one component). An example is the monovalent oral polio vaccine type 1 (mOPV1) which targets only poliovirus type 1. Monovalent vaccines are useful when immunity to one specific strain is needed or for simplified immune responses. (Contrast with multivalent vaccine |
| 397 | Structural vaccinology | A vaccine design approach that uses high-resolution structural information of antigens and immune complexes to guide the creation of improved immunogens. It’s essentially the fusion of reverse vaccinology with structural biology. By examining the 3D structure of antigens (and how antibodies bind them), scientists can engineer stabilized proteins or expose key neutralizing epitopes optimally. Structural vaccinology has yielded successes like stabilized pre-fusion RSV F protein vaccines. It involves iterative cycles of protein engineering and structure determination to optimize vaccine antigens. |
| 280 | Nasal Spray Vaccine (Intranasal Vaccine) | A vaccine delivered as a mist or drops into the nostrils, targeting the nasal mucosa. The leading example is the FluMist® live attenuated influenza vaccine, which is a liquid squirted into the nose. Intranasal delivery aims to induce strong mucosal immunity (IgA and tissue-resident cells in the respiratory tract) in addition to systemic immunity, providing a first line of defense at the entry portal of many pathogens. Nasal vaccines can be live attenuated (as FluMist is) or inactivated/subunit formulations often combined with a mucosal adjuvant (since the mucosa tends to be a tolerogenic environment). Benefits of nasal vaccines include ease of administration (no needles), and the potential to block infection and transmission by raising local immunity. They are especially appealing for respiratory viruses (flu, RSV, coronaviruses). Challenges include ensuring the vaccine remains in the nasal passages long enough and is taken up effectively, as well as avoiding excessive reactogenicity or nerve impact (some intranasal vaccine trials failed due to adverse effects like Bell’s palsy from an adjuvant). Nonetheless, intranasal COVID-19 vaccine candidates are in trials, and some veterinary intranasal vaccines exist (for example, against Bordatella in dogs). A successful nasal vaccine could not only protect the individual from illness but also significantly reduce shedding and spread by neutralizing the pathogen at the point of entry. |
| 4 | Acellular vaccine | A vaccine containing partial cellular material (specific antigenic parts) instead of whole cells of a pathogen. For example, acellular pertussis vaccines include purified components of Bordetella pertussis rather than the entire bacterium. |
| 479 | Virus-like particle (VLP) vaccine | A vaccine consisting of virus-like particles – these are molecules that mimic the structure of viruses but contain no genetic material, so they are non-infectious. VLPs present viral antigens in a highly organized, repetitive array (like a real virus), which is very immunogenic. Examples: HPV vaccines are VLP vaccines (composed of self-assembling HPV L1 proteins that form an empty capsid); the hepatitis B vaccine is effectively a VLP (the HBsAg surface antigen forms spherical particles). VLP vaccines stimulate strong B-cell responses due to their particle structure and are considered very safe. They represent a modern vaccine design approach for viruses like HPV, HBV, and are being explored for others (e.g., VLPs for flu, norovirus). |
| 247 | Live Attenuated Vaccine | A vaccine consisting of live microbes that have been weakened (attenuated) so they can replicate to a limited extent without causing disease in immunocompetent recipients. Because they closely mimic natural infection, live attenuated vaccines elicit strong, broad, and lasting immunity, often after one dose. Examples include measles, mumps, rubella (MMR), varicella (chickenpox), yellow fever, and the oral polio vaccine. Attenuation is achieved through methods like serial passage in non-human cells or targeted genetic modification, resulting in a strain that grows poorly or causes no harm in human tissues. These vaccines induce robust T cell and B cell responses and often generate mucosal immunity if given via natural route (e.g., oral polio). However, they carry certain risks: people with severe immunodeficiency can develop disease from the vaccine strain, and there’s a small chance an attenuated virus reverts to virulence (as seen rarely with oral polio vaccine reverting to circulating vaccine-derived poliovirus). Live attenuated vaccines typically require refrigeration and are sensitive to heat. Despite these caveats, they are highly effective – the immune response can be nearly as good as encountering the wild pathogen, but without (most of) the danger. |
| 219 | Inactivated Vaccine | A vaccine composed of microbes (bacteria or viruses) that have been killed (inactivated) by heat, chemicals, or radiation, so they cannot replicate but still present antigenic components to the immune system. Inactivated vaccines include classic examples like the inactivated polio vaccine (IPV), whole-cell pertussis (old DTP), and many influenza vaccines (flu shots are chemically inactivated viruses). Because the pathogen is dead, these vaccines cannot cause the disease, even in immunocompromised individuals, which is a safety advantage. However, inactivated vaccines generally induce a weaker immune response compared to live vaccines, typically requiring multiple doses (priming and boosters) and possibly adjuvants to achieve strong immunity. They mainly induce humoral immunity (antibodies), with little CTL response since no live replication occurs inside cells. Durability of protection may be shorter, hence boosters are often needed. Production involves growing large amounts of the pathogen and then inactivating it, which must be done carefully to ensure complete inactivation while preserving antigen structure. Overall, inactivated vaccines are a tried-and-true modality that is safe and effective for many diseases, although the responses can be improved with adjuvants or newer delivery systems. |
| 330 | Polysaccharide vaccine | A vaccine composed of long-chain sugar molecules that make up the surface capsule of certain bacteria. Pure polysaccharide vaccines (e.g., the old pneumococcal 23-valent vaccine, PPSV23) can provoke B-cell responses but not strong T-cell help, so they tend not to generate robust immune memory and are ineffective in infants. To overcome this, conjugate vaccines link polysaccharides to proteins to invoke T-cell dependent immunity. Pure polysaccharide vaccines are uncommon in pediatric schedules now, having been largely replaced by conjugates for organisms like Haemophilus influenzae type b and pneumococcus. |
| 264 | Microneedle patch | A vaccine (or drug) delivery system in the form of a small patch with an array of tiny needles (microneedles) that painlessly penetrate the outer skin layer to deliver the payload intradermally or transdermally. Microneedle patches can be made of silicon, metal, or dissolvable polymers that contain the vaccine. They are applied like a bandage, pressed onto the skin, allowing the microneedles (generally <1 mm in length) to breach the stratum corneum. Delivery via microneedle patch is envisioned to be “an alternative to hypodermic injection that is less painful, safer and simpler”. The skin is rich in immune cells (e.g., Langerhans cells, dermal dendritic cells), so microneedle delivery can provoke robust immune responses. Microneedle patches have been tested for various vaccines (influenza, polio, measles, etc.) and hold promise for improving vaccine accessibility (possibly allowing self-administration and reducing cold chain burdens if thermostable). |
| 276 | Multi-epitope subunit vaccine | A vaccine (often designed in silico) that combines several epitopes – fragments from different proteins or different parts of a protein – into one construct. Computational tools help identify a set of epitopes that cover multiple strains or elicit both B and T cell responses. These epitopes can be linked together in a single protein or peptide (sometimes with spacers or pan-HLA helper epitopes) to ensure broad coverage. Multi-epitope vaccines are being explored for highly variable viruses (HIV, Hepatitis C, etc.) and cancers, using immunoinformatics to choose epitopes that are conserved and immunogenic in diverse populations. |
| 185 | Heterologous prime-boost | A vaccination strategy in which the prime (initial dose) and the boost (subsequent dose) are of different types or platforms, but they carry antigens for the same pathogen. For example, priming with a DNA or viral-vector vaccine and boosting with an mRNA or protein vaccine encoding the same antigen is a heterologous prime-boost regimen. The rationale is to elicit a broader or more robust immune response than a homologous (same-vaccine) boost, possibly by engaging the immune system in complementary ways. “Heterologous prime-boost immunization is administration of two different vectors or delivery systems expressing the same or overlapping antigenic inserts”. This approach has been used in research for HIV, TB, malaria, and was applied during the COVID-19 pandemic by mixing vaccine types. It often helps avoid anti-vector immunity or to amplify responses by presenting antigen in a new form to an immune system that has been primed by the first dose. |
| 336 | Prime-boost strategy | A vaccination approach in which an initial dose (“prime”) is given to start building an immune response, and one or more subsequent doses (“boosters”) are given later to enhance and broaden immunity. The prime and boost may use the same vaccine or different vaccine types (heterologous prime-boost). For instance, an Ebola vaccine strategy used a prime with an adenovirus-vectored vaccine and a boost with an MVA-vectored vaccine encoding the same antigen. The prime-boost approach often leads to higher antibody titers and more durable immunity than a single dose. |
| 44 | B cell (B lymphocyte) | A type of white blood cell (lymphocyte) that is an essential part of the adaptive immune system. B cells mature in the bone marrow and differentiate into plasma cells that produce antibodies against pathogens. They can also function as antigen-presenting cells. Once activated by an antigen (with T-cell help), B cells proliferate and form plasma cells (antibody factories) and memory B cells for long-term immunity. |
| 10 | Adenoviral Vector or Adenovirus vector vaccine (Ad Vector) | A type of viral vector using an adenovirus backbone to deliver vaccine antigens. Adenoviruses are common DNA viruses that cause mild infections (like colds). For vaccine use, the adenovirus is modified: the genes needed for it to replicate are removed, and a gene for the target antigen (e.g., a flu hemagglutinin or coronavirus spike) is inserted. The modified virus can infect cells and cause them to make the antigen, but it cannot spread to new cells (non-replicating vector). Adenoviral vectors elicit strong T-cell responses and decent antibody responses and can be given via intramuscular or other routes. Different human Ad serotypes (Ad5, Ad26, Ad35, etc.) or non-human adenoviruses (chimpanzee Ads) are used to avoid issues with anti-vector immunity. The Ad5 vector was used in some COVID-19 vaccines and earlier HIV vaccine trials; Ad26 is used in the J&J COVID vaccine (as well as an Ebola vaccine as one of a two-dose regimen). The safety profile is generally good, though mild adenovirus-like symptoms (fever, sore arm) are common post-shot. Rare side effects like blood clotting disorders in some COVID Ad vector vaccines have been observed, possibly linked to platelet factor 4 interaction, these are under study. Adenoviral vectors have versatility and stability (they can be freeze-dried) and have become a leading platform for both human and veterinary vaccines. |
| 82 | Conjugate vaccine | A type of vaccine in which a poorly immunogenic antigen (often a bacterial polysaccharide from the pathogen’s capsule) is chemically linked (conjugated) to a carrier protein to improve its immunogenicity. This strategy helps provoke a stronger immune response (including in infants). Examples: Hib conjugate vaccine (polysaccharide from Haemophilus influenzae type b linked to tetanus toxoid) and pneumococcal conjugate vaccines. |
| 410 | T cell (T lymphocyte) | A type of lymphocyte that plays a central role in adaptive immunity. There are two primary subsets: Helper T cells (CD4?), which coordinate immune responses by releasing cytokines and activating B cells, macrophages, and cytotoxic T cells; and Cytotoxic T cells (CD8?), which directly destroy infected cells or cancer cells. T cells develop in the thymus and each T cell is specific to a particular antigen fragment presented on an MHC molecule. Vaccines generate memory T cells in addition to antibodies. For instance, COVID-19 mRNA vaccines induce helper T cells that assist in robust antibody production and cytotoxic T cells that can kill virus-infected cells, contributing to protection even if antibodies wane. |
| 64 | Challenge trial (human challenge study) | A type of clinical study in which participants are intentionally exposed to a pathogen under controlled conditions, after receiving (or concurrently with) an experimental vaccine or treatment. The purpose is to directly assess vaccine efficacy or study disease mechanisms in a controlled setting. According to the WHO, “participants are intentionally challenged… with an infectious disease organism” in a human challenge trial. These trials are done with extensive ethical oversight and often only with treatable or attenuated infections. Human challenge studies can expedite vaccine development by providing quick efficacy data, but they carry ethical considerations since volunteers are deliberately exposed to pathogens. |
| 426 | Trans-amplifying RNA (taRNA) | A two-component RNA vaccine system designed to overcome the size limitation of long replicating RNAs. One RNA fragment encodes the antigen of interest, and a separate RNA encodes the replicase. Co-delivered into cells, the replicase RNA amplifies the antigen-encoding RNA in trans. This “split replicon” approach retains the amplification advantage of saRNA while simplifying manufacturing by using two shorter RNA strands. |
| 165 | Germinal center | A transient microstructure that forms in secondary lymphoid organs (like lymph nodes and spleen) within B-cell follicles during T-dependent immune responses. Germinal centers are the sites of intense B cell proliferation, somatic hypermutation, affinity maturation, and selection of high-affinity B cell clones, as well as B-cell differentiation into plasma cells or memory B cells. “Germinal centers in secondary lymphoid tissues are sites of intense B-cell proliferation, selection, maturation, and death during antibody responses”. A germinal center has a dark zone (packed with proliferating B cells called centroblasts undergoing mutation) and a light zone (where B cells called centrocytes interact with follicular dendritic cells and T follicular helper cells for selection). Germinal centers are crucial for generating high-affinity, long-lived antibody responses and immunological memory. |
| 149 | Exon Skipping | A therapeutic strategy to bypass a faulty exon during pre-mRNA splicing, often using antisense oligonucleotides. The ASO masks the exon or its flanking splice sites, causing the cell’s splicing machinery to “skip” that exon. This can restore the reading frame in genes with deletions or mutations (as done in Duchenne muscular dystrophy to skip mutated exons and produce a shorter but functional dystrophin protein). Exon skipping effectively turns certain genetic mutations into milder ones by altering the mRNA splice isoform. |
| 314 | Personalized Neoantigen Vaccine | A therapeutic cancer vaccine custom-made for an individual patient, incorporating epitopes from that patient’s tumor mutations (neoantigens). After sequencing the tumor and identifying immunogenic neoantigens via computational prediction, a vaccine is formulated, often as a long peptide cocktail, an mRNA vaccine, or a dendritic cell vaccine, encoding several of these neoantigens. The goal is to induce a T cell response against each neoantigen-bearing cancer cell. Clinical trials (e.g., in melanoma) have shown that personalized neoantigen vaccines can expand T cells that recognize the tumor and, in combination with checkpoint inhibitors, may lead to tumor regression. This approach represents a precision immunotherapy, leveraging the unique mutational signature of a patient’s cancer to create a tailor-made vaccine. While logistically complex and expensive, it exemplifies the frontier of individualized vaccine design. |
| 9 | ADAR-Mediated RNA Editing | A therapeutic approach leveraging Adenosine Deaminase Acting on RNA (ADAR) enzymes to edit RNA transcripts in situ. ADARs can convert adenosine to inosine (read as guanine) in double-stranded RNA regions. By providing a guide RNA (or a modified antisense) that base-pairs with an mRNA around an adenosine, one can direct ADAR to deaminate a specific adenosine, effectively “rewriting” a single nucleotide in the mRNA (for example, correcting a G-to-A mutation by changing an A back to I/G in the mRNA). This transient editing does not alter DNA and can correct certain genetic mutations at the RNA level. Several groups are developing guide RNA systems to recruit endogenous ADAR for therapeutic RNA editing as a precision medicine technique. |
| 396 | Stringent Regulatory Authority (SRA) | A term used to denote a national regulatory agency that is considered to perform at a high standard of competence and rigor. Historically, WHO defined SRAs as those authorities that were members or observers of the International Council for Harmonisation (e.g., US FDA, EMA, Japan’s PMDA, etc.), or closely tied to such members. The SRA designation has been used by global programs as a benchmark – for instance, vaccines approved by an SRA are often accepted for procurement faster. (WHO is now transitioning to a “WHO Listed Authority (WLA)” framework, which uses benchmarking assessments to designate trusted regulators beyond the legacy SRA definition.) |
| 490 | Zero-dose child | A term used in global immunization to describe a child who has not received any routine vaccines (such as the first dose of DTP) by a certain age. pmc.ncbi.nlm.nih.gov. Zero-dose children often live in underserved, remote, or conflict areas and are at high risk of multiple vaccine-preventable diseases. Reaching zero-dose children is a priority for Gavi and WHO to achieve equity in immunization coverage. pmc.ncbi.nlm.nih.gov. Identifying pockets of zero-dose children helps target immunization drives and health system strengthening in those communities. |
| 194 | Hybrid immunity | A term describing the enhanced immunity observed in individuals who have immunity from both vaccination and natural infection. For example, someone who had COVID-19 and later gets vaccinated may develop very broad and robust immunity (sometimes dubbed “super-immunity”). Hybrid immunity can result in higher neutralizing antibody levels and broader T-cell responses than either infection or vaccination alone. Studies during COVID-19 found hybrid immunity provided strong protection against variants. |
| 178 | Health Technology Assessment (HTA) | A systematic, multidisciplinary evaluation of the clinical, economic, social, and ethical aspects of a health intervention (such as a new vaccine). HTA provides evidence on a vaccine’s effectiveness, safety, and cost-effectiveness to inform policy decisions. Many countries use HTA to decide whether to include an expensive new vaccine in their national program by assessing its added value and budget impact. |
| 368 | Rumor Surveillance | A systematic process of actively collecting and verifying unofficial reports (rumors) about health events or outbreaks to reduce misinformation and inform timely public health response. |
| 292 | No-fault compensation program | A system to compensate individuals who suffer serious vaccine-related injuries without needing to prove error or negligence (“no fault”). These programs provide prompt, standardized payouts to help those affected, thus maintaining public confidence and relieving manufacturers and healthcare providers from protracted litigation. Prior to COVID, many high-income countries had such schemes for routine vaccines (e.g., the U.S. Vaccine Injury Compensation Program). For COVID-19, a global no-fault compensation program was created by COVAX for the 92 lowest-income countries – the first-ever international vaccine injury compensation mechanism.Funded by a levy on each dose, it offers a lump-sum benefit to people who experienced serious adverse events from COVAX-distributed vaccines, avoiding court cases. Establishing this program was crucial to get manufacturers to supply countries that didn’t have their own liability protections. In the long run, there’s discussion that no-fault compensation should be standard in all countries to enhance trust in vaccines. |
| 172 | Good Manufacturing Practice (GMP) | A system of strict guidelines and regulations that manufacturers must follow to ensure vaccine quality, purity, and consistency. GMP covers all aspects of production, B179from raw materials, facility hygiene, and equipment validation to record-keeping and quality control. Vaccine manufacturers are regularly inspected for GMP compliance. Adherence to GMP is critical because the safety of vaccines depends on reliable production free of contamination or errors. |
| 126 | Early Warning System | A surveillance system or process designed to detect signals of emerging health threats (e.g. unusual disease clusters, new pathogen variants) as early as possible. |
| 38 | Antigenic shift | A sudden, major change in a virus’s antigenic structure, typically through reassortment or exchange of gene segments, leading to a new virus subtype. Antigenic shift can result in viruses to which populations have little or no pre-existing immunity (for example, the emergence of a novel influenza A subtype), sometimes causing pandemics. (In influenza, antigenic shift refers to the abrupt appearance of a new hemagglutinin and/or neuraminidase via reassortment.) |
| 304 | Outbreak | A sudden increase in cases of a disease in a specific time and place, more than expected. An outbreak is essentially a localized epidemic. Public health responses to outbreaks often include emergency vaccination campaigns to raise immunity quickly (for example, vaccinating people in a community during a measles outbreak, or ring vaccination around an Ebola case). The size of an outbreak can vary from a few cases to many; rapid response (testing, isolation, vaccination) is key to controlling it. |
| 104 | Cytotoxic T cell | A subset of T lymphocytes (also called CD8^+ T cells) that directly kill virus-infected cells or cancerous cells. Cytotoxic T cells are key effectors in cell-mediated immunity. Upon recognizing an infected cell’s antigen (presented on MHC I), a cytotoxic T cell releases perforin and granzymes to induce apoptosis of that cell. Vaccine-induced cytotoxic T cells can help eliminate cells harboring intracellular pathogens. (See T cells.) |
| 49 | Biologics License Application (BLA) | A submission to the FDA requesting approval to introduce a new biological product (such as a vaccine) into interstate commerce. A BLA must include extensive data on the product’s safety, purity, potency, manufacturing, and labeling. The FDA defines a BLA as a request for “permission to introduce, or deliver for introduction, a biologic product into interstate commerce”. Approval of the BLA is required for a vaccine to be marketed in the U.S. |
| 377 | Serosurvey | A study that examines blood samples from a population to measure seroprevalence – the proportion of people who have antibodies against a given pathogen. Serosurveys help estimate how much of the population is immune (via infection or vaccination). For example, a serosurvey might find that 85% of a population has antibodies to rubella (through vaccination or past infection). This informs public health decisions, identifying immunity gaps and guiding vaccine campaigns. |
| 348 | Randomized Controlled Trial (RCT) | A study in which participants are randomly assigned to receive either the vaccine being tested or a control (placebo or another comparator), and outcomes are compared between groups. Randomization minimizes bias by equalizing known and unknown factors between groups. RCTs are considered the highest level of evidence for determining a vaccine’s efficacy and safety. For example, large RCTs demonstrated ~95% efficacy of mRNA COVID-19 vaccines by comparing COVID illness rates in vaccine vs placebo groups. In vaccine RCTs, blinding (double-blind design) is also used to prevent bias. |
| 121 | Double-Blind Study | A study design where neither the participants nor the researchers (including those assessing outcomes) know who has received the vaccine versus the control. Blinding helps prevent bias in reporting or evaluating symptoms and outcomes. For example, in a double-blind vaccine trial, participants won’t know if their injection was vaccine or placebo (so their behavior or likelihood to report a minor symptom is not influenced), and clinicians evaluating them or lab personnel counting antibody levels also do not know group assignments. The blind is maintained usually via coded labels, with a separate party holding the code until it’s time for analysis or in case of an emergency unblinding. Double-blind trials are standard in Phase III. If only the participant is unaware and the researcher knows, it’s single-blind (rare in vaccine trials). In summary, double-blinding is crucial to ensure the validity of the efficacy and safety findings by eliminating observation bias. |
| 349 | Randomized Controlled Trial (RCT) | A study design in which participants are randomly assigned to receive either the vaccine candidate or a control (placebo or another vaccine), and outcomes are compared in a blinded manner. RCTs are the gold standard for demonstrating causality – that the vaccine caused a reduction in disease , by minimizing bias and confounding. In vaccine RCTs, neither the participants nor investigators typically know who got vaccine vs placebo (double-blind), to ensure objective assessment of outcomes. RCTs have rigorous protocols for enrollment, randomization, and analysis. For example, in a Phase III RCT for a COVID-19 vaccine, ~30,000 people might be randomly split between vaccine and saline placebo, followed for several months to count COVID-19 cases in each group. If significantly fewer cases occur in the vaccine arm, efficacy is established. RCTs also provide comparative safety data (rates of AEFIs in vaccine vs placebo). While RCTs are critical for initial licensure, they are sometimes not feasible post-licensure for ethical or practical reasons – hence the reliance on observational studies for some Phase IV questions. |
| 249 | Logic Model | A structured representation (often diagrammatic) of the relationships between program resources, activities, outputs, and outcomes, used to plan and evaluate interventions. |
| 328 | Poly(A) tail | A stretch of adenosine nucleotides (adenine bases) added to the 3? end of eukaryotic mRNA molecules. In mRNA, the poly(A) tail (often ~100–250 A’s long in mammals) is added post-transcriptionally and is important for mRNA stability, nuclear export, and translation efficiency. The tail binds poly(A)-binding proteins which protect the mRNA from exonucleases and also synergize with the 5? cap structure to promote ribosome recruitment. In the context of mRNA vaccines, a proper poly(A) tail is critical for the mRNA’s function in cells. For instance, synthetic mRNAs are engineered with a poly(A) tail to ensure stability and efficient protein production. A longer poly(A) tail generally correlates with longer mRNA half-life. Thus, the poly(A) tail is an essential feature of mature mRNA, acting like a time-stamp for mRNA lifespan and a handle for translation initiation complexes. (This is standard molecular biology knowledge.) |
| 71 | Cocooning | A strategy of protecting a vulnerable individual (typically a young infant) from infectious disease by vaccinating those in close contact with them (family members, caregivers). For example, “pertussis cocooning” involves immunizing parents, siblings, and caregivers with Tdap to create a protective buffer of immunity around a newborn who is not yet fully vaccinated. Cocooning reduces the chance that a contagious caregiver could transmit diseases like whooping cough or flu to the baby. |
| 257 | Market shaping | A strategic approach by global health organizations to influence vaccine markets in favor of affordability and sufficient supply. Market shaping can include aggregating demand and financing (as Gavi does) to negotiate lower prices, incentivizing new manufacturers to enter the market, and ensuring healthy competition. For example, Gavi’s model of pooled procurement and long-term funding commitments has led industry to produce vaccines at tiered prices, thereby shaping the market so that low-income countries are charged less. |
| 199 | Immune exhaustion (T cell exhaustion) | A state of dysfunction that occurs in T cells (and sometimes other immune cells) during chronic infections or cancer, due to prolonged antigen exposure. Exhausted T cells exhibit markedly reduced effector functions (such as decreased cytokine production and cytotoxicity), altered transcriptional profiles, and upregulation of multiple inhibitory receptors (e.g., PD-1, LAG-3, TIGIT). It is often a “stepwise and progressive loss of T-cell functions” under persistent antigenic stimulation. For instance, in chronic hepatitis or HIV infection, T cells become exhausted and cannot clear the virus effectively. While exhaustion can dampen immunopathology, it also allows pathogen persistence. Reinvigorating exhausted T cells (for example, via checkpoint blockade therapy) is a major approach in cancer immunotherapy. Exhaustion is distinct from anergy or senescence, though overlapping in reduced responsiveness. |
| 213 | Immunosuppression (Immunocompromise) | A state in which the immune system’s ability to fight infections is reduced or absent. Immunosuppression can be caused by certain diseases (like untreated HIV, leukemia), medications (such as high-dose steroids, chemotherapy, or immunosuppressant drugs), or congenital conditions. Individuals who are immunosuppressed may have special vaccine recommendations – for instance, they generally should not receive live attenuated vaccines because of the risk of uncontrolled infection. They should receive inactivated vaccines, often on adjusted schedules, to protect against vaccine-preventable diseases (which can be more severe in immunocompromised hosts). |
| 20 | Alphavirus replicon vaccine | A specific type of replicon vaccine derived from alphaviruses (e.g. Sindbis or Venezuelan equine encephalitis virus). Alphavirus replicons can be delivered as RNA or packaged into VRPs. They have a potent replicase that boosts antigen production in host cells. For instance, an alphavirus-based replicon vaccine encoding influenza antigens showed high immunogenicity. An interesting variant is the DNA-launched alphavirus replicon, where a plasmid encodes the alphavirus replicon RNA (with the antigen), combining DNA delivery with RNA replication. Alphavirus replicon vaccines are notable for inducing both robust antibody and T-cell responses. |
| 144 | Epitope | A specific piece of an antigen (such as a short peptide segment of a protein or a distinct molecular surface) that is recognized and bound by an immune receptor. B-cell epitopes are the portions of an antigen recognized by antibodies – these can be linear epitopes (a contiguous amino acid sequence) or conformational epitopes (discontinuous regions brought together in the folded protein). T-cell epitopes are short peptides (usually 8–20 amino acids) that result from antigen processing and are presented on MHC molecules to T cell receptors. Vaccines often aim to include the key epitopes of a pathogen’s proteins to elicit targeted immunity. |
| 89 | Correlate of protection | A specific immune response (such as a certain antibody level or T-cell response) that is statistically associated with protection against infection or disease. A correlate of protection is a measurable sign that an individual is immune. For example, an antibody titer above a certain threshold might correlate with protection. Correlates of protection are used to evaluate vaccines (e.g. licensing new vaccines by immunobridging when direct efficacy data are unavailable). |
| 287 | Neonatal Fc receptor (FcRn) | A specialized receptor that binds the Fc region of IgG antibodies (and albumin) and is responsible for two key functions: extending the half-life of IgG by protecting it from degradation, and transferring maternal IgG to the fetus (across the placenta) and to neonates (via intestinal absorption of breast milk IgG in some species). FcRn is so-named because it was first discovered in neonatal rodents transporting IgG from mother’s milk. In humans, FcRn in the placenta transports IgG from mother to fetus, conferring passive immunity. It also rescues IgG from lysosomal degradation by binding internalized IgG at low pH and recycling it to circulation, thus accounting for IgG’s unusually long half-life. “Important properties of IgG, such as long half-life and placental transport, are facilitated by the neonatal Fc receptor (hFcRn)”. By extending IgG longevity, FcRn enhances the efficacy of IgG-dependent immune responses. (This receptor is also a target for therapeutic modulation in autoimmune diseases to reduce pathogenic IgG levels.) |
| 325 | Plasmid | A small, typically circular, double-stranded DNA molecule that replicates independently of a cell’s chromosomal DNA. Plasmids are commonly found in bacteria and often carry genes (e.g., for antibiotic resistance). In biotechnology and vaccine contexts, plasmids are used as vectors to carry genetic information. For example, DNA vaccines use plasmids encoding an antigen: after administration, host cells take up the plasmid and express the antigen to induce an immune response. Plasmids used in medicine are engineered to be safe (non-replicating in human cells, containing only the gene of interest and necessary regulatory elements). They are propagated in bacteria during manufacturing. Due to their ease of manipulation and ability to drive protein expression, plasmids are fundamental tools in genetic engineering, gene therapy, and DNA vaccination. |
| 464 | Vaccine Vial Monitor (VVM) | A small heat-sensitive sticker placed on vaccine vials that irreversibly changes color as cumulative heat exposure increases. It provides a visual indication of whether a vaccine has been kept within the proper temperature range. For example, a VVM might start as a light circle and gradually darken; if it reaches a certain dark color (above a threshold mark), it signals that the vial has been exposed to too much heat and should be discarded. VVMs are essential in immunization programs because they empower health workers to use vaccines that have traveled through warm areas only if they are still potent. They were a major innovation by WHO and partners to reduce heat-damaged vaccine usage, especially for outreach in hot climates. VVMs come in different categories depending on vaccine heat stability (some vaccines tolerate more heat and thus have slower-changing VVMs). |
| 462 | Vaccine stockout | A situation in which a vaccine is unavailable at the health facility (or higher supply level) when needed, due to depletion of stock. Stockouts halt immunization services and can erode caregiver trust, as families turned away may not return. Common causes include poor forecasting, delayed deliveries, funding shortfalls, or cold chain failures leading to wastage. Preventing stockouts requires robust vaccine supply chain management – including buffer stocks, stock monitoring, and timely procurement. Many countries use stock level indicators and dashboard systems (often part of LMIS – Logistics Management Information Systems) to track inventory and act before a stockout occurs. Internationally, mechanisms like UNICEF’s stockpile for emergency vaccine supply and Gavi’s vaccine forecasts help mitigate the risk of stockouts in low-income countries. |
| 153 | Filter Bubble | A situation arising from personalized algorithms (e.g. social media feeds) that isolates users in a narrow informational sphere aligned with their existing beliefs, limiting exposure to diverse perspectives. |
| 86 | Controlled Temperature Chain (CTC) | A short-term vaccine delivery approach allowing vaccines to be kept above standard cold-chain temperatures for a limited time (e.g. up to +40?°C for 3 days) under controlled conditions prior to use. |
| 411 | T-Cell Epitope | A short peptide fragment of an antigen that is displayed by Major Histocompatibility Complex (MHC) molecules on cell surfaces and recognized by T cell receptors. CD8? cytotoxic T cells typically see epitopes ~8–11 amino acids long bound to MHC class I, while CD4? helper T cells recognize ~13–25 amino acid peptides on MHC class II. T-cell epitopes usually derive from internal regions of proteins after processing. Identifying which peptide epitopes are dominantly recognized (and from which HLA alleles) is important for vaccine design, especially for eliciting T-cell immunity. Computational tools (e.g., NetMHC) predict peptide binding to MHC to aid in finding T-cell epitopes. |
| 382 | Small Activating RNA (saRNA) | A short double-stranded RNA that upregulates (rather than silences) a target gene by targeting promoter regions – a phenomenon termed RNA activation (RNAa). saRNA therapeutics are experimental; by boosting expression of beneficial genes (e.g. a tumor suppressor), they offer a novel gene-regulation strategy complementary to RNAi and ASOs. |
| 22 | Anaphylaxis | A severe, life-threatening allergic reaction that can occur rapidly after exposure to an allergen (including, rarely, a vaccine component). Symptoms include difficulty breathing, a drop in blood pressure, and loss of consciousness. Anaphylaxis after vaccination is very rare but requires immediate medical treatment (e.g. epinephrine). |
| 415 | Tetanus | A serious infectious disease caused by a neurotoxin from Clostridium tetani bacteria, usually entering through contaminated wounds. Tetanus causes muscle stiffness and severe spasms (lockjaw), and can be fatal. It is not contagious person-to-person. The tetanus vaccine is a toxoid (inactivated toxin) that induces antibodies neutralizing the tetanus toxin. Tetanus toxoid is given as part of combination vaccines (DTaP, Tdap, etc.) and requires booster doses approximately every 10 years to maintain immunity. Due to vaccination, tetanus cases are now extremely rare in developed countries. |
| 135 | ELISpot (Enzyme-Linked ImmunoSpot) Assay | A sensitive cellular assay that detects individual cells secreting a specific cytokine or antibody. In an ELISpot for T cells, a plate is coated with an antibody to a cytokine (e.g., IFN-?). Immune cells from a vaccinated individual are added, along with specific antigen peptides. If a T cell recognizes the peptide, it will release IFN-?, which is captured around that cell. After washing, a detection antibody and enzyme are added, producing a colored “spot” where each activated T cell was. By counting spots, one quantifies antigen-specific T cells in the sample (each spot ? one reactive T cell). ELISpot is widely used to measure T cell responses in vaccine trials (for IFN-? from Th1 or CTLs, IL-5 for Th2, etc.) and can also be adapted to B cells secreting antibodies. It has single-cell sensitivity and is a standard method for monitoring cellular immunity. |
| 340 | Pseudovirus Neutralization Assay | A safer alternative to PRNT that measures neutralizing antibodies using a “pseudovirus” – a recombinant virus that carries the surface proteins of the pathogen of interest but is rendered non-pathogenic (e.g., a vesicular stomatitis or lentivirus core decorated with coronavirus spike). When pseudoviruses are mixed with serum and added to permissive cells, neutralizing antibodies will prevent the pseudovirus from entering cells, often measured by a reporter gene (like luciferase) encoded in the pseudovirus. These assays can be done at lower biosafety levels and are highly useful for viruses like HIV or SARS-CoV-2. Pseudovirus neutralization titers correlate with live virus neutralization and have been instrumental in large-scale testing of COVID-19 vaccine responses. |
| 197 | Immune checkpoint | A regulatory pathway in the immune system that acts as a brake to immune responses, maintaining self-tolerance and preventing excessive damage. Key immune checkpoints are receptor-ligand pairs like PD-1 with PD-L1/PD-L2, and CTLA-4 with B7, which are inhibitory signals for T cells. Under normal conditions, these checkpoints modulate the amplitude and duration of immune responses. Tumors can exploit these checkpoints by expressing ligands (like PD-L1) to turn off T cells. As described, “immune checkpoints are inhibitory pathways of the immune system that maintain self-tolerance and prevent autoimmunity”. The advent of checkpoint inhibitor drugs (antibodies blocking PD-1, PD-L1, or CTLA-4) has revolutionized cancer therapy by releasing these brakes and allowing T cells to attack tumors. However, removing checkpoints can also lead to immune-related side effects, reflecting their role in restraining immunity. |
| 305 | PAHO Revolving Fund | A regional pooled procurement mechanism operated by the Pan American Health Organization since 1979 to help countries in the Americas purchase vaccines, syringes, and related supplies collectively. Member countries contribute funds into the Revolving Fund, which PAHO then uses to negotiate and buy vaccines in bulk on their behalf. This ensures reliable supply and flat, affordable pricing for all participating countries. The Revolving Fund has been credited with improving vaccine access and equity in Latin America by allowing even small countries to benefit from bulk pricing and by smoothing out funding shortfalls through its revolving credit structure. |
| 45 | B-Cell Epitope | A region of an antigen recognized by the antigen-binding site of a B cell receptor or antibody. B-cell epitopes can be linear sequences of amino acids or conformational shapes formed by protein folding. When designing vaccines or immunogens, identifying major B-cell epitopes is crucial for inducing neutralizing antibodies. Tools like epitope mapping and structural analyses help pinpoint these antibody-binding sites, which are sometimes shielded (e.g., by glycan) or variable on pathogens. An effective vaccine often exposes stable, conserved B-cell epitopes to the immune system. |
| 267 | Minicircle DNA vaccine | A refined type of DNA vaccine using minicircle DNA – plasmids engineered to remove all non-essential bacterial sequences. These minicircle vectors contain only the antigen gene and necessary regulatory elements, resulting in a smaller, supercoiled DNA molecule with higher expression efficiency. Minicircles have higher transfection rates and lower risk of anti-vector immunity than conventional plasmids. In studies, minicircle DNA (mcDNA) showed more efficient gene expression and potency than regular plasmid DNA, making them an attractive next-gen DNA vaccine platform. |
| 466 | Vaccine-induced immune thrombotic thrombocytopenia (VITT) | A recently identified rare adverse reaction characterized by blood clots in combination with low platelet counts, occurring after certain COVID-19 adenovirus-vector vaccines. VITT is thought to result from an autoimmune reaction where vaccine-triggered antibodies activate platelets (similar to heparin-induced thrombocytopenia). It typically occurs 5–30 days post-vaccination and can cause cerebral venous sinus thrombosis or other major clots. VITT is serious but extremely rare; its discovery has led to increased monitoring of thrombotic events after vaccines. In terms of biomarkers, patients with VITT have antibodies (often IgG) to platelet factor 4 (PF4) that cause platelet activation. The condition is treatable if recognized (with IVIG and anticoagulation). VITT highlighted the importance of global pharmacovigilance and agile investigation – within weeks of first cases, scientists had a working case definition and plausible mechanism, which informed vaccine policy adjustments for certain age groups. |
| 398 | Structural Vaccinology (Structure-Based Vaccine Design) | A rational approach to engineer vaccine antigens using high-resolution structural information of the pathogen’s proteins and their complexes with antibodies. By determining an antigen’s 3D structure (often via X-ray crystallography or cryo-EM) and mapping where potent neutralizing antibodies bind, scientists can redesign the antigen to stabilize key neutralizing epitopes and remove distracting or variable parts. This process, also called structure-based antigen design, has led to breakthroughs like the prefusion-stabilized RSV F protein and coronavirus spike modifications. Structural vaccinology leverages tools like AlphaFold-predicted structures and structure-guided mutagenesis to create improved immunogens that elicit focused, effective immune responses. |
| 175 | Guillain–Barré Syndrome (GBS) | A rare immune-mediated neurological disorder in which the body’s immune system attacks peripheral nerves, causing muscle weakness and sometimes paralysis. GBS can occur after infections and, very rarely, after vaccines. Symptoms typically begin as tingling and weakness in the feet or legs that ascend upward. Most patients recover, but severe cases require medical support. Large studies find either no link or an extremely small increased risk of GBS after certain vaccines (for example, on the order of approximately 1–2 extra cases per million following some flu vaccines). Monitoring for GBS is part of vaccine safety surveillance. |
| 487 | X-linked agammaglobulinemia (XLA) | A rare genetic immunodeficiency (affecting males) where patients cannot produce antibodies. Mentioned here because individuals with XLA cannot mount responses to most vaccines (since they lack B cells to produce immunoglobulins). They rely on passive immunity (IVIG) and herd immunity for protection. Live vaccines are contraindicated in such patients. This highlights the concept of cocooning and community immunity – those who cannot be immunized depend on others being immunized. |
| 21 | Anamnestic Response | A rapid and robust immune response observed upon re-exposure to an antigen, due to the presence of immunological memory from a prior exposure (through infection or vaccination). “Anamnestic” literally means recalling to memory. In practical terms, if someone has been primed, a booster dose or reinfection leads to a much faster rise in antibodies (often within days) and to higher titers than the first time, this is an anamnestic response. For example, the first dose of a vaccine may yield modest antibodies, but the second dose (weeks later) causes a jump to much higher levels, the hallmark of memory B cells differentiating into plasma cells. An anamnestic response often also produces more high-affinity antibodies and different isotypes (class switching). Clinicians sometimes use a test for an anamnestic response to distinguish recent infection from old infection: e.g., a single booster of Hib vaccine can cause a big antibody increase in a child who had been infected before (indicating immunologic memory). In summary, an anamnestic response is evidence that the immune system “remembers” the antigen and is a desired outcome of vaccination, ensuring long-lasting protection that can be quickly recalled. |
| 483 | WHO prequalification (PQ) | A quality assurance program managed by WHO to assess vaccines (and other health products) for use in international procurement. WHO prequalification involves rigorous review of clinical data, manufacturing practices, and quality control to ensure that vaccines meet global standards of quality, safety, and efficacy. Vaccines that are “prequalified” are then eligible for purchase by UN agencies (like UNICEF) and Gavi. This process is especially important for vaccines used in low-income countries, providing an international stamp of approval and streamlining regulatory requirements for countries that rely on WHO’s assessment. |
| 167 | Global Polio Eradication Initiative (GPEI) | A public-private partnership launched in 1988 with the goal of eradicating polio worldwide. Key partners include WHO, UNICEF, CDC, Rotary International, and the Gates Foundation. Through GPEI, billions of oral polio vaccine doses have been delivered, and polio cases have decreased by over 99.9%. The initiative conducts National Immunization Days (mass polio campaigns), acute flaccid paralysis surveillance, and outbreak response. As of 2025, wild poliovirus remains endemic in only a couple of countries (Pakistan and Afghanistan), but challenges like conflict, vaccine hesitancy, and circulating vaccine-derived polioviruses (cVDPVs) complicate the endgame. GPEI has had to adapt strategies, introducing inactivated polio vaccine (IPV) globally, developing novel OPV strains that are less likely to revert, and intensifying community engagement. GPEI represents the largest internationally coordinated disease program in history, offering lessons (both positive and cautionary) for other initiatives like measles elimination. One legacy will be the infrastructure it created – labs, workforce, and systems that can be repurposed for other health needs once polio is gone. |
| 162 | Gavi, the Vaccine Alliance | A public-private global health partnership that provides funding and support to expand vaccine access in low- and lower-middle-income countries. Gavi pools donor funds and negotiates prices to help introduce new vaccines (such as rotavirus, pneumococcal, HPV) and strengthen immunization systems in eligible countries. Since its launch in 2000, Gavi has contributed to the immunization of hundreds of millions of children, using innovative financing (like AMC and IFFIm) and co-financing requirements to improve affordability and sustainability of vaccine programs. |
| 177 | Health Belief Model | A psychological model suggesting that people’s health-related actions are determined by their beliefs about susceptibility, severity, benefits, and barriers (often used to study vaccine uptake; beyond single citation scope). |
| 308 | Pandemic Treaty (WHO CA+) | A proposed international agreement under negotiation (as of 2023–2025) to strengthen pandemic prevention, preparedness, and response. The World Health Assembly agreed to draft a “WHO convention, agreement or other international instrument on pandemic prevention, preparedness and response” – informally called the Pandemic Treaty. The idea is to learn from COVID-19 shortcomings and bind countries to certain commitments: e.g., timely sharing of pathogen samples and genomic data (to avoid issues of viral sovereignty), equitable access to countermeasures (possibly reserving a % of vaccines for global allocation), funding for surveillance, and accountability mechanisms. The treaty might also address research and development cooperation and governance (perhaps empowering WHO more during emergencies). It’s under negotiation by an Intergovernmental Negotiating Body. If agreed, it would complement the International Health Regulations. Challenges include balancing national sovereignty with global solidarity and ensuring compliance. The target is to present a draft for approval by 2024’s World Health Assembly. |
| 431 | TRIPS waiver (for vaccines) | A proposal at the World Trade Organization to temporarily waive certain intellectual property rights under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) for COVID-19 health products. The TRIPS waiver (initiated by India and South Africa in 2020) aimed to suspend patent protections for COVID-19 vaccines, treatments, and diagnostics during the pandemic so that more manufacturers (especially in low- and middle-income countries) could produce them. Proponents argued this would expand global vaccine supply by allowing production without risk of patent infringement, thereby improving access in poorer nations. |
| 161 | Gavi Vaccine Investment Strategy (VIS) | A process used by Gavi to evaluate and decide which new vaccines or immunization-related investments to support in the coming years. The VIS assesses factors like disease burden, cost-effectiveness, impact on equity, financial implications for countries, and vaccine supply landscape. For example, through past VIS exercises Gavi added support for vaccines such as HPV, rubella, and cholera. The VIS reflects a policy approach to use limited global resources on the vaccines that will save the most lives and reduce illness in Gavi-eligible countries, while also considering introduction feasibility and sustainability. |
| 482 | WHO Prequalification (PQ) | A process managed by the World Health Organization that assesses vaccines (and other health products) for quality, safety, efficacy, and suitability for low-resource settings, in order to facilitate their international procurement. Many UN agencies and Gavi-supported countries require WHO prequalification for vaccines they purchase. The PQ process involves reviewing manufacturing data, results of clinical trials, and inspecting production facilities to ensure they meet Good Manufacturing Practices. It’s somewhat akin to an international quality stamp. If a vaccine is “prequalified,” it means WHO is satisfied that it is safe, effective, and produced to high standards, and it becomes eligible for bulk purchase by agencies like UNICEF. PQ also looks at practical aspects like labelling, packaging (in multi-dose vials, VVMs presence), and cold-chain stability in tropical climates. Prequalification greatly helps developing countries that may not have the capacity to rigorously evaluate every product on their own – they can rely on WHO’s assessment. For manufacturers, obtaining PQ is crucial to accessing large global markets. The process is collaborative: often, if a vaccine is approved by a stringent regulatory authority (SRA), that data can be leveraged, but PQ might still inspect and require certain format submissions. WHO PQ also coordinates a lot release system and monitors post-market performance. It has been a cornerstone in expanding access to quality-assured vaccines worldwide. With new vaccines (like COVID vaccines), WHO’s Emergency Use Listing (EUL) acted similarly to PQ by expediting assessments for emergency use in many countries simultaneously. |
| 338 | Proportionate (Proportional) Universalism | A principle in health policy which holds that interventions should be universal (available to all), but with a scale and intensity that is proportionate to the level of need or disadvantage. In the context of immunization, this means ensuring vaccination for everyone while directing extra effort and resources toward communities with lower coverage or greater barriers. Under proportionate universalism, services are universally available but delivered with greater intensity to underserved groups, so as to reduce inequitiesThis approach was emphasized by the Marmot Review on health inequalities as a way to improve overall outcomes while closing gaps. |
| 170 | Global vaccine as a public good | A principle advocated by various leaders and the UN that COVID-19 vaccines (and by extension other crucial vaccines) should be treated as global public goods, not as ordinary market commodities. A public good in economic terms is non-excludable and non-rivalrous, while vaccines physically are rivalrous (a dose can only go to one person), the idea is policies should make them non-excludable (available to all) and invest in supply to meet global demand. This concept underpinned calls for open sharing of vaccine technology, waiver of IP rights, and donations to poorer nations. The phrase “vaccines as a global public good” appeared in UN General Assembly resolutions. It’s more a moral/political commitment than a strict definition, but it guides initiatives like COVAX and tech transfer hubs (like the mRNA vaccine manufacturing hub in South Africa). Operationalizing this means funding production for the commons, ensuring affordability, and preventing hoarding – essentially the opposite of vaccine nationalism. |
| 421 | Tiered pricing (differential pricing) | A pricing strategy whereby vaccine manufacturers charge lower prices in low-income markets and higher prices in wealthier markets for the same product. This policy allows low-income countries to pay a fraction of what high-income countries pay, improving affordability. Tiered pricing is enabled by pooled demand and funding (e.g., through Gavi) that give manufacturers the incentive to offer reduced prices for poorer countries. |
| 200 | Immune globulin (Immunoglobulin) | A preparation of antibodies (immunoglobulins) purified from donor plasma, used for passive immunization. Immune globulin can provide immediate, short-term protection by transferring ready-made antibodies. Examples: hepatitis B immune globulin (HBIG) given after exposure to HBV, or rabies immune globulin as part of rabies post-exposure prophylaxis. “IVIG” refers to intravenous immune globulin used in various immune deficiencies. |
| 113 | Diphtheria | A potentially fatal bacterial infection caused by Corynebacterium diphtheriae. It primarily affects the throat and airways, producing a toxin that can cause a thick gray membrane in the throat and lead to breathing problems. Complications include heart and nerve damage. Diphtheria is prevented by the diphtheria toxoid vaccine (as in DTaP/TD vaccines), which induces antibodies that neutralize the toxin. |
| 456 | Vaccine mandate | A policy that requires individuals to be vaccinated, often as a condition for attending school, working in certain jobs, or participating in specific activities. Mandates are used by governments or institutions to achieve high coverage and protect public health, especially when voluntary uptake is insufficient. Examples include school entry requirements for childhood vaccinations (common in many U.S. states and other countries) or hospital systems mandating influenza or hepatitis B vaccination for healthcare workers. Mandates typically allow exemptions (medical, and sometimes religious or philosophical, depending on jurisdiction). While evidence shows mandates can effectively raise immunization rates, they can also spark controversy and legal challenges, so they are often implemented alongside efforts to educate and build public support. |
| 134 | Electroporation | A physical method of delivering substances (such as DNA vaccines) into cells by applying short, high-voltage electrical pulses to create temporary pores in cell membranes. Electroporation of a tissue (for example, muscle or skin) where a DNA plasmid has been injected facilitates the DNA’s entry into cells, thereby greatly improving uptake and expression. In DNA vaccination, “a short electric pulse (electroporation) optimizes [DNA vaccine] delivery” by transiently permeabilizing cells. Electroporation can dramatically increase the immunogenicity of DNA vaccines by ensuring more cells take up the plasmid. Clinically, devices with electrode needles administer the electric pulses immediately after intramuscular or intradermal DNA injection. |
| 425 | Trained immunity (innate immune memory) | A phenomenon where the innate immune system displays memory-like behavior. Traditionally, immunological memory was ascribed only to adaptive immunity, but research shows certain innate cells can undergo long-term reprogramming. After an initial stimulus (like a live vaccine or infection), cells such as monocytes, macrophages, and NK cells respond more robustly to subsequent, even unrelated challenges. This is mediated by epigenetic and metabolic reprogramming of the cells. For instance, the BCG vaccine (for tuberculosis) has been observed to reduce infant mortality from various infections, thought to be via training innate immunity. Trained immunity blurs the line between innate and adaptive responses and is being harnessed to develop vaccines or adjuvants that provide broad protection by “training” innate defenses. |
| 201 | Immune Imprinting (Original Antigenic Sin) | A phenomenon where the immune system’s first exposure to a pathogen (or vaccine) biases the response to future exposures of related strains. First described in influenza, it was termed “original antigenic sin” by Thomas Francis Jr., meaning the antibodies made in a first infection dominate responses to later slightly different strains, even if suboptimal. In effect, the immune memory ‘imprints’ on initial antigens and can be less adaptable to new variants. This can result in reduced efficacy of vaccines if a person was first exposed to a distantly related strain. Immune imprinting is a topic of active study for COVID-19 (how prior SARS-CoV-2 variants or vaccines influence responses to new variants). Vaccine strategies like updated boosters attempt to overcome imprinting by focusing responses on novel epitopes. |
| 30 | Antibody-dependent enhancement (ADE) | A phenomenon where binding of antibodies to a pathogen paradoxically enhances its entry into host cells or its pathogenicity, rather than neutralizing it. ADE is well known in dengue virus: non-neutralizing antibodies from a previous infection can facilitate a second serotype’s infection of Fc-receptor bearing cells, leading to severe disease. In vaccine contexts, ADE is a safety concern, vaccines must be evaluated to ensure they don’t induce mostly non-neutralizing antibodies that could worsen infection. ADE was investigated during COVID-19 vaccine development (e.g., due to SARS and MERS vaccine studies showing immune pathology in animals). Effective vaccines are designed to elicit strongly neutralizing antibodies to avoid this risk. ADE is also referred to in Vaccine-Associated Enhanced Disease (VAED), where a vaccinated person experiences worse disease than if they hadn’t been vaccinated (historically an issue with some inactivated measles and formalin-inactivated RSV vaccines in the 20th century). |
| 29 | Antibody-dependent enhancement (ADE) | A phenomenon in which binding of a pathogen by non-neutralizing or suboptimal antibodies actually enhances the pathogen’s entry into host cells and can worsen the infection. ADE has been observed in certain viral infections (e.g. dengue); it was a theoretical concern for COVID-19 vaccines, though not observed in authorized vaccines. |
| 110 | Dendritic Cell Vaccine | A personalized vaccine approach where dendritic cells (the immune system’s most potent antigen-presenting cells) are harvested from a patient, “loaded” with tumor antigens or other antigens ex vivo, and then re-infused into the patient to initiate a strong T cell response against those antigens. Dendritic cell (DC) vaccines have been explored mainly in cancer immunotherapy. The process typically involves isolating monocytes via leukapheresis, culturing them with cytokines to differentiate into immature DCs, then exposing them to the target antigens (through peptides, tumor lysate, RNA, or fusion proteins), along with maturation stimuli, to produce activated DCs presenting the desired epitopes. These are injected back (often intradermally) into the patient, where they migrate to lymph nodes and activate antigen-specific T cells. Sipuleucel-T (Provenge) for metastatic prostate cancer is an FDA-approved dendritic cell vaccine: patient’s DCs are loaded with a prostate antigen (PAP) linked to an immunostimulatory factor (GM-CSF). DC vaccines can induce robust T-cell responses and some clinical successes, but they are labor-intensive and costly since they are tailor-made for each patient. They illustrate the principle of maximizing the body’s own antigen presentation capacity to fight disease. Research is ongoing to streamline DC vaccines or use in vivo targeting of antigens to dendritic cells as an alternative (to avoid the ex vivo step). |
| 379 | Shingles (Herpes Zoster) | A painful skin rash with blisters, caused by reactivation of the varicella-zoster virus (which causes chickenpox). After a person has chickenpox (or varicella vaccination), the virus can lie dormant in nerve cells and reactivate years later as shingles, typically in older or immunocompromised individuals. Shingles can lead to complications like postherpetic neuralgia (chronic nerve pain). A vaccine for shingles (the recombinant zoster vaccine) is recommended for older adults and is highly effective at preventing both shingles and neuralgia. |
| 226 | Internal ribosome entry site (IRES) | A nucleotide sequence element (typically in RNA) that allows ribosomes to initiate translation from an internal site on the mRNA, rather than the 5? end cap. IRES elements were first discovered in picornaviruses, enabling cap-independent translation of viral proteins when host cap-dependent translation is shut off. In biotechnology, IRES sequences are used in vectors to express multiple proteins from one mRNA (the ribosome can start at the IRES to translate a second open reading frame). “An Internal Ribosome Entry Site (IRES) is a sequence in certain eukaryotic mRNAs that enables translation initiation by directly recruiting the ribosome internally (cap-independently)”. For instance, in a bicistronic plasmid, the first gene is translated in the standard way, and an IRES preceding the second gene permits the ribosome to bind and translate the second gene as well. IRES elements are also relevant in some cellular mRNAs (often active under stress conditions when cap-dependent translation is impaired) and have been used in designing circular RNA vaccines (since circRNAs lack 5? caps, they may include IRES to drive protein production). |
| 286 | Neoantigen (Tumor Neoantigen) | A novel peptide antigen that arises from a tumor-specific mutation in cancer cells (not present in normal cells), making it a completely “new” antigen for the immune system. Neoantigens result from DNA mutations in tumors that alter protein sequences, these mutant peptides can be presented on cancer cell MHC molecules and recognized as foreign by T cells. They are attractive targets for cancer vaccines because they should not be subject to central tolerance (the immune system hasn’t seen them during development) and thus can induce a strong immune response selectively against the tumor. Each patient’s cancer can have a unique set of neoantigens. Modern techniques sequence a tumor’s genome and use algorithms to predict which mutations produce MHC-binding peptides; these neoantigens can then be crafted into a personalized vaccine to stimulate T cells that seek and destroy tumor cells carrying those mutations. |
| 339 | Pseudouridine | A naturally occurring modified nucleoside, which is an isomer of uridine (the ribose is attached to the uracil base in a carbon-carbon bond instead of the normal nitrogen-carbon bond). Pseudouridine (?) is the most abundant RNA modification found in tRNAs, rRNAs, and snRNAs. Importantly, incorporating pseudouridine in place of uridine in mRNA can have notable effects: it can increase mRNA stability, reduce activation of innate immune sensors (making the mRNA less inflammatory), and enhance translation. In fact, the mRNA used in COVID-19 vaccines contains N1-methylpseudouridine in place of uridine for these reasons. As one source notes, “pseudouridine modification improves the stability of mRNA, enhances its translation ability and reduces immunogenicity”. This modification was a key breakthrough that made mRNA vaccines feasible by preventing the mRNA from immediately triggering interferon responses or being degraded in the cell before producing enough antigen. |
| 366 | RNA Interference (RNAi) | A natural cellular mechanism for gene silencing harnessed for therapy. It involves small double-stranded RNAs that trigger degradation of a specific messenger RNA, preventing production of its protein. Therapeutically, RNAi is induced by delivering short interfering RNAs or related molecules into cells, selectively “knocking down” genes involved in diseases. |
| 441 | Vaccine Adverse Event Reporting System (VAERS) | A national vaccine safety surveillance system co-managed by the CDC and FDA for collecting reports of adverse events after vaccination in the United States. VAERS serves as an early warning system to detect possible vaccine-related problems. Anyone (health providers, patients, caregivers) can submit a VAERS report. The system accepts all reports, from mild side effects to serious events, regardless of certainty of causation. VAERS data are monitored for patterns (e.g., higher-than-expected incidence of a particular event after a vaccine) that might signal a safety issue requiring further investigation. It is a spontaneous reporting system and subject to underreporting and reporting biases, so identified signals are studied in more controlled ways (e.g., using VSD or clinical studies). |
| 283 | National Immunization Technical Advisory Group (NITAG) | A national committee of independent experts that advises the government on immunization policy. NITAGs review evidence on vaccine safety, efficacy, disease burden, and cost-effectiveness to make recommendations on vaccine schedules, new vaccine introductions, and other strategies. The idea is to have an objective, scientific body guide decisions (e.g., “Should we include the HPV vaccine in our program? Who should get the COVID booster first?”) rather than purely political or external donor influence. By 2020, over 90% of countries had a NITAG or equivalent. A functioning NITAG typically includes experts in pediatrics, epidemiology, public health, etc., meets regularly, declares conflicts of interest, and issues written advisories. Their role has grown – for example, during COVID-19, NITAGs determined priority groups and whether to use certain vaccines. Strengthening NITAGs (through training, information access, and linkages with global guidance like SAGE) is an IA2030 strategy to ensure decisions are locally appropriate and evidence-based. |
| 244 | Lipid nanoparticle (LNP) | A nanoscale particle composed of lipids, used as a delivery vehicle for drugs and vaccines, most prominently for nucleic acids like mRNA. Lipid nanoparticles typically consist of an ionizable cationic lipid (which binds and encapsulates the negatively charged mRNA and facilitates endosomal escape), plus helper lipids (phospholipids, cholesterol for stability, and PEGylated lipids for longevity and dispersion). In mRNA vaccines, the mRNA is formulated in LNPs ~80–100 nm in size, which protect the mRNA from degradation and promote uptake into cells. LNPs are essentially tiny fat droplets that fuse with cell membranes to deliver the mRNA into the cytoplasm. They “encapsulate the mRNA within a lipid shell, enabling its delivery into host cells” (as demonstrated by the COVID-19 mRNA vaccines). LNP technology has been critical for the success of mRNA vaccines, providing a potent adjuvant effect and efficient in vivo delivery. |
| 2 | Access to COVID-19 Tools Accelerator (ACT-A) | A multilateral initiative established in 2020 to speed up the development and equitable distribution of COVID-19 diagnostics, therapeutics, and vaccines. ACT-A is a collaboration of WHO, Gavi, CEPI, UNICEF, the Global Fund, and other partners. Its vaccines pillar is COVAX. ACT-A created a framework for pooling resources and expertise globally to ensure all countries, not just rich ones, could access life-saving tools during the pandemic. In essence, ACT-A recognized that defeating a pandemic requires a coordinated global response to develop and deliver tools as global public goods. (ACT-A began winding down in 2023 as COVID-19 moved past the emergency phase). |
| 227 | International Finance Facility for Immunisation (IFFIm) | A multilateral fund that uses capital market mechanisms to raise upfront financing for vaccination in low-income countries. Backed by long-term government pledges, IFFIm issues “vaccine bonds” to investors, immediately generating funds for Gavi-supported immunization programs. This frontloading provides predictability and accelerates vaccine access, while donor governments pay back the bonds over time. IFFIm has enabled billions of dollars to be available quickly for immunization efforts. |
| 232 | Japanese encephalitis (JE) | A mosquito-borne viral infection prevalent in parts of Asia that can cause encephalitis (brain inflammation). JE virus is a flavivirus. While most infections are asymptomatic, a small percentage lead to severe neurological disease with high mortality or long-term disability. JE vaccines (inactivated Vero cell-derived or live attenuated recombinant) are available and recommended for travelers to endemic areas and for residents in those regions. Routine childhood JE vaccination is implemented in some Asian countries, which has markedly reduced disease incidence. |
| 491 | Zika virus | A mosquito-borne flavivirus that caused a major outbreak in the Americas in 2015–2016, notable for causing birth defects (microcephaly) when pregnant women are infected. While no licensed Zika vaccine exists yet, multiple vaccine candidates (DNA, mRNA, live attenuated, VLP, etc.) have been in development and some progressed to clinical trials. The Zika outbreak waned before a vaccine was ready, but research continues in case of re-emergence. Zika highlighted the need for rapid vaccine R&D for emerging zoonotic viruses. |
| 481 | which contains multiple strains or antigens.) mRNA (messenger RNA) | A molecule of RNA that carries genetic instructions from DNA to the cellular machinery (ribosomes) for protein synthesis. mRNA is the template for building proteins. In the context of vaccines, mRNA vaccines use a synthetic mRNA encoding a viral or bacterial antigen (such as the SARS-CoV-2 spike protein). After injection, cells take up the mRNA and use it to produce the antigen, which then elicits an immune response. The mRNA in vaccines is typically modified (e.g., using pseudouridine) to increase stability and reduce reactogenicity. It is important to note that mRNA does not integrate into DNA and is transient. |
| 312 | Pathogen | A microorganism that can cause disease (such as a virus, bacterium, parasite, or fungus). Vaccines are designed to mimic specific pathogens (or parts of them) to train the immune system without causing illness. For example, the measles vaccine uses an attenuated measles virus (pathogen), and the pneumococcal vaccine uses components of the Streptococcus pneumoniae bacterium (pathogen). |
| 344 | Quality-Adjusted Life Year (QALY) | A metric that combines both the quantity and quality of life lived, used to assess the value of medical interventions. One QALY equates to one year of life in perfect health. Vaccines (especially in health technology assessments in high-income settings) may be evaluated in terms of cost per QALY gained, with lower ratios indicating more cost-effective vaccines. |
| 443 | Vaccine confidence index | A metric developed by researchers to quantify the level of confidence in vaccines among a population. The Vaccine Confidence Project, for instance, conducts surveys globally and produces an index based on trust in vaccine safety, efficacy, importance, and religious compatibility. An index allows comparisons over time and between countries or regions. Policymakers watch these trends – a declining confidence index might predict uptake problems or hesitancy clusters. By identifying populations with low confidence through such indices, targeted engagement can be initiated. These indices have revealed, for example, varying confidence levels in different European countries or shifts in confidence following vaccine scares, underscoring the need for ongoing measurement and responsive communication strategies. |
| 420 | Thimerosal | A mercury-containing antiseptic and preservative (ethylmercury compound) that was used in multi-dose vials of some vaccines to prevent bacterial/fungal contamination. It has been largely removed or reduced to trace amounts in childhood vaccines in many countries since 1999 as a precaution, despite no convincing evidence of harm at the doses used. Thimerosal contains ethylmercury, which is cleared from the body faster than methylmercury (the kind in some fish). Numerous studies have shown no link between thimerosal in vaccines and autism or other neurodevelopmental problems. Today, most routine vaccines (except some multi-dose flu vaccine vials and certain adult vaccines) are thimerosal-free or only contain trace residuals. |
| 293 | No-Fault Compensation Program | A mechanism to provide financial compensation to individuals who suffer rare serious adverse events from vaccination, without requiring the individual to prove negligence or fault on the part of healthcare providers or manufacturers. These programs recognize that while vaccines are overwhelmingly safe and beneficial for society, on very rare occasions they can cause harm (e.g., vaccine-associated paralytic polio from OPV, or severe allergic reactions). To maintain public trust and ensure fairness, many countries have established vaccine injury compensation schemes – “no-fault” means the claimant does not have to go through a lengthy legal process to establish blame; they just must show a likely link between the vaccine and the injury. For example, the U.S. has the National Vaccine Injury Compensation Program (VICP) which has compensated for certain adverse events according to a Vaccine Injury Table. During COVID-19, because vaccines were rolled out widely under emergency conditions, a special no-fault program was set up by COVAX for the AMC countries, the first of its kind on an international scale. This program allowed people in low-income countries to apply for compensation if they experienced a serious adverse reaction to a COVAX-distributed vaccine, providing support without resorting to litigation. The existence of no-fault compensation is seen as an ethical complement to immunization programs, and practically, it helps reduce lawsuits against manufacturers (who might otherwise be deterred from producing vaccines). Overall, these programs underscore societal commitment to care for the few who are harmed while pursuing the greater good of herd immunity. |
| 27 | Antibody-dependent cellular cytotoxicity (ADCC) | A mechanism of immune defense in which effector cells lyse a target cell that has been bound by specific antibodies. In ADCC, an effector cell (such as an NK cell) recognizes the Fc region of antibodies coating a target (e.g. a virus-infected cell) and releases cytotoxic molecules to kill that cell. It is “a mechanism of cell-mediated immune defense whereby an effector cell of the immune system kills a target cell whose membrane-surface antigens have been bound by specific antibodies”. NK cells most classically mediate ADCC via IgG antibodies, but macrophages, neutrophils, and eosinophils can also participate (e.g. eosinophils targeting helminths via IgE). |
| 114 | Disability-Adjusted Life Year (DALY) | A measure of overall disease burden that combines years of life lost due to premature death and years lived with disability. One DALY represents one lost year of healthy life. In immunization economics, the DALYs averted by vaccines (through preventing illness and death) are often estimated; a low cost per DALY averted indicates a highly cost-effective vaccine intervention. |
| 402 | Supplementary Immunization Activity (SIA) | A mass vaccination campaign conducted in addition to routine services, usually to interrupt transmission of a disease or boost population immunity. SIAs target a specified age group regardless of prior vaccination status – for example, nationwide National Immunization Days for polio where every child under 5 is given OPV, or periodic measles follow-up campaigns immunizing all children 9 months to 5 years. These campaigns “supplement” routine immunization by reaching children who may have been missed and topping up immunity in the cohort. SIAs are a cornerstone of polio eradication and have been used for measles, yellow fever, meningitis, and cholera control. While effective in raising coverage quickly, they require significant logistics and are meant to be an interim measure until routine systems can reliably reach all children. |
| 147 | Epitope prediction and vaccine design | A major focus of computational vaccinology where algorithms predict the specific pieces of an antigen (epitopes) that immune receptors recognize. Tools exist for B-cell epitope prediction (to guess peptide or structural epitopes on proteins that antibodies will bind) and T-cell epitope prediction (identifying peptides likely to be presented by MHC and seen by T-cells). By computationally mapping these epitopes, researchers design multi-epitope vaccines or peptide vaccines that include the most immunogenic regions. In silico epitope prediction was widely used to propose vaccine candidates for emerging viruses (like identifying SARS-CoV-2 spike T-cell epitopes early in the pandemic). |
| 261 | Memory cell | A long-lived lymphocyte (either a memory B cell or memory T cell) that was generated in response to an initial exposure to an antigen and “remembers” that antigen. Memory cells persist in the body and allow the immune system to mount a faster and stronger response upon re-exposure to the same pathogen. Vaccines aim to produce memory B cells (which quickly produce antibodies upon re-infection) and memory T cells. For instance, memory B cells against measles can last decades after vaccination, providing long-term immunity. |
| 48 | Hepatitis E | A liver virus (HEV) transmitted similarly to hepatitis A (fecal-oral route, often via contaminated water). Hepatitis E causes acute illness and is especially risky in pregnant women. There is a vaccine against HEV licensed in China, but not yet globally available. Preventative measures include ensuring safe drinking water. |
| 35 | Hepatitis D | A liver virus (HDV) that is unusual because it requires the presence of hepatitis B virus to replicate. HDV co-infection or superinfection can worsen hepatitis B. There is no dedicated hepatitis D vaccine, but hepatitis B immunization prevents hepatitis D because HDV cannot establish without HBV. |
| 300 | OPV (Oral Polio Vaccine) | A live attenuated poliovirus vaccine given orally. OPV contains weakened strains of poliovirus that induce intestinal and systemic immunity. It has the advantage of aiding herd immunity by secondary spread (vaccine virus can shed and immunize contacts), and it is easy to administer. However, in rare instances OPV can revert to a neurovirulent form and cause vaccine-derived poliovirus outbreaks or vaccine-associated paralytic polio (approximately 2–4 cases per 1 million births for first doses). OPV was crucial in polio eradication campaigns due to ease of use and strong herd effect; some regions have switched to IPV after eliminating wild polio. (Compare IPV, the inactivated polio vaccine.) |
| 229 | International Health Regulations (IHR) | A legally binding international framework (last revised in 2005) that commits 196 countries to detect and report public health emergencies of international concern, and to uphold certain core capacities for surveillance and response. The IHR require countries to promptly notify WHO of events like novel pathogens, unusual clusters of disease, etc., and allow WHO to declare Public Health Emergencies of International Concern (PHEIC). The IHR also contain provisions to avoid unwarranted travel and trade restrictions. Under the IHR, countries had to report SARS-CoV-2 early cases (China’s notification at end of 2019 fell under this). The IHR (2005) were a response to SARS and meant to improve transparency and cooperation – they did, but COVID-19 showed some weaknesses (countries were slow to share information or implemented chaotic travel measures). Reforms are being discussed alongside the pandemic treaty. For immunization, IHR is relevant in that proof of vaccination can be used for travel requirements if approved by WHO (like yellow fever vaccination is in IHR). COVID-19 raised the question of whether COVID vaccination should be an IHR travel requirement, but it wasn’t added formally. |
| 228 | International Health Regulations (IHR, 2005) | A legally binding international agreement under WHO that defines countries’ rights and obligations in handling public health events that could spread internationally. The IHR require all 196 States Parties to develop minimum core capacities for surveillance and response, to promptly notify WHO of events that might constitute a public health emergency of international concern, and to cooperate on controlling international spread of disease. The IHR framework seeks to prevent and contain risks while avoiding unnecessary interference with travel and trade. |
| 81 | Compulsory licensing | A legal provision that allows a government to authorize the production or importation of a patented product without the consent of the patent owner, typically with certain conditions (like paying royalties). In context of vaccines, if a country cannot access a needed vaccine due to cost or insufficient supply, it could issue a compulsory license to have it made generically or to import generics from elsewhere. TRIPS Article 31 outlines this process and it’s been used for medications (notably HIV dru+B84gs). For COVID-19 vaccines, no country ultimately went ahead with full compulsory licensing for local production (likely due to technical complexity of manufacturing), but some prepared laws to enable it. Compulsory licensing remains a tool for future pandemics or situations where a breakthrough vaccine might be held by one company, it provides leverage for negotiations or a path to ensure supply in emergencies. |
| 320 | Phase III trial | A large-scale clinical trial (often thousands or tens of thousands of participants) aimed at determining the vaccine’s efficacy in preventing the target disease, as well as collecting more comprehensive safety data. Phase III trials are usually randomized, placebo-controlled, and blinded. Researchers compare the incidence of the disease between the vaccinated group and the placebo group. For instance, a Phase III trial might show that a vaccine has 95% efficacy (only 5% of cases in vaccine group relative to placebo). Phase III also detects any relatively rare side effects. Successful Phase III results are typically required for regulatory approval. |
| 256 | Macrophage | A large phagocytic white blood cell that engulfs and digests pathogens, cellular debris, and other foreign particles. Macrophages are part of the innate immune system and also act as antigen-presenting cells. They reside in tissues throughout the body (often with specific names like Kupffer cells in liver, microglia in brain). In vaccination, macrophages may ingest the vaccine antigen and present it to T cells, and they also produce cytokines that help orchestrate the immune response. |
| 288 | Neutralization assay | A laboratory test that measures the ability of antibodies to neutralize a pathogen (usually a virus). In a neutralization assay, serial dilutions of a serum (from a vaccinated person, for instance) are mixed with live virus, and the mixture is then added to cell cultures. If the antibodies in the serum can neutralize the virus, they prevent the virus from infecting cells. The highest dilution of serum that still protects cells from infection is the neutralizing antibody titer. These assays are considered the gold standard for assessing functional antibody immunity (e.g., post-vaccine). |
| 404 | Surrogate Endpoint (Immunologic Surrogate) | A laboratory or clinical measurement used in trials as a substitute for a true clinical endpoint, on the assumption that changes in the surrogate predict changes in the clinical outcome. In vaccinology, immunological surrogates of protection are often used – for instance, instead of waiting to observe disease occurrence, a certain antibody titer is used as a surrogate endpoint for protection (because it correlates with protection). Regulatory bodies sometimes accept surrogate endpoints for approval, especially when direct efficacy trials are unethical or difficult. An example is the immune correlate of protection for influenza (HI titer of 1:40), or using neutralizing antibody titers to approve updated COVID variant vaccines by immunobridging. The surrogate must be well-validated; not all immune responses serve as true surrogates (e.g., simply inducing any antibodies doesn’t guarantee protection unless specific threshold or quality is met). Good surrogates greatly speed up vaccine development by allowing smaller immunogenicity trials to infer likely protection, but they rely on previous knowledge linking that immune marker to clinical efficacy. |
| 148 | Erythema multiforme | A hypersensitivity reaction that can occur after infections or, rarely, vaccinations, characterized by target-like red lesions on the skin and mucous membranes. It is usually self-limited. This term appears in vaccine glossaries because erythema multiforme has been reported rarely following certain vaccines, though establishing causality is difficult. (In general, it’s more commonly triggered by infections like herpes simplex.) |
| 327 | Poliomyelitis (Polio) | A highly infectious disease caused by poliovirus that can invade the nervous system and cause paralysis. Polio mainly affects children and is spread via fecal-oral route. In the pre-vaccine era, polio epidemics caused thousands of cases of paralysis annually. Thanks to vaccines (OPV and IPV), polio has been eliminated from most countries. The IPV (Inactivated Polio Vaccine), given by injection, and OPV (Oral Polio Vaccine), given orally, have both been used in immunization campaigns. Polio remains endemic in only a couple of countries as of 2025, and global eradication efforts continue. |
| 384 | Smallpox | A highly infectious and often fatal disease caused by the variola virus. Smallpox was characterized by high fever and a distinctive rash with pus-filled sores; it had a mortality rate of ~30% for major strains. It is the first (and so far only) human disease eradicated by vaccination. The smallpox vaccine (using vaccinia virus) led to the global eradication declared in 1980. Routine smallpox vaccination ended thereafter, but some countries maintain vaccine stockpiles due to bioterrorism concerns. The vaccine is live and left a characteristic scar. Smallpox serves as a proof of concept of herd immunity and ring vaccination in eradication. |
| 259 | Measles | A highly contagious viral disease characterized by fever, cough, conjunctivitis, and a generalized maculopapular rash. Measles can lead to serious complications like pneumonia or encephalitis. It is caused by the measles (rubeola) virus, transmitted by respiratory droplets. The measles vaccine (as part of the MMR live attenuated vaccine) is extraordinarily effective and has led to elimination of endemic measles in some regions. However, measles outbreaks still occur when vaccination coverage falls, due to its very high R? (around 12–18). (Measles is also referred to as rubeola.) |
| 241 | Learning Health System | A health system that continuously and systematically integrates data and evidence from practice into ongoing improvement, so that care is routinely enhanced with real-time learning. |
| 242 | Leave no one behind | A guiding principle of the Sustainable Development Goals (including health goals) which calls for deliberate focus on the needs of the most marginalized and ensuring that progress reaches everyone. In immunization policy, “leave no one behind” translates to identifying population groups with low coverage (due to geography, poverty, conflict, minority status, etc.) and implementing pro-equity strategies to include them. It underpins efforts like reaching slum dwellers, mobile populations, or disabled children with vaccines. This principle is explicitly embraced in Immunization Agenda 2030 – success will be measured not just by overall coverage, but by closing coverage gaps across different communities. |
| 16 | Advisory Committee on Immunization Practices (ACIP) | A group of medical and public health experts that develops recommendations on vaccine use in the U.S. civilian population. ACIP guidelines (e.g. vaccine schedules, target groups) are considered public health guidance for safe and effective vaccine use. |
| 324 | Plaque Reduction Neutralization Test (PRNT) | A gold-standard functional assay to quantify virus-neutralizing antibodies in serum. In a PRNT, serial dilutions of serum are mixed with a live virus and then added to cell cultures. After an incubation period, any non-neutralized virus forms “plaques” (zones of infected cell destruction). Neutralizing antibodies in the serum will reduce the number of plaques. The PRNT titer is defined as the highest serum dilution that causes a specific reduction in plaque count (often 50% or 90% reduction, referred to as PRNT. For many viral vaccines (measles, polio, yellow fever, etc.), PRNT is used to evaluate the neutralizing antibody response and establish correlates of protection. It is labor-intensive and requires live virus and biosafety measures, but it directly indicates the functional ability of antibodies to block virus infection. |
| 70 | Coalition for Epidemic Preparedness Innovations (CEPI) | A global partnership launched in 2017 to finance and coordinate the development of new vaccines against emerging infectious diseases with epidemic potential. CEPI brings together governments, industry, philanthropy, and civil organizations to invest in vaccine R&D for threats like Nipah, Lassa fever, MERS, and “Disease X,” and it played a key role in funding COVID-19 vaccine development. CEPI’s mission is to accelerate vaccine development and ensure equitable access to those vaccines during outbreaks, aiming for innovative approaches such as the 100-day vaccine initiative (to have a vaccine within 100 days of a pathogen’s identification). |
| 150 | Expanded Programme on Immunization (EPI) | A global initiative launched by WHO in 1974 to ensure that all children have access to life-saving vaccines. The EPI initially focused on six diseases (polio, measles, diphtheria, pertussis, tetanus, and tuberculosis) and has expanded to include many others. Thanks to EPI and national immunization programs, vaccine coverage worldwide has greatly increased, preventing millions of deaths. |
| 189 | Hotspot | A geographic area where the convergence of ecological, environmental, and social factors makes the emergence or transmission of diseases (especially zoonoses) particularly likely. |
| 100 | CRISPR–Cas9 Gene Editing | A genome editing technology adapted from a bacterial immune system, employing a guide RNA (gRNA) to direct the Cas9 endonuclease to a specific DNA sequence. The gRNA (a short synthetic RNA complementary to the target gene) ensures Cas9 cuts at the desired locus, allowing genes to be knocked out or modified. In therapeutic contexts, CRISPR–Cas9 is being explored to treat genetic diseases by correcting mutations or disabling problematic genes. (While CRISPR works at the DNA level, the required components – Cas9 mRNA or protein and gRNA – are often delivered similarly to RNA therapeutics, e.g. via LNPs.) |
| 393 | Strain | A genetic variant or subtype of a microorganism (virus, bacterium, etc.). Strains of a pathogen can differ in transmissibility, virulence, and antigenic properties. Vaccines may be strain-specific or polyvalent. For example, there are multiple strains of poliovirus (types 1, 2, 3), influenza (H1N1, H3N2, etc.), and HPV (over 100 types, with about 9 targeted in vaccines). When a new strain emerges that is not well-covered by existing immunity (like a drifted flu strain or a new SARS-CoV-2 variant), vaccine updates or boosters may be needed. |
| 342 | Public Health Emergency of International Concern (PHEIC) | A formal declaration by the WHO Director-General of an extraordinary public health event that carries risk of international spread and may require a coordinated international response. A PHEIC is defined in the IHR (2005) as “an extraordinary event which is determined to constitute a public health risk to other States through the international spread of disease and to potentially require a coordinated international response”. Declaring a PHEIC (as done for polio in 2014, COVID-19 in 2020, etc.) mobilizes global attention and guidance through temporary recommendations to help manage the emergency. |
| 373 | Self-amplifying RNA (saRNA) vaccine | A form of RNA vaccine that includes genetic instructions for both the target antigen and a replicase enzyme. After delivery into cells, the replicase amplifies the RNA, creating a “built-in printing press” that generates additional copies of the antigen-encoding RNA. By producing more antigen per dose, saRNA vaccines can achieve potent immune responses at lower doses than traditional mRNA vaccines. (Example: saRNA COVID-19 vaccines under development.) |
| 230 | Intracellular Cytokine Staining (ICS) | A flow-cytometry-based method to detect cytokine production by T cells (or other cells) at the single-cell level, following antigen stimulation. In an ICS assay, peripheral blood mononuclear cells from a vaccinated individual are incubated with the vaccine antigen or peptide pool for several hours. A secretion inhibitor (like brefeldin A) is added to retain cytokines (e.g., IFN-?, IL-2, TNF-?) inside the cells. The cells are then fixed, made permeable, and stained with fluorescent antibodies specific to those cytokines and to cell-surface markers (to distinguish CD4 vs CD8 T cells, etc.). Flow cytometry is used to quantify what proportion of T cells produced each cytokine (and combinations thereof). ICS provides a detailed functional readout of T cell responses – for example, showing that X% of CD4 T cells produce IFN-? in response to the vaccine, or that polyfunctional T cells producing IFN-?+TNF+IL-2 increase after boosting. It’s an important tool for vaccine trials, especially for vaccines aiming to induce T-cell immunity (TB, HIV, etc.), complementing ELISpot data. |
| 88 | Coronavirus | A family of viruses (Coronaviridae) with crown-like spikes on their surface. Several coronaviruses infect humans, causing illnesses ranging from the common cold to severe diseases. SARS-CoV-2 is the coronavirus responsible for COVID-19. Vaccines for COVID-19 (including mRNA, viral vector, and inactivated vaccines) are designed to induce immunity to SARS-CoV-2’s Spike protein. (See also COVID-19 and SARS-CoV-2.) |
| 294 | NOD-like receptor (NLR) | A family of intracellular (cytosolic) pattern recognition receptors that detect microbial motifs or signs of cell damage. “NOD” refers to the first discovered members (Nucleotide-binding Oligomerization Domain-containing proteins). NLRs often act as sentinels inside the cell for things like bacterial peptidoglycans (e.g., NOD1, NOD2) or perturbations that lead to complex assembly like inflammasomes (e.g., NLRP3 detects diverse stress signals and forms an inflammasome to activate IL-1?). They are “highly conserved cytosolic pattern recognition receptors” playing “critical functions in surveying the intracellular environment” for infection or stress. Upon activation, NLRs typically initiate inflammatory signaling pathways. For instance, NOD2 recognizing muramyl dipeptide from bacterial cell walls leads to NF-?B activation, and NLRP3 sensing ATP or crystalline substances leads to caspase-1 activation and cytokine maturation. NLRs are key players in innate immunity and inflammation, linking intracellular detection to appropriate immune effector responses. |
| 383 | Small Interfering RNA (siRNA) | A double-stranded RNA (~20–25 base pairs) that mediates RNAi by incorporating into the RNA-induced silencing complex (RISC) and guiding it to cleave a complementary mRNA. siRNA therapeutics are designed to silence specific genes – for example, siRNA drugs have been approved to lower pathogenic transthyretin or cholesterol-related genes. Effective delivery (often via lipid nanoparticles) is key to their clinical use. |
| 454 | Vaccine Information Statement (VIS) | A document produced by the CDC that explains the benefits and risks of a vaccine to vaccine recipients (or their parents/guardians). U.S. federal law requires that the appropriate VIS be provided to the patient (or parent) prior to administration of each dose of certain vaccines. VISs are written in plain language and cover what the vaccine is for, who should/shouldn’t get it, common side effects, and what to do about them. They help ensure informed consent. For example, there are VISs for MMR, for influenza vaccines, for COVID-19 vaccines, etc., updated as needed. |
| 118 | DNA-launched replicon vaccine | A DNA-based vaccine that, once inside the cell, transcribes into a self-replicating RNA (replicon). This approach uses a plasmid DNA to “launch” an RNA replicon encoding the antigen and viral replicase. The replicon RNA multiplies inside host cells, leading to high antigen levels without producing infectious virus. DNA-launched replicons combine the stability of DNA vaccines with the high immunogenicity of replicating RNA, as shown in chikungunya vaccine studies. |
| 23 | Anthroponosis (Reverse Zoonosis) | A disease or infection that can be transmitted from humans to animals under natural conditions. |
| 473 | Vector-Borne Disease | A disease in which the pathogen is transmitted from one host to another by a vector organism. |
| 133 | Electronic Vaccine Intelligence Network (eVIN) | A digital logistics management system that provides real-time information on vaccine stocks and storage temperatures across the supply chain. Pioneered in India with support from UNDP, eVIN uses a smartphone app and cloud database to enable health workers and managers to update and monitor vaccine inventory at every cold store and health facility. It replaces paper-based stock registers with an integrated dashboard showing stock levels, expiries, and temperature data from continuous temperature loggers. eVIN has improved vaccine availability by predicting shortages and preventing overstock, and has helped maintain cold chain integrity by alerting officials to temperature excursions. It’s an example of how digital tools enhance transparency and efficiency in immunization programs. Similar systems are being adopted in other countries as part of smart supply chain management. |
| 171 | Glycan shield | A dense array of sugar molecules (glycans) attached to a pathogen’s surface proteins that helps the pathogen evade immune recognition. Many viruses (e.g., HIV, SARS-CoV-2, influenza) and some parasites heavily glycosylate their surface proteins. These host-derived glycans can mask underlying protein epitopes from antibody binding (since sugars are often seen as “self” and are poorly immunogenic). The “glycan shield is a sugary barrier that helps [viral] spikes evade the immune system”. In HIV-1, for example, the envelope glycoprotein is cloaked by N-linked glycans that sterically hinder many antibodies – only broadly neutralizing antibodies have evolved to penetrate or accommodate this shield. Understanding glycan shields is important for vaccine design, as vaccines may need to induce antibodies targeting glycan-protected sites or exploit rare vulnerable spots in the shield. |
| 472 | Vector (in vaccinology) | A delivery vehicle used to carry vaccine antigens or genetic material into the body. In the context of viral vector vaccines, a harmless virus is used as a vector to deliver genes encoding antigen(s) of the target pathogen. For example, adenovirus vectors are used in some COVID-19 vaccines to ferry the spike protein gene into human cells. Vectors can also refer to plasmids in DNA vaccines, or to the mosquitoes in disease transmission (biologically, a mosquito is a “vector” for malaria parasites – but in vaccines, “vector” usually refers to a carrier virus or bacterium). Viral vectors used in vaccines are often replication-deficient (they can enter cells and express antigen but not replicate). |
| 450 | Vaccine Hesitancy | A delay in acceptance, or refusal, of vaccines despite availability of vaccine services. It is complex and context-specific, varying across time, place, and vaccines. Vaccine hesitancy is influenced by factors such as complacency (not perceiving the need for or value of vaccines), convenience (access issues), and confidence (trust in the vaccine or provider) – sometimes summarized as the “3 Cs”. Hesitancy can manifest as concerns about safety (fear of side effects), mistrust of health authorities or pharmaceutical companies, influence of misinformation, religious or philosophical beliefs, or past historical abuses causing lack of trust. The WHO has identified vaccine hesitancy as a top global health threat, as it can lead to decreased coverage and outbreaks (e.g., measles resurgence in areas with growing hesitancy). Combatting hesitancy requires tailored strategies: community engagement, transparent communication about risks and benefits, involvement of trusted local leaders or healthcare providers, and sometimes policy measures (like vaccination requirements or incentives). It’s important to note that the hesitant population is heterogeneous – from those simply needing assurance to a small minority strongly opposed (often called anti-vaxxers). Listening to concerns and addressing them respectfully is key. During COVID-19, hesitancy in various populations affected uptake of the new vaccines, demonstrating that even with high vaccine availability, achieving high coverage requires building and maintaining public confidence. |
| 451 | Vaccine hesitancy | A delay in acceptance or refusal of vaccines despite availability of vaccination services. It is a complex, context-specific phenomenon influenced by factors such as complacency, convenience, and confidence (the “3 Cs”). WHO’s SAGE defines vaccine hesitancy as a motivational state of being conflicted about, or opposed to, getting vaccinated – it encompasses doubts and indecision as well as outright refusal. Importantly, hesitancy is not the same as being unvaccinated due to access issues; it specifically refers to attitude and behavior. Tackling vaccine hesitancy requires understanding the underlying concerns (e.g., fear of side effects, religious beliefs, misinformation) and tailoring interventions like counseling by health workers, engagement of community leaders, or mass communication to address those. |
| 63 | cGAS-STING pathway | A crucial innate immune sensing pathway for cytosolic DNA. cGAS (cyclic GMP-AMP synthase) is a cytosolic enzyme that detects double-stranded DNA in the cytoplasm (a sign of infection or cellular damage) and produces a messenger molecule cGAMP. cGAMP then binds to STING (Stimulator of Interferon Genes) on the endoplasmic reticulum membrane, activating it. The activated STING pathway triggers downstream signaling leading to type I interferon production and other inflammatory responses. In summary, “the cGAS–STING pathway is a component of the innate immune system that functions to detect the presence of cytosolic DNA and, in response, activate immune defenses”. This pathway is not only important for antiviral immunity (e.g., sensing DNA viruses or retroviral DNA) but also for anti-tumor immunity and is being explored in adjuvant design. |
| 245 | Lipid nanoparticle (LNP) delivery | A critical delivery system for nucleic acid vaccines, especially mRNA. LNPs are tiny fat-based particles that encapsulate and protect the fragile RNA or DNA molecules and facilitate their entry into host cells. LNP formulations both shield the nucleic acid from degradation and promote uptake by cells, acting as an adjuvant by provoking innate immunity. The success of mRNA vaccines (e.g., for COVID-19) is largely due to advances in LNP delivery, which ensures the mRNA reaches the cytoplasm to be translated into antigen. |
| 17 | AEFI surveillance and vaccine safety monitoring | A critical component of immunization programs is ongoing monitoring of adverse events following immunization (AEFIs) to detect any rare risks and respond appropriately. This includes passive surveillance systems like VAERS (Vaccine Adverse Event Reporting System) in the US, or national AEFI reporting systems where health workers and the public can report any health issue after vaccination. It also includes active surveillance (proactively checking on certain patients or using electronic health records to flag events) and phase IV studies. Globally, WHO’s Global Advisory Committee on Vaccine Safety (GACVS) regularly reviews safety signals and data from different countries to provide guidance. For instance, if one country notices unusual reports (like an allergy cluster, or something like VITT), a network of regulators and WHO can quickly share and analyze data to see if it’s a real issue and issue alerts or updated guidance. Strengthening AEFI surveillance, particularly in low- and middle-income countries, has been an ongoing effort, B21including training on causality assessment (to distinguish coincidental events from true vaccine reactions). The COVID-19 vaccine rollout saw probably the most intensive safety monitoring ever, resulting in quick identification of rare side effects (e.g., VITT, myocarditis) and updated recommendations to optimize safety. |
| 97 | COVID-19 Vaccine, bivalent | A COVID-19 vaccine formulation that targets two different antigens (e.g., the original virus strain and a variant strain). Bivalent mRNA COVID-19 vaccines, for instance, contain mRNA coding for the spike protein of the original SARS-CoV-2 strain and of an Omicron variant, broadening immune coverage. (By contrast, a monovalent vaccine targets a single strain.) |
| 284 | National Regulatory Authority (NRA) | A country’s governmental agency responsible for regulating medical products (including vaccines) by ensuring their quality, safety, and efficacy. An NRA’s functions include authorizing clinical trials, licensing new vaccines, inspecting manufacturing facilities, evaluating batch quality (lot release), and monitoring adverse events. A well-functioning NRA provides independent oversight of vaccines in the country. (For example, the U.S. FDA or India’s CDSCO are NRAs.) WHO actively helps build NRA capacity so that vaccines are properly regulated worldwide. |
| 362 | Ring vaccination | A containment strategy in which, when a case of an infectious disease is detected, all people who have been in close contact with that case (and contacts of contacts, as appropriate) are rapidly vaccinated to form a “ring” of immunity around the case. This approach was famously used in the smallpox eradication program: instead of mass vaccination of an entire population, health workers traced each smallpox case and vaccinated household members, neighbors, and other contacts, effectively stopping transmission. Ring vaccination has also been used in Ebola outbreaks (with an investigational Ebola vaccine) – vaccinating contacts and contacts-of-contacts to curtail spread. It works best for diseases with relatively close-contact transmission and where cases can be identified and reached quickly. |
| 132 | Electronic Immunization Registry (EIR) | A confidential, computerized database that records individual vaccination histories for a defined population. An EIR allows health facilities and programs to capture and store data on each person’s vaccines, generating a reliable record that can be used to remind caregivers about upcoming doses and to identify defaulters. It also provides aggregated data for monitoring coverage in real time. Implementing EIRs (often via mobile or web applications) is increasingly seen in countries as they modernize their immunization information systems – examples include Nicaragua’s nominal register or Tanzania’s electronic immunization system. EIRs improve data accuracy (reducing reliance on paper) and support better targeted outreach, though they require investment in IT and data security. |
| 331 | Precaution (in vaccination) | A condition that may increase the risk of an adverse reaction or complicate the interpretation of vaccine-associated symptoms, such that vaccination should be considered carefully (risk vs benefit) rather than automatically deferred. An example of a precaution is a moderate acute illness with or without fever – vaccination might be postponed until recovery. Another example: a history of Guillain–Barré syndrome is a precaution for certain vaccines. Precautions are not absolute contraindications, but warrant careful evaluation. |
| 85 | Contraindication (to Vaccination) | A condition or factor that increases the risk of a serious adverse reaction to a vaccine, to such an extent that administering that vaccine is not advised. Contraindications can be permanent (e.g., a history of a severe allergic reaction like anaphylaxis to a previous dose or a vaccine component is a contraindication to further doses) or temporary (e.g., a person with a moderate to severe acute illness might postpone vaccination until recovery). Examples: pregnancy is a contraindication for live attenuated vaccines like rubella (due to theoretical risk to the fetus), severe immunodeficiency is a contraindication to live vaccines (risk of uncontrolled infection), and a history of intussusception is a contraindication to rotavirus vaccines. Vaccination should be deferred or avoided in such cases to prevent harm. It’s important to distinguish contraindications from precautions (conditions that require careful consideration but not absolute avoidance). Screening for contraindications is a key part of safe immunization practice. |
| 84 | Contraindication | A condition or factor that increases the risk of a serious adverse reaction to a vaccine, such that the vaccine should not be administered in that circumstance. For example, a severe allergic reaction (anaphylaxis) to a prior dose or to a vaccine component is a contraindication to further doses. Contraindications differ from precautions, which are conditions that require assessing risks vs benefits before deciding to vaccinate. |
| 346 | Quasispecies | A concept in virology describing a population of rapidly mutating organisms (typically RNA viruses) as a cloud of genetic variants rather than a single homogeneous genotype. Because RNA viruses often have high mutation rates, an infected individual will harbor a swarm of related but non-identical viral genomes. This “mutant swarm” is the quasispecies. It is characterized by a distribution of variants around a consensus sequence, with competition and collaboration between variants. “Viral quasispecies refers to a population structure of viruses with a large number of variant genomes (related by mutations)”. The quasispecies nature of RNA viruses (like HIV, HCV, influenza) allows them to adapt quickly to selective pressures (like immune responses or antivirals), as some variants in the swarm may survive new pressures. It also means that defining a singular “strain” genetically can be challenging. The quasispecies theory has implications for vaccine design and antiviral therapy, emphasizing the need to target highly conserved elements of the virus. |
| 36 | Antigenic distance and vaccine update | A concept closely tied to antigenic cartography and flu vaccine policy. Antigenic distance measures how different a virus strain is from another in terms of antibody recognition. A threshold of antigenic distance often guides whether a vaccine strain should be updated – if the circulating strain is antigenically “far” from the vaccine strain, vaccine effectiveness drops. This concept was formalized in influenza (“strain X is 4 units distant from strain Y on the map”). Computational models now incorporate antigenic distance to predict vaccine performance against evolving strains (such as quantifying how much a SARS-CoV-2 Omicron is antigenically drifted from Delta or ancestral strain). This helps determine the need for variant vaccines. |
| 34 | Antigenic Cartography | A computational method to visualize and quantify antigenic differences among virus strains. It creates a map in which distances between points (viruses and sera) reflect antigenic relationships derived from neutralization or hemagglutination inhibition titers. For example, in influenza vaccine selection, antigenic cartography is used to map how far a drifted influenza strain has “moved” antigenically from the current vaccine strain. Points that cluster together are antigenically similar. This technique helps decision-makers select vaccine strains by identifying clusters and gaps in population immunity. In essence, antigenic cartography projects complex serological data into an interpretable 2D or 3D map, guiding strain updates for vaccines. |
| 449 | Vaccine equity index | A composite metric intended to quantify disparities in vaccine coverage or access among different population groups or regions. For example, a COVID-19 Vaccine Equity Index was developed in some settings to identify and illustrate vaccination gaps between racial/ethnic or socio-economic groups. A higher equity index indicates more equitable distribution (smaller disparities), whereas a lower value signals significant inequities in who is getting vaccinated. Policymakers use such indices to monitor fairness in immunization programs and target interventions to underserved groups. |
| 246 | Lipopolysaccharide (LPS) | A component of the outer membrane of gram-negative bacteria that can act as a potent immune stimulator (endotoxin). While not a vaccine itself, LPS (or derivatives like monophosphoryl lipid A) is sometimes used as a component in adjuvants to enhance immune responses. For instance, AS04 adjuvant (used in some HPV and hepatitis B vaccines) contains MPL, a detoxified form of LPS, to activate innate immunity and improve vaccine immunogenicity. |
| 11 | Adjuvant | A component added to some vaccines (distinct from the active antigen) that enhances the immune response to the vaccine antigen. Adjuvants (such as aluminum salts) boost immunogenicity, helping the body produce a stronger or longer-lasting immunity. |
| 191 | Human papillomavirus (HPV) | A common sexually transmitted virus, of which certain “high-risk” strains cause cancers (such as cervical, anal, oropharyngeal cancers) and other strains cause warts. Persistent infection with high-risk HPV (especially types 16 and 18) is the principal cause of cervical cancer. Highly effective HPV vaccines (recombinant virus-like particle vaccines) protect against the most dangerous HPV types. and widespread vaccination programs are significantly reducing HPV infections and related cancers. |
| 141 | Enzyme-Linked Immunosorbent Assay (ELISA) | A common laboratory test (immunoassay) used to detect or measure specific antibodies or antigens in a sample. In an ELISA, an antigen or antibody is affixed to a plate, and an enzyme-linked detection antibody produces a color change or signal if the target is present. ELISAs are used to assess immune responses to vaccines (e.g. measuring antibody titers), as well as for diagnostic purposes (such as HIV tests). |
| 282 | National Immunization Technical Advisory Group (NITAG) | A committee of national experts that provides independent, evidence-based vaccine policy recommendations to a country’s health authorities. NITAGs are multidisciplinary (e.g., epidemiologists, pediatricians, economists) and review data on disease burden, vaccine efficacy, safety, cost-effectiveness, etc., to advise on immunization schedules and new vaccine introductions. For instance, a NITAG might recommend including rotavirus vaccine in the national program or adjusting the timing of booster doses. A well-functioning NITAG strengthens immunization decision-making by grounding it in local evidence and context, and WHO actively supports NITAG capacity globally. |
| 125 | DTaP vaccine | A combination vaccine that protects against three diseases: Diphtheria, Tetanus, and Pertussis (whooping cough). The “a” stands for “acellular pertussis,” meaning the pertussis component contains purified antigens rather than whole cells (making it an acellular vaccine). DTaP is given to infants and children in a series of doses. (A different formulation called Tdap is used as a booster for older children and adults, with reduced diphtheria and pertussis antigen content.) |
| 159 | Fridge stable (vaccine) | A colloquial term indicating that a vaccine is stable for storage at standard refrigerator temperatures (2–8 °C). Most routine vaccines are fridge-stable. Some newer vaccines (or formulations) are being developed to be fridge stable rather than requiring freezing or ultracold storage, which greatly facilitates distribution. For example, the lyophilized formulations of some vaccines are fridge stable until reconstitution. |
| 79 | Community-Based Participatory Research | A collaborative research approach that equitably involves community members and researchers in all phases of program development and implementation. |
| 460 | Vaccine Safety Datalink (VSD) | A collaborative project between the CDC and several large healthcare organizations (integrated health systems) in the U.S. that uses electronic health records to monitor vaccine safety continuously. The VSD covers millions of patients and can be used to conduct robust epidemiological studies on vaccine risks (and also effectiveness). It can rapidly test hypotheses that arise from VAERS signals. For instance, VSD studies were used to evaluate the risk of febrile seizures after the 2010 flu vaccine in young children, and the risk of myocarditis after mRNA COVID-19 vaccines. The VSD is a cornerstone of active post-marketing surveillance in the USA. |
| 323 | Placebo-controlled trial | A clinical trial in which a control group receives a placebo – an inactive substance designed to resemble the vaccine or drug – to serve as a comparison for the group receiving the active intervention. This is considered the gold standard for testing efficacy, as it allows researchers to distinguish the true effect of the vaccine from psychological or other factors. In a placebo-controlled vaccine trial, one group gets the candidate vaccine and another gets a placebo (such as a saline injection), and outcomes (infection rates, immune responses, etc.) are compared. Blinding is usually employed so that participants and investigators do not know who got vaccine vs placebo, to eliminate bias. An example is the Phase III trial of an COVID-19 vaccine where approximately half the participants got the vaccine and half got a saline shot – only by comparing COVID-19 cases in each group could efficacy be measured. The use of a placebo control ensures that any difference in outcome can be attributed to the vaccine, accounting for the placebo effect where expectations alone might influence perceived effects. |
| 122 | Double-blind trial | A clinical trial design in which neither the participants nor the investigators know who is receiving the vaccine (experimental product) and who is receiving a placebo (or comparator) until the study ends. Double-blinding minimizes bias in reporting and assessing outcomes. This is considered the gold standard for vaccine efficacy trials. (In a single-blind trial, only the participant is unaware of the treatment, while investigators know.) |
| 209 | Immunobridging | A clinical trial approach where a new vaccine’s efficacy is inferred by comparing its immune responses (antibody titers or other markers) to those of a known effective vaccine, rather than directly measuring disease prevention. Immunobridging studies are used to bridge protection when direct efficacy trials are not feasible – for example, to approve a vaccine in a different age group or an updated strain vaccine. The assumption is that if the new vaccine induces an immune response that is “non-inferior” (no worse than, or above some percentage) to the response of an earlier vaccine with proven efficacy, then the new vaccine will also be effective. A case of immunobridging was the authorization of bivalent COVID-19 boosters targeting Omicron: their approval was based on showing similar or better neutralizing antibody titers to the new variant compared to the original vaccine’s response, rather than waiting for clinical outcome data. Immunobridging requires that a correlate of protection or at least a well-established immune marker exists. It is a powerful tool to accelerate vaccine updates (e.g., annual flu shot strain changes are done via immunobridging on antibody titers). However, it is crucial that regulators have confidence in the surrogate marker used; otherwise, immunobridging could mislead if the immune marker isn’t truly predictive of protection. |
| 190 | Human Challenge Trial (Controlled Human Infection Model) | A clinical study in which volunteers are intentionally exposed to an infectious agent under controlled conditions, to study the infection or test vaccine efficacy more quickly. In a vaccine context, a human challenge trial (HCT) typically involves giving participants either a candidate vaccine or placebo, and then “challenging” them with the pathogen (or a weakened form) to see if the vaccine protects them. These trials are done with extensive ethical oversight, only for diseases that are treatable or self-limited, and usually with a well-characterized challenge strain. HCTs have been used for diseases like influenza, malaria, typhoid, cholera, and recently proposed for COVID-19. The advantage is the ability to get an early readout of vaccine efficacy in a small number of participants without having to wait for natural exposure. The risk is that volunteers might develop illness (which is why only certain pathogens are used and participants are closely monitored with rescue therapies available). Challenge trials also help in understanding correlates of protection and pathogenesis by capturing the infection process in real time. They complement, but do not replace, large field trials for definitive efficacy data. |
| 160 | Fully Immunized Child (FIC) | A child who has received all the doses of all vaccines included in the national immunization schedule by a certain age (often by 12 months). For example, an infant is fully immunized by age one if they have received BCG, three doses of DTP (or pentavalent), three doses of polio, and one dose of measles-containing vaccine (per traditional EPI schedule). The FIC coverage is an indicator that reflects overall performance of the immunization program. Surveys like Demographic and Health Surveys (DHS) often report the percentage of children 12–23 months who are fully immunized. Achieving a high FIC rate means the program is not only reaching children initially but ensuring they complete the series for all antigens, a comprehensive measure of program success. |
| 250 | Lymphocyte | A category of white blood cells comprising B cells, T cells, and natural killer cells. Lymphocytes are the central cells of adaptive immunity. B lymphocytes are responsible for humoral immunity (antibody production), while T lymphocytes are responsible for cell-mediated immunity (helper T cells coordinate immune responses; cytotoxic T cells kill infected cells). Vaccines work by stimulating lymphocytes specific to the pathogen’s antigens, generating immune memory. (See also B cell, T cell.) |
| 39 | Antigenic variation | A broad term for the strategies by which pathogens alter their surface antigens to evade immune responses. This includes mechanisms like antigenic drift and shift in viruses, as well as programmed gene rearrangements in parasites or bacteria. By changing antigenic epitopes, pathogens avoid recognition by existing antibodies or T cells. For example, “altering its antigens… is particularly important for extracellular pathogens” to escape antibody-mediated immunity. Antigenic variation can occur via point mutations, recombination, gene conversion, or switching expression among variant antigen genes (as in African trypanosomes with their VSG coat), and poses a challenge for vaccine design. |
| 19 | AlphaFold | A breakthrough AI system (released by DeepMind in 2021) that predicts protein 3D structures from amino acid sequences with very high accuracy. AlphaFold effectively “solved” the long-standing problem of protein folding for many cases and provided structural models for virtually all proteins in numerous organisms. In vaccinology, AlphaFold’s influence is profound, it provides reliable structures of pathogen proteins and immune receptors in cases where experimental structures are lacking, thereby fueling structural vaccinology efforts. Scientists can examine predicted epitopes, model antigen-antibody complexes, and design immunogens using AlphaFold models as starting points. The availability of AlphaFold’s protein structure database has greatly accelerated structure-based vaccine design and broadened it to more targets, including those that are difficult to crystallize. |
| 181 | Hepatitis C | A blood-borne viral liver disease caused by the Hepatitis C virus (HCV). It often becomes chronic and can cause liver damage or cancer. There is currently no vaccine for hepatitis C (unlike A and B), but antiviral treatments can cure most infections. Vaccine research is ongoing. |
| 440 | Vaccine | A biological preparation that improves immunity to a particular disease by stimulating the body’s immune system to recognize and fight the pathogen, without causing the disease itself. A vaccine typically contains an agent that resembles a disease-causing organism or a part of it – such as weakened or killed microbes, purified antigens, or genetic instructions for antigens. This stimulates an immune response that yields immunological memory, so that the immune system can respond more effectively upon future exposure to the actual pathogen. For example, the polio vaccine contains inactivated polioviruses that induce immunity and prevent paralysis without causing polio. Vaccines have led to the control, elimination, or eradication of many infectious diseases. |
| 176 | Haemophilus influenzae type b (Hib) | A bacterium that can cause severe invasive diseases, especially in young children, such as meningitis, pneumonia, and epiglottitis. Hib was a leading cause of bacterial meningitis in children before the Hib conjugate vaccine. The Hib vaccine (a polysaccharide-protein conjugate) is now a routine childhood vaccine and has dramatically reduced Hib disease. |
| 477 | Virulence | • The degree of pathogenicity of a microorganism, i.e. its ability to cause disease. Highly virulent strains cause severe disease, whereas attenuated strains have low virulence. Virulence factors are molecules produced by pathogens that contribute to disease severity (like toxins, enzymes, etc.). Vaccines often use non-virulent or attenuated strains, or non-pathogenic vectors, to safely induce immunity. Monitoring if a pathogen changes virulence is important; for example, vaccine-driven evolution could (in theory) select for strains of lower or higher virulence, but most vaccines have not been shown to increase virulence of pathogens. |
| 470 | VAQTA | (Brand name) One of the inactivated hepatitis A vaccines (VAQTA, made by Merck). (Included here for completeness – VAQTA is equivalent to other hepatitis A vaccines in efficacy. It is given in two doses 6 months apart to provide long-term protection against hepatitis A.) |
| 221 | Indemnity and liability in vaccine distribution | Vaccine manufacturers often require indemnification when supplying new vaccines during emergencies, meaning purchasing countries (or platforms like COVAX) assume the risk of compensating any injury claims rather than the company. During COVID-19, because of the speed of development, companies sought protection from lawsuits over unforeseen side effects. As a result, many governments signed indemnity agreements; in low-income settings, COVAX had to negotiate a blanket indemnity and set up a no-fault compensation program to handle claims. This was “one of the thorniest problems” that COVAX had to solve. The principle is that to encourage rapid innovation and distribution in a pandemic, companies shouldn’t bear full financial risk for rare adverse events – otherwise many would be hesitant to deploy vaccines widely. However, indemnity must be coupled with a fair compensation system for those injured. This balance is now a standard part of pandemic response plans (e.g., WHO has a model indemnity agreement and a model compensation scheme for future use). |
| 78 | Community vaccine champions | Trusted individuals within the community who advocate for vaccination and help address concerns. They might be local religious leaders, elders, teachers, or even ordinary parents who are passionate about immunization. By leveraging their respect and social networks, champions can influence peers in ways that outside health officials cannot. For example, imams in certain countries have been champions by issuing messages that polio drops are permissible in Islam, countering rumors. Training community volunteers to conduct door-to-door dialogues or having survivors of a disease share their stories are other forms of championing. This grassroots endorsement humanizes the message that vaccines are beneficial, thereby improving acceptance. |
| 75 | Cold chain | The temperature-controlled supply chain required to store, transport, and handle vaccines in potent condition from the manufacturer all the way to the vaccination site. The cold chain includes all equipment (cold rooms, freezers, refrigerators, cold boxes, vaccine carriers) and procedures used to keep vaccines within recommended temperatures (commonly 2–8°C for routine vaccines). It begins at the production plant and continues through international shipping, national and district stores, down to health facility refrigerators and portable carriers for outreach. Maintaining the cold chain is crucial because vaccines can lose efficacy if exposed to heat or freezing. Investments in solar-powered fridges, temperature monitoring devices, and training are all part of cold chain strengthening. |
| 174 | Guide RNA (gRNA) | The RNA component of CRISPR systems that defines the sequence target for gene editing. In CRISPR–Cas9, the guide RNA is usually a ~20 nucleotide sequence within a larger scaffold (tracrRNA) that complexes with Cas9. The gRNA binds to its complementary DNA target, bringing Cas9 to that site to induce a double-strand break. By redesigning the guide sequence, scientists can retarget Cas enzymes to virtually any gene. gRNAs are central to genome editing tools and are being optimized for specificity and efficacy in therapeutic gene editing. |
| 413 | Technology Transfer (for Vaccines) | The process of sharing manufacturing knowledge, techniques, and intellectual property from the developer of a vaccine to other manufacturers, often in different regions or countries, to expand production and supply. Tech transfer can involve training personnel, transferring cell banks, divulging the minutiae of the production process (e.g., how to grow the antigen, purification steps, quality tests), and licensing IP rights. For example, to scale up global production of COVID-19 vaccines, original manufacturers engaged in tech transfer to contract manufacturing organizations or partners in other countries (AstraZeneca notably transferred technology to the Serum Institute of India, among others). Successful tech transfer allows a vaccine to be made to the same standards by multiple producers, increasing volume and potentially lowering cost through competition or local production. It’s crucial for building vaccine self-reliance in regions; e.g., the Meningitis A conjugate vaccine involved a unique tech transfer to African manufacturer Bio-Manguinhos in Brazil. The WHO also set up an mRNA vaccine technology transfer hub in South Africa in 2021 to help low-middle income countries gain know-how to produce mRNA vaccines. Tech transfer is complex – it often takes many months to years for a receiving site to fully absorb the process and get regulatory approvals. It may be facilitated by patent pooling or voluntary licensing. Ultimately, effective tech transfer can shorten the time lag between vaccine development and its availability in underserved regions, and is a key strategy for pandemic preparedness and equitable access. |
| 216 | Implementation Science | The field of study that examines methods and strategies to integrate effective health interventions into routine practice and policy. |
| 69 | Co-financing | In vaccine programs, co-financing refers to national governments contributing to the cost of vaccines alongside external donors. Under Gavi’s co-financing policy, countries gradually pay for an increasing share of the vaccines introduced with Gavi support. This approach is meant to foster country ownership and sustainability by having governments finance some required doses themselves, progressively moving toward full self-financing as national income grows. |
| 265 | Microplanning | In immunization, microplanning is the bottom-up process of planning vaccination activities at the local level (health facility or district), taking into account the community’s specific details such as population distribution, villages, session scheduling, logistics, and staffing. A microplan typically maps all communities and target populations, sets a schedule for fixed and outreach immunization sessions, estimates resource needs (vaccines, syringes, fuel for transport), and assigns responsibilities. Under the RED strategy, every health unit develops a microplan to ensure every settlement is served. Effective microplanning helps identify gaps (e.g., areas with no regular sessions or understaffed clinics) and is essential for reaching remote and marginalized groups. It translates national policy into concrete field operations and is updated regularly based on monitoring data and community feedback. |
| 109 | Demand generation | Efforts and interventions aimed at creating and sustaining public desire for vaccination. This can involve social mobilization campaigns, advocacy by community leaders, mass media communications, reminder-recall systems (like SMS reminders to parents), and even incentives. The idea is to encourage people to actively seek vaccines rather than only relying on health worker outreach. For example, a campaign might showcase local celebrities endorsing vaccines or use mothers’ groups to spread positive messages. Generating demand is especially important in settings with lingering hesitancy or where immunization has lost momentum. A strong communication plan that highlights the benefits of vaccines, addresses fears, and makes the act of vaccinating visible and normalized in society will boost demand. High demand, coupled with good service delivery, leads to high uptake and coverage. |
| 452 | Vaccine hesitancy | Delay in acceptance or refusal of vaccines despite the availability of vaccination services. It’s a complex phenomenon influenced by factors such as complacency (not perceiving a need for a vaccine), lack of confidence (distrust in vaccines or health systems), and convenience (access issues). WHO’s SAGE defines vaccine hesitancy as behavior influenced by the “3 Cs”: confidence, complacency, and convenience. Hesitancy exists on a spectrum – from mild concerns leading to delaying vaccines, up to outright refusal of all vaccines. It’s highly context-specific (varying by time, place, and vaccine). Examples include hesitancy due to misinformation (e.g., false rumors about infertility), historical distrust in government/medical institutions, or fears of side effects. Combating vaccine hesitancy requires community engagement, transparent communication, and sometimes policy measures like mandates or incentives. It has been listed by WHO as a top 10 global health threat (2019) because it can undermine control of diseases (as seen in measles resurgence). |
| 243 | Life-course immunization | An approach to immunization that extends beyond the traditional focus on infants and children, to provide vaccines throughout an individual’s life (adolescence, adulthood, and older age). Life-course immunization means offering age-appropriate vaccines at different stages – for example: HPV vaccine in adolescence, influenza and COVID-19 vaccines for adults and seniors, tetanus for pregnant women, etc. The aim is to protect populations at every age and to integrate vaccination into a continuum of care. Embracing a life-course approach is increasingly important as new vaccines for older age groups become available and as countries aim to maintain immunity in adults (e.g., boosters) while still prioritizing children. |
| 321 | Phase IV trial | Also known as post-marketing surveillance or post-licensure studies, these are conducted after a vaccine is approved and in widespread use. Phase IV studies continue to monitor the vaccine’s safety in a real-world population (to catch very rare adverse events or long-term effects not seen in Phase III) and sometimes effectiveness under field conditions. They may also explore use in subpopulations, schedule optimizations, or interference with other vaccines. For example, ongoing surveillance for adverse events like Guillain-Barré syndrome after some vaccines is part of Phase IV. Phase IV can include formal studies or just continuous monitoring systems (like VAERS in the US). In short, Phase IV ensures that even after approval, the vaccine’s performance and safety are continuously evaluated in the general population, and it provides data that might lead to updates in recommendations or label indications. |
| 272 | Mosaic Vaccine | A vaccine that uses computationally optimized antigens created from multiple variant sequences to maximize coverage of diverse strains. In a mosaic antigen, sequences from different strains are combined (in mosaic fashion) into a single composite sequence that contains as many potential T-cell or B-cell epitopes from the variants as possible. The mosaic vaccine approach is being explored for highly variable viruses like HIV: e.g., a “mosaic” HIV vaccine might include antigens that are hybrids representing global HIV diversity, aiming to stimulate immune responses to epitope variants found across many clades. Johnson & Johnson’s investigational HIV-1 vaccine regimen is an example, using mosaic antigens to broaden T-cell responses. Mosaic vaccines can be delivered via viral vectors or DNA and have shown expanded breadth of immune recognition in preclinical studies, addressing the challenge of pathogen diversity. |
| 401 | Subunit Vaccine | A vaccine that includes only specific components (antigens) of a pathogen rather than the whole organism. These components can be purified from the pathogen or, more commonly, produced via recombinant DNA technology in yeast, bacteria, or cell cultures. Subunit vaccines often contain proteins (for example, the hepatitis B surface antigen, or the HPV L1 capsid protein that assembles into virus-like particles). Because they contain no live agent and no genetic material, they are extremely safe – there’s no risk of infection. However, as purified antigens, they may be less immunogenic by themselves. Most subunit vaccines require adjuvants and multiple doses to generate a sufficient immune response. Examples: Hepatitis B vaccine (recombinant HBsAg protein), Human Papillomavirus (HPV) vaccines (virus-like particles of the L1 protein), acellular pertussis (contains several purified pertussis antigens instead of whole cells), and protein-based COVID-19 vaccines (e.g., Novavax’s Spike protein nanoparticle with adjuvant). Subunit vaccines tend to induce primarily antibody responses; including T-cell epitopes or using adjuvants can broaden the response. Their production is focused on including the most protective antigens and excluding components that cause side effects, which often yields a better safety profile (e.g., acellular pertussis is less reactogenic than the older whole-cell pertussis). The challenge is ensuring these subunits maintain conformations that induce the right immunity (hence the use of virus-like particles for HPV to mimic the actual virus structure). |
| 478 | Virus-like particle (VLP) vaccine | A vaccine that contains virus-like particles – self-assembled protein shells that mimic the outer structure of viruses but contain no genetic material. VLPs are highly immunogenic because they present repetitive antigenic surfaces to the immune system. They are used in current vaccines (e.g., HPV and hepatitis B vaccines are VLP-based) and in development for others. Novel VLP vaccines can be produced via recombinant expression systems (yeast, insect cells, plants) and represent a safe way to induce strong antibody responses without live virus. |
| 111 | Design Thinking | A user-centered, creative problem-solving approach to designing healthcare interventions that address unmet needs through iterative prototyping. |
| 269 | Missed communities | A term for populations or geographical areas where clusters of zero-dose and under-immunized children live, often characterized by systemic disadvantages. These communities might face lack of health services, extreme poverty, remote location, conflict or insecurity, and sociocultural barriers (including gender-related barriers) that result in low vaccination uptake. Missed communities require targeted strategies – such as outreach clinics, community engagement, and tailored communication – to overcome access issues and build trust in vaccines. Focusing on missed communities is essential to “leave no one behind” and ensure immunization equity. |
| 154 | Flow Cytometry | A technology that analyzes and/or sorts cells in a fluid stream by passing them through a laser beam. Each cell can be labeled with fluorescent antibodies against surface or intracellular markers, and as it passes the laser, the fluorescence is detected. In vaccine evaluation, flow cytometry is used for immunophenotyping (determining frequencies of various immune cell subsets, e.g. memory B cells, CD4? Tcells, etc.), and for assessing T cell function via Intracellular Cytokine Staining (ICS). For ICS, cells are stimulated with vaccine antigen, then treated with drugs to trap cytokines inside, and stained for markers like IFN-?, TNF, IL-2 along with T cell markers. Flow cytometry then reveals what fraction of T cells produced cytokines in response to antigen, and even polyfunctionality (cells making multiple cytokines). The technique is extremely powerful for dissecting the quality of immune responses beyond simple quantity – e.g., identifying a rare subset of antigen-specific T cells or measuring expression of homing receptors, activation markers, etc. Flow cytometric assays are critical for a comprehensive analysis of vaccine-induced cellular immunity. |
| 137 | Emergency Use Authorization (EUA) | A regulatory mechanism, most notably used by the U.S. FDA, to allow the use of unapproved medical products or unapproved uses of approved products during a declared public health emergency. An EUA can be issued when certain criteria are met (such as a serious threat and evidence that the product “may be effective” and the benefits outweigh the risks). EUAs helped facilitate the early use of COVID-19 vaccines in the U.S. and similar emergency pathways were used by other regulators. EUAs are time-limited and require ongoing data submission until full licensure can be obtained. |
| 129 | Edible Vaccine (Plant-Based Vaccine) | A novel concept where transgenic plants are used to produce vaccine antigens, and consuming the plant (or a derived edible product) delivers the antigen to the individual. For example, potatoes, tomatoes, rice, or lettuce have been engineered to express antigens like Hepatitis B surface antigen or Norovirus capsid proteins. The idea is that eating the raw plant (or pills made from it) could immunize the person in a low-cost, needle-free way. Edible vaccines could simplify distribution (seeds could be grown locally) and appeal in places where cold-chain and sterile injections are difficult. They inherently target mucosal immunity in the gut. However, there are challenges: dosage control is tricky (antigen concentration can vary in plants), ensuring antigens survive digestion and are taken up by the immune system, and regulatory issues of using GMOs for food. So far, edible vaccines remain largely in experimental stages. One trial had people eat raw potatoes with E. coli toxin antigen – it induced some immune response, but eating raw potatoes in needed quantities was unpalatable. Now, more refined plant-based oral capsules are considered (e.g., algae or rice-derived). Additionally, the plant-production system has yielded some traditional vaccines (e.g., a plant-made flu vaccine, though delivered via injection). Edible vaccines present an intriguing vision of pain-free, culturally acceptable immunization (imagine children getting immunized by eating a banana with vaccine antigen), but significant scientific and logistic hurdles remain to be overcome. |
| 92 | Cost-effectiveness (analysis) | A method to evaluate an intervention by comparing its costs to its health outcomes. In immunization, cost-effectiveness is often expressed as the cost per health outcome gained (e.g. cost per disease case or death averted, or per disability-adjusted life year saved). Decision-makers use cost-effectiveness analysis to judge if a vaccine provides good value for money relative to other health interventions. |
| 62 | CEPI (Coalition for Epidemic Preparedness Innovations) | A global partnership launched in 2017 (at Davos) with the mission to finance and coordinate development of new vaccines for emerging infectious diseases, especially those with pandemic potential. CEPI’s focus is on “Disease X” – being prepared for unknown pathogens – as well as known threats like Nipah, Lassa, MERS, Rift Valley fever, and previously Ebola. It uses public, private, and philanthropic funds to give grants to vaccine R&D projects, emphasizing speed and equitable access (grantees often must agree to certain access provisions). CEPI played a critical role in COVID-19 by investing early in various vaccine platforms (it supported the University of Oxford’s adenovirus vaccine, Moderna’s mRNA, Novavax’s protein subunit, among others). The 100 Days Mission is a CEPI-promoted goal to have a vaccine against a new pandemic virus ready for trials in 100 days. CEPI embodies the new approach to pandemic preparedness: proactive development of vaccines up to phase 1 or 2 for threats before outbreaks, which can then be quickly finished and deployed when needed. |
| 1 | 3Cs model | A framework proposed by WHO to understand the drivers of vaccine hesitancy, focusing on Confidence, Complacency, and Convenience. Confidence is trust in the vaccines and health system; Complacency is low perceived disease risk reducing the motivation to vaccinate; Convenience (or Constraints) refers to practical barriers to access. Sometimes a fourth C, Communication, is added in discussion, or Context is considered. The 3Cs model helps categorize interventions: for confidence issues, one might improve transparency and dialogue; for complacency, increase awareness of disease risk; for convenience, make services more user-friendly. It’s a handy mnemonic that vaccine program managers use to diagnose why coverage might be suboptimal even when vaccines are available, ensuring that strategies address the correct underlying issue. By tackling all three Cs, an immunization program can holistically improve uptake and trust. |
| 252 | Lyophilized (freeze-dried) vaccine formulation | A formulation approach to improve vaccine stability by removing water under low temperature and vacuum. Many nucleic acid vaccines, such as mRNA, are exploring lyophilization to create a powder that is more stable at higher temperatures, easing cold chain needs. A freeze-dried mRNA-LNP vaccine can potentially be stored at refrigerated or ambient temperatures and reconstituted before use, which is a significant innovation for thermostable vaccines. This area is under active research to enable mRNA vaccines that don’t require ultra-cold storage. |
| 233 | Jet Injector (Needle-Free Injector) | A device that delivers vaccines (or drugs) through the skin using a high-pressure, narrow stream of liquid instead of a hypodermic needle. The jet injector forces the vaccine fluid at high velocity, creating an ultrafine stream that penetrates the skin into the underlying tissue. This needle-free approach has been used historically in mass vaccination campaigns (e.g., for smallpox and other vaccines in the mid-20th century) and continues to be refined. Modern jet injectors can be single-use or have replaceable nozzle caps to prevent cross-contamination (older multi-use-nozzle designs raised concerns of disease transmission). Jet injectors can deliver intradermally, subcutaneously, or intramuscularly depending on the pressure and design. Advantages include elimination of needle-stick injuries and sharps waste, and potentially better dispersion of vaccine in tissue. They also may improve acceptability for needle-phobic individuals. An example of current use: some influenza vaccines and COVID-19 vaccines have been delivered intradermally by specialized jet injectors (e.g., the PharmaJet device). Jet injectors are also used in DNA vaccine trials, often with a spring or gas mechanism to drive the liquid (sometimes combined with electroporation for DNA uptake). While the sensation is not entirely painless (can feel like a small snap), they avoid a visible needle. Ensuring consistent dose delivery and avoiding splash-back are technical points that modern devices have addressed. Jet injection remains an important alternative delivery method in immunization programs, particularly where needles pose logistical or safety challenges. |
| 486 | World Health Organization (WHO) | The United Nations specialized agency for international public health. WHO plays a key role in vaccines by coordinating global immunization programs (like the Expanded Programme on Immunization), setting vaccine quality and safety standards (prequalification of vaccines), facilitating research and development especially for diseases of low-income countries, and advising on vaccine policies and schedules worldwide. WHO also leads or partners in global initiatives such as Gavi and COVAX for vaccine access. During health emergencies, WHO may declare Public Health Emergencies and coordinate international responses including vaccination campaigns (e.g., during Ebola outbreaks). |
| 351 | Rational vaccine design | The deliberate design of vaccine antigens using knowledge of the pathogen’s structure and the immune system, rather than empirical attenuation or inactivation. This approach often involves identifying vulnerable sites on a pathogen (such as a conserved receptor-binding site) and designing an antigen that focuses the immune response on that site. Examples include computationally designed immunogens that mimic a virus’s neutralization-sensitive epitopes while eliminating distracting parts. Rational design overlaps with structural vaccinology and immunogen engineering – it’s an iterative, hypothesis-driven creation of vaccine candidates aimed at eliciting broadly protective immunity. |
| 46 | BCG vaccine (Bacille Calmette–Guérin) | A live attenuated vaccine derived from Mycobacterium bovis (bovine tuberculosis bacillus) used to prevent tuberculosis, especially severe TB in children. The BCG vaccine contains weakened bacteria that stimulate an immune response but do not cause disease. (BCG is also used as a bladder cancer therapy.) |